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Summary 
As illustrated in recent literatures, the asymmetric synthesis of sulfoxides of very high 
ee-value is now possible using a wide variety of approaches. In the Andersen method, the 
stereochemically pure sulfinates serve as an excellent starting material for easy preparation of 
certain enantiopure sulfoxides. But the drawbacks of this method are the limited availability 
of the required sulfinic acid derivatives in stereochemicallly pure form and use of these 
reagents in stoichiometric quantity. On the other hand, the stoichiometric oxidation of 
sulfides is of preparative interest only in a limited number of cases. While catalytic 
enantioselective sulfide oxidation is highly desirable, and can be used to generate sulfoxides 
with excellent ee-values, it suffers from a lack of generality, and the catalyst must also be 
optimized and able to adjust to the structure of the sulfides. Another problem is the 
competitive oxidation of sulfoxide into sulfone, which leads to a decrease in yield, although 
the ee-values may be increased by kinetic resolution.   
In comparison with the methods mentioned above, the sulfinate anion strategy is a 
complementary and conceptually novel approach. Recently, an experimentally simple method 
for the generation of sulfenate anions from β-sulfinyl sulfones and asymmetric alkylation of 
sulfenate anions under the phase transfer condition has been reported in good yield but with 
moderate enantioselectivity. Therefore, due to this limitation, further development of novel 
designed phase-transfer catalysts for the trapping the in situ generated sulfenate anions with 
various electrophiles for highly enantioenriched sulfoxides is still needed.  
Recently our group has developed novel C2-symmetric chiral phase-transfer catalysts: 
pentanidiums which have been successfully applied in asymmetric Michael addition and α-
hydroxylation of oxindoles with excellent yields and enantioselectivities. We envisioned that 
our pentanidiums or guanidiniums which should have strong ion-pairing and other no-
covalent interactions with reaction substances may provide a new direction for the 
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development of phase-transfer catalysts. Therefore, in this thesis we aim to obtain a series of 
enantioenriched sulfoxides through the optimization of the reaction conditions and 
modification of catalyst structures. 
The synthesis and comprehensive characterizations of a variety of pentanidiums with 
modified steric and electronic structures were firstly conducted. Besides, the bis-
guanidiniums with novel designed structure was also fully characterized and to our delight 
they exhibited very high activity and exceptional ability of enantiocontrol in certain reactions, 
such as the KMnO4 oxidation. Meanwhile the catalytic performances of new pentanidiums in 
the synthesis of enantioenriched sulfoxides by using in situ-generated sulfenate anions 
strategy were mainly studied. It was found that halogenated pentanidiums could lead to 
excellent enantioselectivity in alkylation of hetero-aromatic sulfenate anions by efficiently 
discriminating lone electron pairs on sulfur atom. Mechanistic study indicated that the 
combination of ion-pairing and other non-covalent interactions, such as halogen bonding 
interaction, may contribute to the formation of tighter complex consisting of the sp2-
quaternized ammonium and sulfenate anions nucleophiles and electrophiles. To our 
knowledge, this is the first time that such sulfoxides with high enantioselectivities have been 
achieved under phase transfer conditions. 
Over all, this study is an extension of previous works in terms of catalyst design and also 
provides a novel methodology to chiral sulfoxides with broad substrates scope and excellent 
asymmetric induction. Besides, a successful large-scale experiment at low catalyst loading of 
0.25 mol % indicates the potential of practical application for this methodology. The 
incorporation of other non-covalent interactions in our phase transfer catalysts was studied by 
computational calculation and experimental details. It may provide a valuable insight into the 
development and design of phase transfer catalysts.  
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1.1. Introduction 
 In chemistry, a chiral molecule is a type of molecule that has a non-
superimposable mirror image.  Molecular chirality is of interest because of its 
application to stereochemistry in inorganic chemistry, organic chemistry, physical 
chemistry, biochemistry, and supramolecular chemistry. In general, chiral molecules 
have point chirality at a single stereogenic atom, which has four different substituents. 
It’s well known the stereogenic atom in chiral molecules is usually carbon, as in many 
biological molecules. However, it may also be nitrogen, phosphorus, or sulfur etc 
(Figure 1.1).  
Figure 1.1 Chiral molecules with nitrogen and phosphorus as stereogenic atoms. 
Since the successful resolution of two sulfur compounds, (CH3)(C2H5)SR1R2 (R1 = 
CH2COC6H5 or CH2COOH, R2 = halogen) into two enantiomeric forms, sulfur has 
been regarded as tetra-covalent, and the observed optical activity is considered similar 
to that of tetrahedral carbon compounds. 1  Sulfur exhibits pyramidal bonding in 
sulfoxides, sulfinic esters, sulfonium salts and sulfites (Figure 1.2). Such pyramidal 
structure can give rise to asymmetry. Generally, a pyramidal structure can undergo an 
atomic inversion through a planar (or near planar) transition state forming an 
enantiomeric, mirror-image structure. For sulfonium ions, the inversion barrier is in 
the range 25-29 kcal mol-1, so that if R1 ≠ R2≠ R3, stable enantiomers may be obtained. 
In the case of sulfoxides, the energy required to invert this stereocenter is sufficiently 
high (35-43 kcal mol-1), so sulfoxides are optically stable at room temperature. For 
                                                     
1 Bentley, R. Chem. Soc. Rev. 2005, 34, 609.  
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similar sulfur compounds, the stable enantiomers are possible if the substituents are 
different.2  
 
Figure 1.2 Sulfur compounds with pyramidal structure. 
Among these sulfur compounds, sulfoxides are of particular importance, it is 
necessary to give a brief account of the bonding of sulfur to oxygen. Generally, 
sulfoxides are represented with the structural formula R–S(=O)–R', where R and R' 
are organic groups. The bond between the sulfur and oxygen atoms differs from the 
conventional double bond between carbon and oxygen. Like an ordinary double bond, 
this double bond contains one s orbital, but the second orbital is not a π orbital formed 
by overlap of half-filled p orbital; instead it is formed by overlap of a filled π orbital 
from the oxygen with an empty d orbital from the sulfur.3 It is called a pπ-dπ orbital. 
The S–O interaction has an electrostatic aspect, resulting in significant dipolar 
character, with negative charge centered on oxygen.  
The first example of an optically active sulfoxide was described in 1926.4 This 
discovery was helpful for discussions regarding the nature of the S=O bond and the 
non-planarity of sulfur. Later, chiral sulfoxides slowly emerged as a class of 
                                                     
2 Mikołajczyk, M.; Drabowicz, J. Topics in Stereochemisty, ed. Allinger, N. L.; Eliel, E. L.; 
Wilen, S. H. Interscience, New York, 1982, vol. 13, pp. 333–468. 
3 Smith, M. B.; March, J. Stereochemistry. March’s Advanced Organic Chemistry, 6th ed.; 
John Wiley & Sons: Hoboken, NJ, 2007; pp 1782. 
4 Harrison, P. W. B.; Kenyon, J.; Phillips, H. J. Chem. Soc. 1926, 2079-2090. 
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compounds of interest in asymmetric synthesis. 5  They have been successfully 
employed as chiral auxiliaries and ligands in a range of reaction classes (Figure 1.3).  
              
Figure 1.3 Enantioenriched sulfoxides as ligands. 
Sulfur is well-suited to the role of an agent for transfer of chirality for several 
reasons.6 The faces of a sulfoxide are highly differentiated due to the large steric 
difference between its substituents, which range from an electron lone pair to large 
alkyl groups like tert-butyl. Both sulfur and oxygen have lone pairs of electrons 
available to coordinate to Lewis acidic functionality, often promoting highly ordered 
transition states. Finally, sulfur can readily form covalent bonds, including 
heteroatoms, and can be cleaved under relatively mild conditions. 
Enantiopure sulfoxides are also important in the pharmaceutical industry, and 
possess a wide range of biological activity from flavour and aroma precursors to 
antimicrobial properties. As a result, many types of pharmaceutical agents became of 
                                                     
5 Wojaczynska, E.; Wojaczynski, J. Chem. Rev. 2010, 110, 4303-4356.;Solladie, G. Synthesis-
Stuttgart 1981, 185-196.; Solladie, G. in: Morrison, J. D. (Ed.), Asymmetric Synthesis, 
Academic Press, New York 1983, vol. 2, pp. 157-199.; Carreno, M. C. Chem. Rev. 1995, 95, 
1717-1760.; Fernandez, I.; Khiar, N. Chem. Rev. 2003, 103, 3651-3705.; Andersen, K. K. in: 
Patai, S.; Rappoport, Z.; Stirling, C. J. M. (Eds.), The Chemistry of  Sulfones and Sulfoxides, 
Wiley, New York, 1988, pp. 55-94.; Drabowicz, J.; Kielbasinski, P.; Mikolajczyk, M.  in: 
Rappoport, Z.; Stirling, C. J. M. (Eds.), The Chemistry of Sulfones and Sulfoxides, Wiley, 
New York, 1988, pp. 235-378.; Pellissier, H. Tetrahedron 2006, 62, 5559-5601. 
6 Sandrinelli, F.; Perrio, S.; Beslin, P. J. Org. Chem., 1997, 62, 8626-8627.; Sandrinelli, F.; 
Fontaine, G.; S. Perrio, S.; Beslin, P.  J. Org. Chem., 2004, 69, 6916-6919.; Sandrinelli, F.; 
Boudou, C.;  Caupѐne, C.; Averbuch-Pouchot, M.-T.; Perrio, S.; Metzner, P. Synlett, 2006, 
3289-3293. 
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special interest as one class of anti-ulcer drugs (Figure 1.4). These properties have 
inspired considerable investigation into the synthetic applications of sulfoxides.  
                                        
Figure 1.4 Enantioenriched sulfoxides as drugs. 
1.2. The Stoichiometric Asymmetric Syntheses of Sulfoxides 
The resolution of a racemic mixture is the first method used to produce chiral 
sulfoxides, by either a chemical approach or an enzymatic reaction. One disadvantage 
of chiral resolution of racemates compared to direct asymmetric synthesis of one of 
the enantiomers is that only 50% of a desired enantiomer is obtained. Meanwhile, it 
usually takes a relatively longer time to optimize the conditions for chiral resolution. 
In this section, two mains methods will be discussed for the stoichiometric 
asymmetric synthesis of sulfoxides by using chiral sulfur precursors and chiral 
oxidants, excluding the chiral resolution processes and enzymatic approaches. 
1.2.1. Stoichiometric Asymmetric Syntheses of Sulfoxides by Using Chiral 
Sulfur Precursors     
Since the 1960s, the transformation of a diastereochemically pure sulfinate has 
been a very useful method by which to obtain sulfoxides with high enantiomeric 
excess (ee) values.  In addition, other chiral sulfur precursors, such as sulfite, 
sulfinamides are also explored for the asymmetric synthesis of sulfoxides. Chiral 
sulfinates are excellent precursors of chiral sulfoxides, and this approach was 
Chapter 1 
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pioneered by Andersen in 1962, using one diastereomer of menthyl ptolylsulfinate 
prepared from (-)-menthol. 7  The now so-called Andersen method is illustrated 
schematically for the synthesis of the p-tolyl sulfoxides 3 (Scheme 1.1). Here, there 
are two important issues: (1) the need to prepare the menthyl p-tolylsulfinates 2 from  
Scheme 1.1 The Andersen method for the preparation of chiral sulfoxides. 
(-)-menthol and p-tolylsulfinyl chloride 1 which can be obtained by in situ reduction 
of p-tolylsulfonyl chloride; and (2) to separate the two epimers at sulfur by 
crystallization as (SS)-2 is crystalline and (RS)-2 is oily. Very soon, the Andersen 
method became the preferred approach when preparing enantiopure sulfoxides of 
known absolute configuration. The large majority of examples used the material 
sulfinate (SS)-2 due to the ease of its preparation, which is crystalline. An important 
improvement of the preparation of (-)-menthyl p-tolylsulfinate (SS)-2 was introduced 
by Mioskowski and Solladié in 1980.8 These authors combined the crystallization step 
in acetone with an in-situ epimerization by a catalytic amount HCl to give (SS)-2 in 90% 
yield. A modification of the preparation of sulfinates was proposed in 1987 by 
Sharpless et al. based on the use of arylsulfonyl chlorides which are reduced in situ by 
trimethyl phosphite in the presence of triethylamine.9 In this way, pure (-)-menthyl p-
toluenesulfinate was prepared at the 0.2 mole scale, with 66% yield. 
                                                     
7 Andersen, K. K. Tetrahedron Lett. 1962, 93-95.; Andersen, K. K.; Foley, J. W.; Gaffield, W.; 
Papaniko.Ne; Perkins, R. I. J. Am. Chem. Soc. 1964, 86, 5637-5646. 
8 Mioskowski, C.; Solladie, G. Tetrahedron 1980, 36, 227-236. 
9 Klunder, J. M.; Sharpless, K. B. J. Org. Chem. 1987, 52, 2598-2602. 
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In order to avoid the separation of diastereomeric sulfinates, the best solution is to 
directly produce one preponderant diastereomer in the esterification step. Some 
kinetic diastereoselectivity has been observed by Whitesell and colleagues in sulfinate 
formation from 2-phenylcyclohexanol 4 (Scheme 1.2).10  One improvement in the 
synthesis of sulfinates was the intermediate formation of chlorosulfite esters by the 
action of thionyl chloride on trans-phenylcyclohexanol 4. The mixture of 
diastereomeric chlorosulfites was then treated with various dialkylzincs over a range 
of conditions, and as a consequence sulfinate ester 6 was obtained with up to 97% 
yield and 92% diastereomeric excess (de). The authors assumed a dynamic kinetic 
resolution process where the chlorosulfinates were in rapid equilibrium in respect to 
the subsequent reaction with dialkylzincs, where one diastereomer reacts faster than 
the other. 
Scheme 1.2 Kinetic diastereoselectivity in sulfinate formation from 2-
phenylcyclohexanol. 
In 1991, Llero, Fernandez and Alcudia made the important discovery that 
diacetone-d-glucose (DAG, 7) was converted stereoselectively in 90% yield into 
either (S)- or (R)-methanesulfinates from methanesulfinyl chloride, according to the 
nature of the amine which was taken as a base(Scheme 1.3). 11  However, the 
                                                     
10 Whitesell, J. K.; Wong, M. S. J. Org. Chem. 1991, 56, 4552-4554.; Whitesell, J. K.; Wong, 
M. S. J. Org. Chem. 1994, 59, 597-601. 
11 Llera, J. M.; Fernandez, I.; Alcudia, F. Tetrahedron Lett. 1991, 32, 7299-7302. 
Chapter 1 
8 
 
replacement of DAG 7 by other alcohols (menthol, cholesterol, borneol, etc.) 
surprisingly gave sulfinates with low de values. 
         
Scheme 1.3 Diastereoselective formation of sugar sulfinates. 
Recently, the asymmetric sulfinylation of achiral alcohols has been reported in the 
presence of stoichiometric or catalytic amounts of chiral tertiary amine such as 
alkaloids. Toru et al. prepared in situ a combination of an arylsulfonyl chloride and a 
cinchona alkaloid (in stoichiometric amounts), acting as a chiral sulfinylating agent 
(Scheme 1.4a).12 In this way, tert-butyl arylsulfinates 10 could be prepared with very 
high ee values. Senanayake et al. described a very general sulfinylating process which 
allowed the asymmetric synthesis of sulfinates and sulfoxides from a stoichiometric 
amount of quinine or quinidine (Scheme 1.4b).13 By applying this method, almost  
     
Scheme 1.4 Use of alkaloids in the preparation of sulfinates. 
                                                     
12 Shibata, N.; Matsunaga, M.; Nakagawa, M.; Fukuzumi, T.; Nakamura, S.; Toru, T. J. Am. 
Chem. Soc. 2005, 127, 1374-1375. 
13 Lu, B. Z.; Jin, F. Q.; Zhang, Y. D.; Wu, X. H.; Wald, S. A.; Senanayake, C. H. Org. Lett. 
2005, 7, 1465-1468. 
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enantiopure tert-butyl alkyl sulfoxides 11 can be obtained. The proposed mechanism 
behind these processes seems to be the dynamic kinetic resolution pathway. 
Another way to get diastereomeric pure sulfinates is to attack chiral sulfites by the 
addition of various Grignard reagents. This approach was investigated in 1991 by 
Kagan et al.14 Crystalline cyclic sulfite 13 was prepared in 70% yield from diol 12 
which itself was issued from (S)-ethyl lactate (Scheme 1.5). The trans-
stereochemistry in sulfite 13 was established using X-ray crystallography. The 
addition of various Grignard reagents resulted in a clean monosubstitution reaction, 
with the formation of sulfinates 14, 15 in a degree of regioselectivity. The 
regioselectivity of the reaction was seen to depend on the Grignard reagent used; 
organometallics, such as PhMgBr or BnMgBr did not provide obvious preferential 
ring cleavage of the sulfite 13 to give the corresponding sulfinates with low selectivity 
(14:15 = 50:50 and 55:45, respectively, R1 = Ph or Bn). This approach was useful for 
preparing tert-butylsulfinate 14, 15 (14:15 = 95:5, R1 = t-Bu), which in turn gave 
access to a variety of enantiopure sulfoxides. 
 
Scheme 1.5 From a chiral sulfite to chiral sulfinates. 
It was established at an early stage that sulfoxides could be obtained from 
sulfonamides by the addition of methyllithium, with an inversion of configuration at 
                                                     
14 Rebiere, F.; Samuel, O.; Ricard, L.; Kagan, H. B. J. Org. Chem. 1991, 56, 5991-5999. 
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sulfur.15 Wudl and Lee prepared 1, 2, 3-oxathiazolidine-2-oxide 17 from (-)-ephedrine 
16 and thionyl chloride in 80% yield as a mixture of diastereomers 17a and 17b 
(72:28) (Scheme 1.6).16 By using a combination of crystallization and HCl-catalyzed 
equilibration, pure 17a (100% de) could be isolated in 65% yield. The addition of a 
Grignard reagent or organolithiums gave sulfonamides 18 in good yields, but with 
only about 50% ee. In 1991, Snyder and Benson reinvestigated this approach and 
optimized the transformation of 17a into sulfinamides 18 by using the Grignard 
reagents.17 In that way, various sulfinates 18 with de values ranging between 95% and 
99% could be isolated in excellent yields. In order to recover various dialkyl or alkyl 
aryl sulfoxides (>99% ee) in good yields, the authors introduced AlMe3 before adding 
the Grignard reagents at -70 °C. As an expansion of this approach, other chiral 
auxiliaries also were investigated, such as β-aminoalcohol 19 and Evans’s 
oxazolidinones 20 and 21(Scheme 1.6).18 
  
Scheme 1.6 Synthesis of chiral sulfoxides from chiral sulfinamides and some chiral 
auxiliaries. 
                                                     
15 Jacobus, J.; Mislow, K. Chem. Commun.  1968, 253-254. 
16 Wudl, F.; Lee, T. B. K. J. Am. Chem. Soc. 1973, 95, 6349-6358. 
17 Benson, S. C.; Snyder, J. K. Tetrahedron Lett. 1991, 32, 5885-5888. 
18 Evans, D. A.; Faul, M. M.; Colombo, L.; Bisaha, J. J.; Clardy, J.; Cherry, D. J. Am. Chem. 
Soc. 1992, 114, 5977-5985.; Han, Z. X.; Krishnamurthy, D.; Grover, P.; Fang, Q. K.; 
Senanayake, C. H. J. Am. Chem. Soc. 2002, 124, 7880-7881. 
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In summary, chiral sulfoxides can be easily obtained from a variety of chiral 
precursors such as sulfinates, sulfites, sulfinamides. The chiral auxiliaries involved in 
these chiral precursors can be released and then recovered at the end of transformation. 
However, for this methodology, stoichiometric chiral reagents are required and it 
takes much time to prepare these precursors in multi-step synthesis. The employing of 
chiral oxidants for direct sulfides oxidation to sulfoxides will be presented in the 
following section. 
1.2.2. Stoichiometric Asymmetric Synthesis of Sulfoxides by Using Chiral 
Oxidants 
Classical oxygen donors are optically active peracids, and this approach has been 
applied in the oxidation of sulphides to chiral sulfoxides, albeit without great success 
(ee-values<10%). 19 , 20  Chiral hydroperoxides (Figure 1.5) such as 22 21  represent 
another class of oxidizing reagent which can provide higher enantiomeric excess than 
chiral peracids. Hydroperoxides such as 2322 were also used as excellent oxidants in 
in the presence of Ti(OiPr)4/L-DET or Ti(O
iPr)4/(R)-BINOL/H2O systems.. In 2001, 
Seebach and Aoki  also investigated (4R,5R)-5-[(hydroperoxydiphenyl)methyl]-2,2 
dimethyl-1,3-dioxolan-4-yl}diphenylmethanol 24 (TADOOH)23  derived from H2O2 
and tetraaryl-1,3-dioxolane-4,5-dimethanol (TADDOL) for  enantioselective 
sulfoxidation, whereby methyl phenyl sulfoxide was produced in 86% ee after 
oxidation at -30 °C in THF in 73% yield, but with sulfone formation. 
                                                     
19 Balenovic, K.; Bregant, N.; Francetic, D. Tetrahedron Lett. 1960, 1, 20-22.; Maccioni, A.; 
Montanari, F.; Secci, M.; Tramontini, M. Tetrahedron Lett. 1961, 607-611. 
20 Folli, U.; Iarossi, D.; Montanar.F; Torre, G. Journal of the Chemical Society C-Organic 
1968, 1317-1322.; Pirkle, W. H.; Rinaldi, P. L. J. Org. Chem. 1977, 42, 2080-2082. 
21 Takata, T.; Ando, W. Tetrahedron Lett. 1986, 27, 1591-1594. 
22 Massa, A.; Siniscalchi, F. R.; Bugatti, V.; Lattanzi, A.; Scettri, A. Tetrahedron-Asymmetry 
2002, 13, 1277-1283. 
23 Aoki, M.; Seebach, D. Helv. Chim. Acta 2001, 84, 187-207. 
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Figure 1.5 Hydroperoxides. 
In 1978, Davis and colleagues reported a new class of aprotic oxidising reagents: 
N-sulfonyloxazaridines (Figure 1.6), which are derived from camphor, for the 
oxidation of sulfides to sulfoxides in good yield.24 The mechanism of the oxidation is 
believed to involve nucleophilic attack by the sulfide on the electrophilic oxygen of 
the oxaziridine, similar to oxidation with peracids. Subsequently, they developed 
several chiral N-sulfonyloxazaridines (Figure 1.6) in the enantioselective oxidation of 
sulfides to sulfoxides, with ee-values in excess of 95% in some cases.   
Figure 1.6 Chiral oxaziridines. 
Initially, oxidising agent 25 was used by Davis to enantioselectively oxidise 
sulfides, For example, methyl phenyl sulfoxide was obtained with modest 
enantiopurity, 14% ee.25 Further investigations in this group led to the discoveries of 
other oxizaridines such as 26a, 26b by tuning the structures, the electronic and steric 
effects. 26  Among them, the oxazaridine 26b oxidation proved to be an excellent 
oxidising reagent of quite broad applicability and allowed the aryl alkyl, dialkyl, and 
functionalized sulfides to sulfoxides with high and predictable stereoselectivities. 
                                                     
24 Davis, F. A.; Jenkins, R.; Yocklovich, S. G. Tetrahedron Lett. 1978, 5171-5174. 
25 Davis, F. A.; Jenkins, R.; Rizvi, S. Q. A.; Panunto, T. W. Journal of the Chemical Society-
Chemical Communications 1979, 600-601. 
26 Davis, F. A.; Thimmareddy, R.; Weismiller, M. C. J. Am. Chem. Soc. 1989, 111, 5964-
5965. 
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Furthermore, the results obtained were at least comparable, if not superior, to those 
obtained by using other available oxidation methods, and the oxidation was carried 
out at room temperature. One crucial structural factor of 26b is the presence of a gem-
dihalo system in the vicinity of the oxaziridine ring. On the basis of the analysis of X-
ray structure, the authors concluded the exceptional enantioselectivities displayed by 
26b are a consequence of a molecular cleft or groove, defined by the oxaziridine 
chlorine atoms and phenylsulfonyl group, on the active-site surface.27 Inspired by this 
research, Bulman Page et al. prepared the dimethoxy analogue 27, which is a good 
enantioselective oxidant for non-aryl sulfides, and complementary of the Davis 
reagents.28 Besides, a family of N-phosphinooxaziridines 28 synthesized by Jennings 
et al.29 proved capable of oxidizing various aryl alkyl sulfides with 34-70% ee. 
In 1988, Davis reported a racemic version of selective oxidation of sulfides to 
sulfoxides using in-situ generated oxaziridines by oxidising imines with Oxone.30 
Later, Bulman Page et al. firstly reported asymmetric sulfide oxidation by using the 
oxidising reagent in-situ generated from chiral sulfonylimines 29 (Figure 1.7) and 
aqueous hydrogen peroxide (30%) under basic conditions, and tert-butyl methyl 
sulfoxide was prepared in 83% yield and 42% ee.31 Further investigations by Page 
established that using the imines 30 and 31 resulted in much higher enantioselectivity, 
with tert-butyl methyl sulfoxide being obtained in quantitative yield and 86% ee when 
                                                     
27 Davis, F. A.; Reddy, R. T.; Han, W.; Carroll, P. J. J. Am. Chem. Soc. 1992, 114, 1428-1437. 
28 Page, P. C. B.; Heer, J. P.; Bethell, D.; Collington, E. W.; Andrews, D. M. Tetrahedron-
Asymmetry 1995, 6, 2911-2914. 
29 Jennings, W. B.; Kochanewycz, M. J.; Lovely, C. J.; Boyd, D. R. Journal of the Chemical 
Society-Chemical Communications 1994, 2569-2570. 
30 Davis, F. A.; Lal, S. G.; Durst, H. D. J. Org. Chem. 1988, 53, 5004-5007. 
31 Page, P. C. B.; Heer, J. P.; Bethell, D.; Collington, E. W.; Andrews, D. M. Tetrahedron Lett. 
1994, 35, 9629-9632. 
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the dimethoxy imine 31 was used in the oxidation. 32 The same author also prepared 
and studied the pseudosaccharin derivatives 32 as chiral mediators in the hydrogen 
peroxide mediated oxidation of sulfides, although the ee-values remained below 
35%.33  
 
Figure 1.7 Chiral sulfonylimines. 
It was first reported in 1988 that acid could catalyse the oxygen transfer from an 
oxaziridine to a sulfide.34 Bohé et al. firstly apply this knowledge into asymmetric 
sulfide oxidation using a Brønsted acid: methanesulfonic acid (MSA) and an 
oxaziridine 33 (Figure 1.8) derived from (1S,2R)-(+)-Norephedrine, and then methyl 
p-tolyl sulfoxide was obtained with an ee-value of less than 43%.35 Overall the results 
were modest compared with other oxidative methods that were available at that time. 
In addition, Schoumacker et al. reported that Lewis acids such as ZnCl2, were able to 
catalyse the enantioselective transfer of oxygen to sulfides from oxaziridine 34.36 
Enantioselectivities ranging from 22% ee to 63% ee with the simplest aryl alkyl 
sulfides were afforded. While the results were modest, this represented the first Lewis 
acid promoted asymmetric oxidation of sulfides by oxaziridines. This reaction was  
                                                     
32 Page, P. C. B.; Heer, J. P.; Bethell, D.; Collington, E. W.; Andrews, D. M. Synlett 1995, 
773-775. 
33 Bethell, D.; Page, P. C. B.; Vahedi, H. J. Org. Chem. 2000, 65, 6756-6760. 
34 Hanquet, G.; Lusinchi, X.; Milliet, P. Tetrahedron Lett. 1988, 29, 2817-2818. 
35 Bohe, L.; Hanquet, G.; Lusinchi, M.; Lusinchi, X. Tetrahedron Lett. 1993, 34, 7271-7274.; 
Bohe, L.; Lusinchi, M.; Lusinchi, X. Tetrahedron 1999, 55, 155-166. 
36 Schoumacker, S.; Hamelin, O.; Teti, S.; Pecaut, J.; Fontecave, M. J. Org. Chem. 2005, 70, 
301-308. 
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Figure 1.8 Chiral oxaziridines. 
recently reinvestigated by Hanquet and coworkers with oxaziridines 35, containing a 
binaphthyl fragment. 37  The oxidations of dialkyl or diaryl sulfides produced the 
corresponding sulfoxides in good yield (up to 86%) with no sulfone formation and 
enantiopurities ranging from 20% ee to 80% ee. Recently, Bohé et al. also prepared 
the first oxaziridinium salt 36 derived from cholesterol as the oxidising agent.38 This 
oxaziridinium salt was proved to be an effective reagent for the highly 
enantioselective oxidation of sulfides to sulfoxides with up to >99% ee and good 
yields. Therefore, it represents a new valuable non-metallic alternative to the existing 
methods for asymmetric sulfoxidation. 
A completely different approach is the asymmetric oxidation of sulfides using 
chiral hypervalent iodine reagents (Figure 1.9). For example, the hypervalent iodine 
(III) reagents 3739, 3840 are able to oxidize sulfides to sulfoxides (ee-values<60%) 
following a basic hydrolytic workup. In 2000, Zhdankin et al. reported the racemic 
and asymmetric oxidation of sulfides using hypervalent iodine (V) based oxidising 
                                                     
37 Akhatou, A.; Rahimi, M.; Cheboub, K.; Ghosez, L.; Hanquet, G. Tetrahedron 2007, 63, 
6232-6240. 
38 del Rio, R. E.; Wang, B.; Achab, S.; Bohe, L. Org. Lett. 2007, 9, 2265-2268. 
39 Imamoto, T.; Koto, H. Chem. Lett. 1986, 967-968. 
40 Ray, D. G.; Koser, G. F. J. Am. Chem. Soc. 1990, 112, 5672-5673. 
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reagents. 41  In 2006, the same author used a chiral benziodoxazine derivative 39 
derived from (S)-proline, in the asymmetric sulfide oxidation to produce methyl p-
tolyl sulfoxide in 84% yield and 29% ee. 42 
 
Figure 1.9 Chiral hypervalent iodine oxidants. 
In summary, chiral sulfoxides can be obtained from the oxidation of prochiral 
sulfides by using various chiral oxidants.  However, for this methodology, 
stoichiometric chiral oxidants are required and it is of preparative interest only in a 
limited number of cases. 
1.3. The Catalytic Asymmetric Syntheses of Sulfoxides 
In this section, two mains methods will be discussed for the catalytic asymmetric 
synthesis of sulfoxides including the direct sulfide oxidation in the presence of 
catalytic amount of chiral metal complexes or organocatalysts, and the novel synthetic 
strategy by using the active intermediate: sulfenate anion.  
1.3.1. Catalytic Enantioselective Sulfide Oxidation 
The catalytic enantioselective oxidation of sulfides represents the most direct 
approach and attractive method to enantiopure sulfoxides. Over the past 30 years a 
variety of catalytic systems have been developed, and some of these are now used at 
the industrial scale. The various representative families of chiral catalysts will be 
                                                     
41 Zhdankin, V. V.; Smart, J. T.; Zhao, P.; Kiprof, P. Tetrahedron Lett. 2000, 41, 5299-5302. 
42 Ladziata, U.; Carlson, J.; Zhdankin, V. V. Tetrahedron Lett. 2006, 47, 6301-6304. 
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briefly presented below, the details and developments of which are available in 
various reviews.43  
Titanium Complexes. 
In 1984, Kagan’s and Moderna’s groups independently reported the asymmetric 
sulfide oxidation using the modified Sharpless epoxidation catalysts. 44  These 
asymmetric sulfide oxidation methods represented the first practical and efficient 
oxidation methods for the metal catalyzed asymmetric oxidation of sulfides. Kagan 
and colleagues used modified Sharpless reagent (Ti(OiPr)4/(R,R)-DET/H2O/TBHP = 
1:2:1:1.) in DCM to oxidize the prochiral sulfides into optically active sulfoxides with 
75-90% ee  for alkyl aryl sulfoxides and 50-71% ee for dialkyl sulfoxides (Scheme 
1.7). By contrast, Modena et al. used a slightly different titanium system, with the 
combination Ti(OiPr)4/(R,R)-DET/TBHP = 1:4:2. Both methods used a titanium 
catalyst, (R,R)-diethyl tartrate (DET) as the chiral auxiliary, tert-butyl hydrogen 
peroxide (TBHP) as the oxidant and are carried out at -20 °C. The Modena method 
used dichloroethane (DCE) as the solvent but did not involve the addition of water to 
the oxidation. 
Scheme 1.7 Kagan’s and Modena’s method for sulfoxidation. 
                                                     
43 Legros, J.; Dehli, J. R.; Bolm, C. Adv. Synth. Catal. 2005, 347, 19-31.; Ramon, D. J.; Yus, 
M. Chem. Rev. 2006, 106, 2126-2208.; Kagan, H. B. In Organosulfur Chemistry in 
Asymmetric Synthesis; Toru, T., Bolm, C., Ed.; WILEY-VCH: Weinheim, 2008, p 1-30.; 
O'Mahony, G. E.; Kelly, P.; Lawrence, S. E.; Maguire, A. R. Arkivoc 2011, 1-110. 
44 Pitchen, P.; Kagan, H. B. Tetrahedron Lett. 1984, 25, 1049-1052.; Pitchen, P.; Dunach, E.; 
Deshmukh, M. N.; Kagan, H. B. J. Am. Chem. Soc. 1984, 106, 8188-8193.; Difuria, F.; 
Modena, G.; Seraglia, R. Synthesis 1984, 325-326. 
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Initially, the titanium complex was used in stoichiometric amounts, but a 
subsequent procedure was devised to function with sub-stoichiometric amounts (50 to 
10 mol %) by replacing water with isopropanol.45 The replacement of TBHP with 
cumyl hydroperoxide (CHP) led to a general improvement in the enantiomeric excess 
of the sulfoxide.46 When the Modena protocol was recently reinvestigated it gave 
interesting results for the enantioselective synthesis of sulfoxides using 
furylhydroperoxides instead of CHP.47  The mechanisms of the Kagan or Modena 
systems are, presumably, very similar, and NMR studies have demonstrated a great 
complexity for the species in equilibrium in solution. 48  The existence of a 
peroxotitanium species A (Scheme 1.7) has been postulated, and this has been well 
supported by the X-ray crystal structure of a peroxotitanium complex B. 49 The effect 
of water in the Kagan oxidation was also investigated by Uemura, who reported that 
too little or too much water present in the reaction could impact detrimentally on the 
enantioselectivity of the reaction.50 
The Kagan oxidation method has received more attention and has been used on 
quite large scales to prepare sulfoxides of industrial interest, either as intermediates or 
products. Some examples (4251, 4352, 4453, 4554, 4655) are listed in Figure 1.10. Von  
                                                     
45 Diter, P.; Samuel, O.; Taudien, S.; Kagan, H. B. Tetrahedron-Asymmetry 1994, 5, 549-552. 
46 Brunel, J. M.; Diter, P.; Duetsch, M.; Kagan, H. B. J. Org. Chem. 1995, 60, 8086-8088. 
47 Massa, A.; Mazza, V.; Scettri, A. Tetrahedron-Asymmetry 2005, 16, 2271-2275. 
48 Potvin, P. G.; Fieldhouse, B. G. Tetrahedron-Asymmetry 1999, 10, 1661-1672. 
49 Boche, G.; Mobus, K.; Harms, K.; Marsch, M. J. Am. Chem. Soc. 1996, 118, 2770-2771. 
50 Komatsu, N.; Nishibayashi, Y.; Sugita, T.; Uemura, S. Tetrahedron Lett. 1992, 33, 5391-
5394. 
51 Pitchen, P.; France, C. J.; Mcfarlane, I. M.; Newton, C. G.; Thompson, D. M. Tetrahedron 
Lett. 1994, 35, 485-488. 
52 Hogan, P. J.; Hopes, P. A.; Moss, W. O.; Robinson, G. E.; Patel, I. Org. Process Res. Dev. 
2002, 6, 225-229. 
53 Song, Z. G.; King, A. O.; Waters, M. S.; Lang, F. G.; Zewge, D.; Bio, M.; Leazer, J. L.; 
Javadi, G.; Kassim, A.; Tschaen, D. M.; Reamer, R. A.; Rosner, T.; Chilenski, J. R.; Mathre, 
D. J.; Volante, R. P.; Tillyer, R. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 5776-5781. 
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Figure 1.10 Applications of the Ti complexes methodology. 
Unge et al. prepared esomeprazole 46 on a multi-kilogram scale using a modification 
of the Kagan procedure but with the addition of N, N-diisopropylethylamine to the 
titanium catalyst (4 mol %) at an elevated temperature 30 °C.55 More recently, Jiang 
et al. reported a titanium-mediated oxidative preparation of esomeprazole 46 and 
similar heteromatic sulfoxides with high yield and enantioselectivity by employing a 
brominated aromatic diol as chiral auxiliary.56 Delamare et al. also reported a new 
Ti(OiPr)4/(1R, 2S)-cis-1-amnio-2-indanol system for asymmetric synthesis of (S)-
tenatoprazole 47 in high yield (>90%) and enantioselectivity (>99% ee).57 Most of the 
investigations into the Kagan-Modena oxidations have focussed on using different 
chiral auxiliaries such as diols, mandelic acid, and amino alcohol derived Schiff base 
to establish if the scope and enantioselectivity of the reaction can be improved. 
Vanadium complexes 
                                                                                                                                                        
54 Bowden, S. A.; Burke, J. N.; Gray, F.; McKown, S.; Moseley, J. D.; Moss, W. O.; Murray, 
P. M.; Welham, M. J.; Young, M. J. Org. Process Res. Dev. 2004, 8, 33-44. 
55 Cotton, H.; Elebring, T.; Larsson, M.; Li, L.; Sorensen, H.; von Unge, S. Tetrahedron-
Asymmetry 2000, 11, 3819-3825. 
56 Jiang, B.; Zhao, X. L.; Dong, J. J.; Wang, W. J. Eur. J. Org. Chem. 2009, 987-991. 
57 Delamare, M.; Belot, S.; Caille, J. C.; Martinet, F.; Kagan, H. B.; Henryon, V. Tetrahedron 
Lett. 2009, 50, 1702-1704. 
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After titanium, vanadium is the most popular metal catalyst in asymmetric sulfide 
oxidation. In 1974, Modena successfully prepared racemic sulfoixdes using TBHP as 
the oxidant and Vanadyl acetylacetonate [VO(acac)2] as the catalyst, identifying 
Vanadium(IV) as the active oxidising species present. 58  Then Fujita et al. firstly 
reported the chiral vanadium Schiff base complex 48 (Figure 1.11) catalysed 
asymmetric catalytic sulfide oxidation using CHP as the oxidant to afford sulfoxides 
with up to 40% ee. 59  
Figure 1.11 Vanadium catalysts for sulfoxidation. 
A significant improvement was introduced by Bolm et al. in 1995 by the 
preparation of highly active vanadium catalysts (used at 0.01 mol % amounts) derived 
from Schiff bases 49 and [VO(acac)2].
60 The oxidant was aqueous H2O2 (30%), and 
the sulfoxides were formed in 50 to 70% ee from aryl alkyl sulfides. Most 
significance includes the use of atmospheric conditions for the oxidation, overcoming 
the extreme sensitivity associated with titanium catalysed oxidations and the use of 
catalytic amount of vanadium catalyst (low to 0.1 mol %). Ellman et al. used the 
Bolm catalyst for the mono-oxidation of di-tert-butyldisulfide into tert-butyl tert-
butanesulfinate (90% ee) and then this reaction was subsequently optimized for large-
                                                     
58  Curci, R.; Difuria, F.; Testi, R.; Modena, G. Journal of the Chemical Society-Perkin 
Transactions 2 1974, 752-757. 
59 Nakajima, K.; Kojima, M.; Fujita, J. Chem. Lett. 1986, 1483-1486. 
60 Bolm, C.; Bienewald, F. Angew. Chem. Int. Ed. 1995, 34, 2640-2642. 
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scale production.61 Following these pioneering work, a number of Schiff base ligand 
for vanadium were investigated to afford sulfoxides with excellent enantioselectivities 
which were achieved through a combination of asymmetric oxidation and 
complimentary kinetic resolution. 62  In 2004, Zhu reported that enantioenriched 
sulfoxides could be successfully prepared by oxidising sulfides in the presence of a 
salan-oxovanadium complex using hydrogen peroxide as the oxidant. 63  After 
screening a number of salan ligands, ligand 50 was found to be the optimum ligand 
for this oxidation method. 
Manganese Complexes 
In 1991, Halterman et al. firstly reported the enantioselective oxidation of sulfides 
by iodosylbenzene in the presence of 0.5 mol % of a D4 symmetric manganese 
tetraphenylporphyrin catalyst; the oxidation gave chemical yield above 82% and 
enantioselectivities ranging from 40 to 68% ee.64 The family of Salen manganese (III) 
provided some active enantioselective catalysts (Figure 1.12). Jacobsen was the first 
one to successfully report a manganese-salen catalyst 51 in asymmetric sulfide 
oxidation using hydrogen peroxide as the oxidant, although only moderate 
enantioselectivity (34-68% ee) was observed. 65  Later, Katsuki et al. prepared the 
                                                     
61 Liu, G. C.; Cogan, D. A.; Ellman, J. A. J. Am. Chem. Soc. 1997, 119, 9913-9914.; Weix, D. 
J.; Ellman, J. A. Abstr. Pap. Am. Chem. Soc. 2003, 226, U150-U150. 
62 Kelly, P.; Lawrence, S. E.; Maguire, A. R. Synlett 2006, 1569-1573.; Kelly, P.; 
Lawrence, S. E.; Maguire, A. R. Eur. J. Org. Chem. 2006, 2006, 4500-4509.; Wu, Y. 
O.; Liu, J. T.; Li, X. S.; Chan, A. S. C. Eur. J. Org. Chem. 2009, 2607-2610. 
63 Sun, J. T.; Zhu, C. J.; Dai, Z. Y.; Yang, M. H.; Pan, Y.; Hu, H. W. J. Org. Chem. 
2004, 69, 8500-8503. 
64 Halterman, R. L.; Jan, S. T.; Nimmons, H. L. Synlett 1991, 791-792. 
65 Palucki, M.; Hanson, P.; Jacobsen, E. N. Tetrahedron Lett. 1992, 33, 7111-7114. 
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Salen–manganese complexes 52, 5366 and catalyzed the enantioselective oxidation of 
sulfides with ee-values of up to 90% (2-nitrophenyl methyl sulfoxide) with 
iodosobenzene as oxidant. Mukaiyama et al. have also studied the family of b-oxo 
aldiminato Mn(III) complex 54 using the combination pivaladehyde/molecular 
oxygen as an oxidant system. In this way, methyl ortho-bromophenyl sulfoxide was 
obtained in 70% ee.67 
    
Figure 1.12 Manganese catalysts for sulfoxidation. 
Iron Complexes 
Ideally, in catalysis, the catalyst used would be cheap and non-toxic, hence iron is 
attractive among the transition metals. In 1990, Groves and Viski developed a chiral 
iron(III) porphyrins as the highly active catalyst of sulfoxidation to afford the 
                                                     
66 Noda, K.; Hosoya, N.; Irie, R.; Yamashita, Y.; Katsuki, T. Tetrahedron 1994, 50, 9609-
9618.; Noda, K.; Hosoya, N.; Yanai, K.; Irie, R.; Katsuki, T. Tetrahedron Lett. 1994, 35, 
1887-1890.; Kokubo, C.; Katsuki, T. Tetrahedron 1996, 52, 13895-13900. 
67 Nagata, T.; Imagawa, K.; Yamada, T.; Mukaiyama, T. Bull. Chem. Soc. Jpn. 1995, 68, 
3241-3246. 
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sulfoxides with only modest enantioselectivity. 68 A successful approach was 
developed by Bolm et al. in 2003, who used 35% aqueous hydrogen peroxide and an 
iron complex (2 mol %) derived from Fe(acac)3 and the Schiff base 55 (Figure 
1.13).69 This protocol was further improved by the introduction of an additive of 10 
mol % p-methoxybenzoic acid. 70  Enantioenriched Sulindac has been successfully 
prepared using this iron catalyzed asymmetric sulfide oxidation.71 Later, Katsuki and 
Egami used a novel chiral Fe(salen) complex 56 (1 mol %) for asymmetric oxidation 
of sulfides using hydrogen peroxide in water.72 Not only alkyl aryl sulfides but also 
various methyl alkyl sulfides were oxidized to the corresponding sulfoxides with high 
enantioselectivities up to 96% ee. It should be noted that the turnover number of 
complex 56 amounts to 8000. Recently, List group reported the oxidization of various 
sulfides with high yields and enantioselectivities employing the concept of 
asymmetric counteranion-directed catalysis 57 which consists of an achiral iron (III)-
salen cation and a chiral phosphate counter anion.73 
Figure 1.13 Iron catalysts for sulfoxidation. 
                                                     
68 Groves, J. T.; Viski, P. J. Org. Chem. 1990, 55, 3628-3634. 
69 Legros, J.; Bolm, C. Angew. Chem., Int. Ed. 2003, 42, 5487-5489. 
70 Legros, J.; Bolm, C. Angew. Chem., Int. Ed. 2004, 43, 4225-4228.; Legros, J.; Bolm, C. 
Chem.Eur. J. 2005, 11, 1086-1092. 
71 Korte, A.; Legros, J.; Bolm, C. Synlett 2004, 2397-2399. 
72 Egami, H.; Katsuki, T. J. Am. Chem. Soc. 2007, 129, 8940-8941.; Egami, H.; Katsuki, T. 
Synlett 2008, 1543-1546. 
73 Liao, S.; List, B. Adv. Synth. Catal. 2012, 354, 2363-2367. 
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Besides the mentioned four classes of chiral metal catalysts, more metal complexes 
have been designed for the asymmetric oxidation of sulfides. In 2003, Thakur and 
Sudalai reported a heterogeneous tungsten catalyst in asymmetric sulfide oxidation.74 
Using WO3 and a cinchona alkaloid (DHQD)2-PYR 57 (Figure 1.14) as the catalyst 
and aqueous hydrogen peroxide as the oxidant, sulfoxides with up to 65% ee were 
isolated in good yield. This system allowed the asymmetric synthesis (84% yield, 88% 
ee) of (R)-lansoprazole, an anti-ulcer drug. While the results obtained were modest in 
comparison to other oxidation methods, this represented the first successful  
            
Figure 1.14 Other catalyst systems for sulfoxidation. 
asymmetric sulfide oxidation catalyzed by tungsten. Recently, Katsuki and co-
workers also developed a chiral aluminium-salalen complex 58 as the catalyst in 
sulfoxidation to give the sulfoxides with ee-values in the range of 97 to 99%.75 The 
oxidation was run in methanol with 2 mol % catalyst, a phosphate buffer (pH 7.4) and 
1.1 equiv. 30% (v/v) H2O2, along with the formation of over-oxidized product sulfone 
between <1% and 10% according to the substrate. The results obtained compare very 
favourably to existing methods, and furthermore the solvents and oxidant employed 
make this a very “green” reaction. Many new approaches to catalytic sulfoxidation 
                                                     
74 Thakur, V. V.; Sudalai, A. Tetrahedron-Asymmetry 2003, 14, 407-410. 
75 Matsumoto, K.; Yamaguchi, T.; Fujisaki, J.; Saito, B.; Katsuki, T. Chemistry-an Asian 
Journal 2008, 3, 351-358. 
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has been proposed by applying transition metal complexes based on such as copper76, 
niobium77, osmium78, zirconium79, molybdenum80, although the yields and overall 
enantioselectivities are modest compared with other available methods. 
Organocatalysts 
Whereas remarkable progress has been made in recent years in developing 
transition-metal-based methodologies for sulfide oxidations employing different 
sources of oxygen donors, less work has yet been devoted to developing metal-free 
and catalytic approaches to this oxidation process. A good review about recent 
advances on this topic was reported by Tsogoeva and coworkers.81 Among them, 
organocatalytic processes, in which small chiral organic molecules catalyse reactions, 
generally have shown their broad utility and advantages, namely, reduced toxicity, 
stability, and availability of the catalysts as well as less demanding reaction 
conditions.  
In 2005, Colonna and Malacria employed an in situ-generated chiral dioxirane 59 
(from fructose-derived ketone and Oxone) for the enantioselective synthesis of 
thiosulfinates as well as for acyclic alkylidenemethylene sulfide sulfoxides.82  The 
same reaction conditions as used for the Shi-epoxidation led to moderate to high 
conversions (66–98%) and an enantiomeric excess of up to 75% ee for a selection of 
different substrates in solvent mixture of CH3CN and Dimethoxymethane (DMM) at 
                                                     
76 Kelly, P.; Lawrence, S. E.; Maguire, A. R. Synlett 2007, 1501-1506. 
77 Miyazaki, T.; Katsuki, T. Synlett 2003, 1046-1048 
78 Kantam, M. L.; Prakash, B. V.; Bharathi, B.; Reddy, C. V. Journal of Molecular Catalysis 
a-Chemical 2005, 226, 119-122. 
79 Bonchio, M.; Licini, G.; Di Furia, F.; Mantovani, S.; Modena, G.; Nugent, W. A. J. Org. 
Chem. 1999, 64, 1326-1330. 
80 Bonchio, M.; Carofiglio, T.; Difuria, F.; Fornasier, R. J. Org. Chem. 1995, 60, 5986-5988.; 
Basak, A.; Barlan, A. U.; Yamamoto, H. Tetrahedron-Asymmetry 2006, 17, 508-511. 
81 Stingl, K. A.; Tsogoeva, S. B. Tetrahedron: Asymmetry 2010, 21, 1055-1074. 
82 Colonna, S.; Pironti, V.; Drabowicz, J.; Brebion, F.; Fensterbank, L.; Malacria, M. Eur. J. 
Org. Chem. 2005, 1727-1730. 
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0 °C. The mono-oxidation of S,S-ketene acetals using 2.1 equiv of KHSO5 led to 70% 
yield of the monosulfoxide and 46% ee as minor products of disulfoxides were also 
observed (Scheme 1.8). 
Scheme 1.8 Chiral ketone catalyzed sulfoxidation. 
The first attempt for a bio-mimetic catalytic asymmetric sulfoxidation using a 
planar chiral flavophene 60 was reported by Shinkai et al. in 1988.83 With 35% 
aqueous H2O2 as the oxygen source about 10 mol % 60 relative to the aryl methyl 
sulfides and in a solvent mixture of H2O/MeOH at -20 °C up to 65% ee and turnover 
numbers of up to 8 of the corresponding enantiomerically enriched product sulfoxides 
could be achieved in 5 days (Scheme 1.9). This becomes possible because the planar  
  
Scheme 1.9 Planar chiral flavin catalyzed sulfoxidation. 
                                                     
83  Shinkai, S.; Yamaguchi, T.; Manabe, O.; Toda, F. Journal of the Chemical Society-
Chemical Communications 1988, 1399-1401. 
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chirality of 60 is firmly maintained through the oxygenation cycle. When the 
flavinmiun salt 60 was treated with aqueous H2O2, the corresponding hydroperoxides 
61 was generated, which was used for oxidation of sulfide 63 to sulfoxide 64. The 
flavin pseudo-base 62 is thought to be unstable in its neutral form but tautomerizes to 
the more stable flavinmiun cation 60 with elimination of water.  
Following this work, Cibulka and Kraus developed the β-Cyclodextrin–flavin 
conjugates 65 (Figure 1.15) as highly efficient catalysts for the sulfoxidation of 
methyl phenyl sulfides with hydrogen peroxide in neat aqueous media operating at 
loadings down to 0.2 mol % and allowing for enantioselectivities up to 80% ee.84  
                    
Figure 1.15 Flavin–Cyclodextrin conjugates. 
They also prepared four structurally different alloxazine–cyclodextrin conjugates 
66 as catalysts for the enantioselective oxidation of prochiral sulfides to sulfoxides by 
hydrogen peroxide in aqueous solutions.85 They found that α-Cyclodextrin conjugate 
having alloxazinium unit attached via a short linker proved to be a 
                                                     
84 Mojr, V.; Herzig, V.; Budesinsky, M.; Cibulka, R.; Kraus, T. Chem. Commun. 2010, 46, 
7599-7601. 
85 Mojr, V.; Budesinsky, M.; Cibulka, R.; Kraus, T. Org. Biomol. Chem. 2011, 9, 7318-7326. 
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suitable catalyst for oxidationsof n-alkyl methyl sulfides, displaying conversions up to 
98% and enantioselectivities up to 77% ee, while β-Cyclodextrin conjugates were 
optimal catalysts for the oxidation of sulfides carrying bulkier substituents; e.g. tert-
butyl methyl sulfide was oxidized with quantitative conversion and 91% ee. Low 
loadings (0.3-5 mol %) of the catalysts were used. No over-oxidation to sulfones was 
observed in this study. 
Recently, Wang group first reported chiral Brønsted acid catalyzed asymmetric 
sulfide oxidation through the electrophilic activation of hydrogen peroxide toward 
nucleophilic prochiral sulfides (Figure 1.16).86 (R)-1,1′-Binaphthyl-2,2′-diol (R-
BINOL) derived chiral phosphoric acid 67 was used as organocatalysts for the 
asymmetric oxidation of a series of aryl alkyl sulfides and 1, 3-dithianes derived from 
aldehydes with aqueous hydrogen peroxide (H2O2) as the terminal oxidant. The  
  
Figure 1.16 Chiral Brønsted acid catalysts for sulfoxidation. 
enantiomerically enriched sulfoxides are obtained in moderate to excellent yield (up 
to 99%) with excellent diastereoselectivity (up to >99:1 dr) and moderate to good 
enantioselectivity (up to 91:9 er). In particular, the present protocol stereoselectively 
provides an efficient access to enantiomerically enriched aryl alkyl sulfoxides and 
                                                     
86 Liu, Z.-M.; Zhao, H.; Li, M.-Q.; Lan, Y.-B.; Yao, Q.-B.; Tao, J.-C.; Wang, X.-W. Adv. 
Synth. Catal. 2012, 354, 1012-1022. 
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dithioacetal mono-sulfoxides, which strictly restrains the formation of the undesirable 
by-products: sulfones or disulfoxides. The tracking experiments also verify that this 
approach proceeds via a direct sulfoxidation process, instead of a kinetic resolution 
route by overoxidation of the resulting sulfoxides. In the same year, List group also 
reported the confined a chiral Brønsted acid 68 (Figure 1.16) catalysed highly 
enantioselective oxidations of sulfides to sulfoxides with hydrogen peroxide.87 The 
obtained levels of enantioselectivity are the highest reported to date for 
organocatalytic sulfoxidation and also rival those of the best metal-catalyzed 
approaches. 
1.3.2. Asymmetric Syntheses of Sulfoxides via Sulfenate Anions  
In contrast to the usefulness of other sulfur nucleophiles, sulfenate anions RSO–
have relatively little synthetic utility, as they are generally not isolable species and 
suffer from a lack of efficient methods for their generation.88 Notwithstanding this 
concern, increased exploration and recent advances with sulfenates have facilitated 
access to increasingly challenging targets. 89, 90 Modern developments in the in situ 
generation of sulfenates involve a sulfur oxidation protocol, 91  fluoride induced 
desilylative fragmentation chemistry 92 and an addition/elimination reaction of the β-
                                                     
87 Liao, S.; Coric, I.; Wang, Q.; List, B. J. Am. Chem. Soc. 2012, 134, 10765-10768. 
88 Kharasch, N.; Potempa, S. J.; Wehrmeister, H. L. Chem. Rev. 1946, 39, 269-332. 
89 O'Donnell, J. S.; Schwan, A. L. J. Sulfur Chem. 2004, 25, 183-211. 
90 Maitro, G.; Prestat, G.; Madec, D.; Poli, G. Tetrahedron-Asymmetry 2010, 21, 1075-1084. 
91 Sandrinelli, F.; Perrio, S.; Beslin, P. J. Org. Chem. 1997, 62, 8626-8627.; Sandrinelli, F.; 
Fontaine, G.; Perrio, S.; Beslin, P. J. Org. Chem. 2004, 69, 6916-6919.; Sandrinelli, F.; 
Boudou, C.; Caupene, C.; Averbuch-Pouchot, M. T.; Perrio, S.; Metzner, P. Synlett 2006, 
3289-3293. 
92 Oida, T.; Ohnishi, A.; Shimamaki, T.; Hayashi, Y.; Tanimoto, S. Bull. Chem. Soc. Jpn. 
1991, 64, 702-704.; Foucoin, F.; Caupene, C.; Lohier, J. F.; Santos, J. S. D. O.; Perrio, S.; 
Metzner, P. Synthesis 2007, 1315-1324. 
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sulfinyl acrylates.93 However, very few of these reported approaches are efficient with 
a broad spectrum of applicability. 
As described in previous sections, two main methods are dominant in the field of 
organic synthesis of enantioenriched sulfoxides. On the other hand, the preparation of 
sulfoxides via the alkylation reaction of sulfenate anions remains sporadic. However, 
the development of complementary and conceptually different routes to chiral 
sulfoxides, such as via alkylation of sulfenates, remains a subject of both relevant 
synthetic and fundamental interest.94 
In 2005, Perrio and co-workers developed a general, efficient, and experimentally 
simple method for the generation of sulfenate salts which is based on a base-promoted 
retro-Michael reaction (Scheme 1.10).95 This is the first example about utilizing this 
process to generate the sulfenate anions using β-sulfinylesters as substrates. By 
introduction of an enantiopure ligand, (-)-sparteine, this allowed an asymmetric 
extension of the methodology, and up to 29% ee value was achieved. Though this 
novel route to enantioenriched sulfoxides does not compete favourably with the 
classic repertoire, it has demonstrated the feasibility of the approach. 
         
Scheme 1.10 Asymmetric alkylation of sulfenate anions. 
                                                     
93 O'Donnell, J. S.; Schwan, A. L. Tetrahedron Lett. 2003, 44, 6293-6296. 
94 Gelat, F.; Jayashankaran, J.; Lohier, J. F.; Gaumont, A. C.; Perrio, S. Org. Lett. 2011, 13, 
3170-3173. 
95 Caupene, C.; Boudou, C.; Perrio, S.; Metzner, P. J. Org. Chem. 2005, 70, 2812-2815. 
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Later, in 2007, the other group, Poli, Madec and their colleagues reported the first 
asymmetric transition-metal-catalysed arylation of sulfenate anions generated using 
the same strategy (Scheme 1.11).96 In the presence of palladium (0) and enantiopure 
ligands, arylation of various sulfenate anions gave the corresponding aryl sulfoxides 
in enantioenriched form, allowing up to 80% ee. 
Scheme 1.11 Asymmetric arylation of sulfenate anions. 
Recently, a novel route to chiral sulfoxides based on the asymmetric alkylation of 
sulfenate salts with alkyl halides mediated by a Cinchona-derived phase-transfer 
catalyst (PTC) has been described by Perrio group.94, 97 Sulfoxides were produced in 
high yields and moderate enantioselectivities (up to 58%) by using commercial 
cinchonidinium derivatives 69 (Scheme 1.12) and β-sulfinyl sulfones as the substrates.  
                   
Scheme 1.12 PTCs catalyzed alkylation of sulfenate anions. 
                                                     
96 Maitro, G.; Vogel, S.; Sadaoul, M.; Prestat, G.; Madec, D.; Poli, G. Org. Lett. 2007, 9, 
5493-5496. 
97 Gelat, F.; Gaumont, A.-C.; Perrio, S. J. Sulfur Chem. 2013, 1-9. 
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Although only moderate results were achieved, the development of carbon-
heteroatom bond formations will expand the reaction scope of phase-transfer catalysis 
in asymmetric synthesis.  
The mechanistic proposal they suggested for the overall process in the presence of 
chiral phase transfer catalyst involves the following cascade reactions: (i) upon 
treatment with an inorganic base, deprotonation of precursors at the interface of the 
two immiscible phases followed by β-fragmentation and liberation of the sulfenates, 
(ii) cation exchange with the chiral ammonium salt to afford a lipophilic species with 
extraction to the organic layer, (iii) and finally reaction with the alkyl halide to give 
the sulfoxides.94 They also hypothesized that if a tight ion pair with the quaternary 
ammonium salt is formed, the discrimination of two enantiotopic lone pairs of the 
sulfenate during the final alkylation step and hence formation of an enantioenriched 
sulfoxide product can be realized.  
So far, there are only two reports about this methodology for synthesis of 
enantioenriched sulfoxides. Due to the moderate enantioselectivities, it is still 
desirable to design efficient phase-transfer catalysts to facilitate higher stereocontrol 
through multi-noncovalent interactions between the sulfenate anions and the catalysts. 
In summary, several approaches for synthesis of chiral sulfoxides were described at 
length; meanwhile, their advantages and limitations were illustrated respectively. 
Overall, these methodologies are complementary to each other and further 
development is still desirable to realise the efficiently synthesis of various enantiopure 
sulfoxides. 
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2.1. Introduction 
2.1.1. General Introduction to Phase Transfer Catalysis 
In 1971, Starks introduced the concept of phase-transfer catalysis as an alternative 
solution to the heterogeneity problem in the reactions between two substances located 
in different immiscible phase.1 According to definition, Phase-transfer catalyst is an 
agent which brings about reaction and transfers one reactant across the interface into 
the other phase so that reaction can proceed. The phase-transfer agent is catalytic and 
not consumed but performs the transport function repeatedly. For instance, the 
displacement reaction of alkyl halides in an organic phase with sodium cyanide in an 
aqueous phase that are totally inhibited because of phase separation is strongly 
accelerated by adding trace amount of tetralkylphosphonium salt. The catalysis is 
believed to be due to phosphonium salts to repeatedly bring the cyanide anion into 
organic phase by forming a quaternary phosphonium cyanide complex which makes 
the cyanide anion sufficiently nucleophilic and suitable for reaction. 
Actually, during the mid to late 1960s, Starks together with Makosza and 
Brandstrom had reported the catalytic activity of quaternary onium salts,2 which was 
the starting point of phase-transfer catalysis. Since then, numerous outstanding 
achievements and steady growth of phase-transfer catalysis (PTC) have been realized. 
Nowadays, it has become one of important techniques for chemists in organic 
synthesis and also in industrial applications, benefitting from its simple experimental 
operations, mild and easy-to-handle reaction conditions, inexpensive and 
environmentally benign reagents and solvents, high efficiencies and the possibility to 
                                                     
1 Starks, C. M. J. Am. Chem. Soc. 1971, 93, 195-199. 
2 Makosza, M. Tetrahedron Lett. 1966, 5489-5492.; Makosza, M. Tetrahedron Lett. 1966, 
4621-4624.; Makosza, M. Tetrahedron Lett. 1969, 673-676.; Makosza, M. Tetrahedron Lett. 
1969, 677-678.; Brändström, A. Adv. Phys. Org. Chem. 1978, 15, 267-330. 
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conduct large-scale preparations. Asymmetric phase-transfer catalysis based on the 
use of structurally well-defined chiral catalysts has become a topic of great scientific 
interest in the last two decades. For instance, the discovery of chiral phase-transfer 
catalysts derived from cinchona alkaloids in 1980s,3 make phase-transfer catalysis 
step into a new era. Many excellent books and reviews on synthetic methods using  
Figure 2.1 Representative chiral phase-transfer catalysts. 
elegantly designed phase-transfer catalyst have been published.4 The representative 
catalysts based on various chiral active motifs such as cinchona alkaloids, ephedrine, 
tartrate, crown-ether, and binaphthyl are depicted in Figure 2.1. 
                                                     
3 Dolling, U. H.; Davis, P.; Grabowski, E. J. J. J. Am. Chem. Soc. 1984, 106, 446-447.; 
O'Donnell, M. J.; William, D. B.; Wu, S. J. Am. Chem. Soc. 1989, 111, 2353–2355. 
4 Starks, C. M.; Liotta, C. L.; Halpern, M. Phase-Transfer Catalysis: fundamentals, 
applications & industrial perspectives; Chapman & Hall: New York, 1934.; Sasson, Y.; 
Neumann, R. Handbook of Phase Transfer Catalysis; Blackie Acadamic & Professional: 
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The detailed mechanisms of these processes involving phase-transfer catalysis have 
been the subject of a great deal of controversy and various mechanisms have been 
suggested. Generally, there are two main different proposed mechanisms accounting 
for the catalytic ability of phase-transfer catalyst, namely Starks extraction 
mechanism5 (Scheme 2.1) and the Makosza interfacial mechanism6  (Scheme 2.2). 
Take the chiral onium cationic phase-transfer catalyst as an example, the phase-
transfer catalyst moves back and forth across the organic and aqueous phases in the 
Starks extraction mechanism. The onium salt equilibrates with the inorganic base in 
the aqueous phase, and extracts hydroxide into the organic phase. The onium 
hydroxide then abstracts hydrogen from the acidic organic compound to give the 
reactive intermediate Q+R- which is the actually active nucleophile for further 
transformation. 
 
Scheme 2.1 Starks extraction mechanism. 
An alternative pathway in Makosza interfacial mechanism is the first formation 
metal carbanion M+R-  at the interface of organic and aqueous phase in the absence of 
phase-transfer catalyst, followed by the extraction of this active species form the 
interface into the organic phase by the onium cationic phase-transfer catalyst. 
                                                                                                                                                        
London, 1997.; Ojima, I. Catalytic Asymmetric Synthesis; 3rd ed.; Wiley: Hoboken, New 
Jersey, 2010.; Maruoka, K. Asymmetric Phase Transfer Catalysis; Wiley-VCH: Weinheim, 
Germany, 2008.; Ooi, T.; Maruoka, K. Angew. Chem., Int. Ed. 2007, 46, 4222-4266.; 
Hashimoto, T.; Maruoka, K. Chem. Rev. 2007, 107, 5656-5682.; O'Donnell, M. J. Acc. Chem. 
Res. 2004, 37, 506-517.; Shirakawa, S.; Maruoka, K. Angew. Chem., Int. Ed. 2013, 52, 4312-
4348. 
5 Starks, C. M. J. Am. Chem. Soc. 1971, 93, 195-199. 
6 Makosza, M. Pure Appl. Chem. 1975, 43, 439-462. 
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Depending on different reaction systems and conditions, both of the proposed 
mechanisms can be plausible for the processes involving the use of phase-transfer 
catalyst.7  
 
Scheme 2.2 Makosza interfacial mechanism. 
2.1.2. Recent Representative Advances in Phase Transfer Catalysis 
Oxidation by Potassium Permanganate (KMnO4) 
Conventional methods for using permanganate as an oxidant for organic substances 
are severely limited by the lack of solvents that can dissolve permanganate salts 
without excessive oxidation of the solvent itself. Fortunately, the PTC technique can 
eliminate the solvent problem because permanganate anion is able to transfer from 
aqueous or solid phase to organic solution in the phase transfer conditions. This 
methodology is well known for its application in oxidation of olefins, alkynes, 
alcohols, sulfides and alkyl-aromatic hydrocarbons with cheap and nontoxic KMnO4 
as oxidant. 8  For asymmetric processes, Brown and co-workers reported the 
Asymmetric phase-transfer dihydroxylation of α, β-unsaturated ketones using chiral 
quaternary ammonium salt 79 as catalyst and KMnO4 as oxidant (Scheme 2.3a).
9 
Although the initial enantioselectivities obtained are good, relatively large quantities 
                                                     
7 Rabinovitz, M.; Cohen, Y.; Halpern, M. Angew. Chem., Int. Ed. 1986, 25, 960-970. 
8  Starks, C. M.; Liotta, C. L.; Halpern, M. Phase-Transfer Catalysis: fundamentals, 
applications & industrial perspectives; Chapman & Hall: New York, 1934. 
9 Bhunnoo, R. A.; Hu, Y. L.; Laine, D. I.; Brown, R. C. D. Angew. Chem., Int. Ed. 2002, 41, 
3479-3480. 
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of the chiral quaternary ammonium salt are required. And this methodology also 
works for asymmetric oxidative cyclization of 1,5-dienes under slightly acidic 
conditions to promote the intramolecular ring closure (Scheme 2.3b).10 The reaction is 
unusual in that up to four new stereocenters are created with control of relative and 
absolute stereochemistry in a single synthetic step from an achiral starting material. 
 Scheme 2.3 Phase-transfer promoted asymmetric oxidation by KMnO4. 
Chiral Quaternary Ammonium (hypo)Iodite 
Over the past two decades, hypervalent iodine compounds have been the focus of 
great attention as environmentally benign oxidation reagents in place of rare or toxic 
heavy metal oxidants. 11  Recently, several chiral hypervalent iodine-catalysed 
enantioselective oxidation reactions with co-oxidant have been reported. An 
impressive example is the enantioselective oxidative cycloetherification of 
ketophenols to 2-acyl-2,3-dihydrobenzofuran derivatives catalysed by in situ-
generated C2-symmetric chiral binaphthyl-based quaternary ammonium (hypo)iodite 
with hydrogen peroxide or tert-butyl hydroperoxide (TBHP)(Scheme 2.4).12  Based 
                                                     
10 Brown, R. C. D.; Keily, J. F. Angew. Chem., Int. Ed. 2001, 40, 4496-4498. 
11 Uyanik, M.; Ishihara, K. Chimica Oggi-Chemistry Today 2011, 29, 18-21 
12 Uyanik, M.; Okamoto, H.; Yasui, T.; Ishihara, K. Science 2010, 328, 1376-1379. 
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on the control experiments, the authors proposed a catalytic cycle involving the chiral 
quaternary ammonium hypoiodite (R4N
+IO-) or iodite (R4N
+IO2
-), which should be  
Scheme 2.4 Possible reaction pathway for oxidative cycloetherification. 
generated in situ from quaternary ammonium iodide (R4N
+I-) 80 and co-oxidant 
(Scheme 2.4). They speculated that enolate intermediate A or B might be generated at 
the initial stage of the reaction, which is the enantiodiscrimination step. If A is a real 
active intermediate, the product is obtained from A through cycloaddition of enolate 
to the oxygen atom of phenyl (hypo)iodite (via path a) or the intramolecular iodine-
transfer reaction of A gives intermediate C or D (path b). The enantioenriched 
cycloether product is obtained through intramolecular SN2 addition of ammonium 
phenoxide C or reductive elimination of D with inversion or retention of 
stereochemistry. If B is a real active intermediate, the enantioenriched cycloether 
product is obtained through enantioselective intramolecular SN2' reaction of 
ammonium phenoxide B. The most important features of this new organocatalytic 
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system are the first use of H2O2 or TBHP as a green co-oxidant in asymmetric iodine 
catalysis and low catalyst loading to 1 mol %. 
Cooperative Phase-Transfer Catalyst 
The use of bifunctional phase-transfer catalyst has become one of the promising 
strategies to achieve highly enantioselective demanding reaction under mild 
conditions.13 The simultaneous activation and coordination of two reaction partners 
with a chiral bifunctional catalyst allows the formation of a highly ordered transition 
state responsible for high enantioselectivities. This concept has been applied for 
decades and the beneficial effect of an additional catalytically active coordination site 
in phase-transfer catalysis has been demonstrated in many research reports. 
For example, in 2005, Maruoka group reported the ammonium salt-catalysed 
stereoselective Michael addition of malonates 83 chalcone derivatives 84. To indicate 
the importance of the hydroxyl groups as an additional recognition site for the 
electrophile trough hydrogen bonding interaction, the performances of two catalyst 85 
and 86 were detected. The catalyst 86 without hydroxyl group led a drastic decrease 
in enantioselectivity (15 % instead of 96 %) of product in comparison with that of 85 
(Scheme 2.5).14  
                                                     
13 Novacek, J.; Waser, M. Eur. J. Org. Chem. 2013, 2013, 637-648. 
14 Ooi, T.; Ohara, D.; Fukumoto, K.; Maruoka, K. Org. Lett. 2005, 7, 3195-3197. 
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Scheme 2.5 Bifuctional Maruoka-type phase transfer catalyst for Michael reaction. 
Although the use of bifunctional onium salts phase transfer catalysts containing 
free OH group has proven its potential for almost three decades now, surprisingly 
only a few reports described the use of other common hydrogen-bonding donors such 
as (thio)ureas in combination with chiral onium salts has so far published. This may 
be due to the challenge in synthesis of these catalysts and thus this explains why this 
strategy is still in its infancy.15  The first synthesis and application of a thiourea-
containing cinchona alkaloid base quaternary ammonium salt was reported by 
Fernandez and Lassaletta et al. in 2010. 16  They investigated the combined 
bifunctionanl catalyst 87 aiming to improve the stereocontrol and the activity. 
Fortunately, this thiourea-ammonium cyanide catalyst can promote the asymmetric 
cyanosilylation of a broad scope of nitroalkenes in high yield with good 
enantioselectivities (Scheme 2.6).  
                                                     
15 Novacek, J.; Waser, M. Eur. J. Org. Chem. 2013, 2013, 637-648. 
16 Bernal, P.; Fernandez, R.; Lassaletta, J. M. Chem.Eur. J. 2010, 16, 7714-7718. 
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Scheme 2.6 Cyanosilylation of nitroalkenes by using of thiourea-ammonium salt. 
In contrast to ammonium centered phase-transfer catalysts, examples with 
phosphonium centered PTCs are rather limited which might due to its instability 
under basic condition. Recent progress in the field includes the binaphthyl-modified 
quaternary phosphonium catalyst and the P-spiro tetraaminophosphonium catalysts 
which significantly expanded the application of phase-transfer catalysis.  In 2013, 
Zhao group17 developed new chiral bifunctional thiourea-phosphonium salts based on 
natural amino acids as highly efficient phase-transfer catalysts for asymmetric aza-
Henry reaction. Based on the control experiments results, they emphasized the 
importance of the cooperative catalysis of these bifunctional thiourea-phosphonium 
salts in this type of catalytic system through dual hydrogen-bonding and electrostatic 
interactions (Scheme 2.7).  
                                                     
17 Cao, D.; Chai, Z.; Zhang, J.; Ye, Z.; Xiao, H.; Wang, H.; Chen, J.; Wu, X.; Zhao, G. Chem. 
Commun. 2013, 49, 5972-5974. 
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Scheme 2.7 Cooperative thiourea-phosphonium PTC in aza-Henry reaction. 
Another impressive catalysis concept is the use of chiral betaines which has been 
introduced over the last years. Betaines can be defined as neutral compounds with an 
onium cationic centre bearing no hydrogen atom and an additional anionic 
functionality that is not directly adjacent to the onium group. The pioneering work 
mainly came from Ooi group18 and Gong group also contributed to the development 
of this field.19  The proposed active mode is illustrated in Figure 2.2.  
                                                              
Figure 2.2 Proposed active mode by using of chiral betaines.   
 A chiral ammonium betaine such as 89, 90 (Figure 2.3) containing a basic anion 
could be capable of deprotonating a pronucleophile to from an ion pair. Meanwhile, 
                                                     
18  Uraguchi, D.; Koshimoto, K.; Ooi, T. J. Am. Chem. Soc. 2008, 130, 10878-10879.; 
Uraguchi, D.; Koshimoto, K.; Miyake, S.; Ooi, T. Angew. Chem., Int. Ed. 2010, 49, 5567-
5569.; Uraguchi, D.; Koshimoto, K.; Sanada, C.; Ooi, T. Tetrahedron: Asymmetry 2010, 21, 
1189-1190.; Uraguchi, D.; Koshimoto, K.; Ooi, T. Chem. Commun. 2010, 46, 300-302.; 
Uraguchi, D.; Oyaizu, K.; Ooi, T. Chem.Eur. J. 2012, 18, 8306-8309.; Uraguchi, D.; 
Koshimoto, K.; Ooi, T. J. Am. Chem. Soc. 2012, 134, 6972-6975. 
19 Zhang, W. Q.; Cheng, L. F.; Yu, J.; Gong, L. Z. Angew. Chem., Int. Ed. 2012, 51, 4085-
4088. 
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together with an additional coordination with the nucleophile through hydrogen 
bonding, these combinational interactions will promote the formation of a highly 
ordered chiral phase-transfer catalyst-nucleophile ion pair. This type of catalyst works 
well in many asymmetric reactions with excellent enantioselectivity, such as Mannich, 
Aldol, and Aza-Henry reactions and so on. 
                  
Figure 2.3 Chiral betaines as phase-transfer catalysts.  
Chiral Anionic Phase-Transfer Catalyst 
As demonstrated previously, most of the prevalent phase-transfer catalyst is based 
on the chiral cationic centres which can activate or interact with the nucleophilic 
intermediates through ion-pairing.  Therefore, in principle it is reasonable to envisage 
that any reaction involving prochiral, cationic intermediates can be conducted 
enantioselectively as a result of generation of chiral ion pairs in the presence of chiral 
anionic phase-transfer catalyst.20,21 In 2003, Nelson group reported their initial effort 
to investigate the stereoselective induction ability of chiral borates in the reactions of 
prochiral cationic intermediates.20 For example, in the ring-opening of an aziridinium 
                                                     
20 Carter, C.; Fletcher, S.; Nelson, A. Tetrahedron: Asymmetry 2003, 14, 1995-2004. 
21  Lacour, J.; Hebbe-Viton, V. Chem. Soc. Rev. 2003, 32, 373-382.; Llewellyn, D. B.; 
Arndtsen, B. A. Tetrahedron:Asymmetry 2005, 16, 1789-1799.; Pan, S. C.; List, B. 
Organocatalysis 2008, 2, 1-43. 
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ion (1,2-diphenyl-3-azonia-spiro [2.4]heptane) with benzylamine, low, but significant, 
(<15%) enantioselectivities were induced in the formation of the diamine. The 
enantiomeric excesses measured were generally higher than the inherent errors 
associated with each measurement. Therefore, the results demonstrated that chiral 
borate anion such as 91 have an effect on the sense, as well as the level, of the chiral 
induction (Figure 2.4).   
                                                                                                   
Figure 2.4 The attempt for asymmetric anionic phase-transfer catalysis. 
Subsequently, this new strategy attracted increasing attention and various anionic 
phase-transfer catalysts were developed. The remarkable progress has been made 
mainly by Toste’s group 22 and List’s group.23 Recently, Rauniyar et al. reported on 
an efficient fluorocyclization reaction that converts achiral compounds containing 
double bond into chiral fluorine derivatives using an anionic chiral phase-transfer 
catalyst (Scheme 2.8).24 The lipophilic, bulky chiral phosphate anion, generated in 
situ by treating the corresponding phosphoric acid 92a with an inorganic base, could 
                                                     
22 Hamilton, G. L.; Kang, E. J.; Mba, M.; Toste, F. D. Science 2007, 317, 496-499.; Hamilton, 
G. L.; Kanai, T.; Toste, F. D. J. Am. Chem. Soc. 2008, 130, 14984-14986.; Sodeoka, M. 
Science 2011, 334, 1651-1652.; Brazeau, J. F.; Zhang, S. Y.; Colomer, I.; Corkey, B. K.; 
Toste, F. D. J. Am. Chem. Soc. 2012, 134, 2742-2749.; Phipps, R. J.; Hamilton, G. L.; Toste, 
F. D. Nat. Chem. 2012, 4, 603-614.; Phipps, R. J.; Hiramatsu, K.; Toste, F. D. J. Am. Chem. 
Soc. 2012, 134, 8376-8379.; Phipps, R. J.; Hiramatsu, K.; Toste, F. D. J. Am. Chem. Soc. 
2012, 134, 8376-8379.; Wang, Y. M.; Wu, J.; Hoong, C.; Rauniyar, V.; Toste, F. D. J. Am. 
Chem. Soc. 2012.; Phipps, R. J.; Toste, F. D. J. Am. Chem. Soc. 2013, 135, 1268-1271.; 
Shunatona, H. P.; Fruh, N.; Wang, Y. M.; Rauniyar, V.; Toste, F. D. Angew. Chem., Int. Ed. 
2013, 52, 7724-7727.; Wu, J.; Wang, Y. M.; Drljevic, A.; Rauniyar, V.; Phipps, R. J.; Toste, 
F. D. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 13729-13733. 
23 Mukherjee, S.; List, B. J. Am. Chem. Soc. 2007, 129, 11336-11337. 
24 Rauniyar, V.; Lackner, A. D.; Hamilton, G. L.; Toste, F. D. Science 2011, 334, 1681-1684. 
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exchange with one or both of the tetrafluoroborate anions associated with Selectfluor 
and help this normally insoluble reagent enter the organic solution. The resulting 
chiral ion pair A could then act the true electrophilic fluorinating reagent and mediate 
the asymmetric fluorinationo of olefin and intramolecular cyclization of the amide 
carbonyl oxygen to afford the fluorinated oxazoline in highly diastereo- and 
enantioselectivity. This strategy is extremely powerful, appealing and also extends the 
scope of phase-transfer catalysis in reactions that use positively charged reagents and 
reaction intermediates. 
                      
Scheme 2.8 Chiral anionic PTC approach for asymmetric electrophilic fluorination. 
2.2. Introduction and Synthesis of Chiral Guanidinium Salts 
2.2.1. Introduction 
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Depending on previous Introduction section, it can be seen that most of the cationic 
phase-transfer catalysts reported so far consists of sp3-hybridized quaternary onium 
salt as the reactive centre. Recently, several phase-transfer catalysts containing 
quaternized sp2-hybridized N-atoms have been investigated, such as guanidinium, 25 
quinolinium cations,26 1,2,3-triazoliums,27 oxopyrimidinium,28 and so on. 
In 2002, Nagasawa reported the enantioselective alkylation of Schiff base by using 
a C2-symmetric chiral pentacyclic guanidinium compound 95 as a novel phase-
transfer catalyst (Scheme 2.9).25 In the presence of 1M KOH, the reaction requires 
very long time to get reasonable yield and good enantioselectivity. From X-ray 
analysis, the methyl substituents on the spiro ether rings of 95 are directed vertically 
up and/or down with respect to the guanidine plane. And it was also found these 
methyl substituents are essential for inducing high enantiomeric excess. 
 
Scheme 2.9 Chiral guanidinium for alkylation of Schiff base. 
1,2,3-triazole derivatives have attracted increasing attention in bioorganic and 
supramolecular chemistry due to their unique properties.27 1,4-disubsituted 1,2,3-
                                                     
25 Kita, T.; Georgieva, A.; Hashimoto, Y.; Nakata, T.; Nagasawa, K. Angew. Chem., Int. Ed. 
2002, 41, 2832-2834. 
26 Blakemore, P. R.; Wang, C. Abstr. Pap. Am. Chem. Soc. 2008, 236. 
27 Ohmatsu, K.; Kiyokawa, M.; Ooi, T. J. Am. Chem. Soc. 2011, 133, 1307-1309. 
28 Sheshenev, A. E.; Boltukhina, E. V.; White, A. J. P.; Hii, K. K. Angew. Chem., Int. Ed. 
2013, 52, 6988-6991. 
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triazole rings have been shown to serve as amide/peptide bond mimics, where the N 
(3) atoms of triazoles act as hydrogen bond acceptors and the polarized C (5) protons 
behave as hydrogen bond donors. Meanwhile, triazole motifs are known to recognize 
anions through an array of C (5)–H…anion hydrogen bonds and their anion bonding 
capacity can be enhanced by converting to triazolium cations possessing strongly 
increased CH-acidity. So these features of triazoles and triazoliums would provide an 
attractive platform for the rational molecular design of anion-recognizable chiral 
organic catalyst. In 2011, Ooi group designed chiral 1,2,3-triazolium 97 as a new 
cationic phase-transfer catalyst and also demonstrated its successful application to the 
Scheme 2.10 Chiral 1,2,3-triazolium for alkylation of 3-substituted oxindoles. 
the asymmetric alkylation of 3-substituted oxindoles (Scheme 2.10). 27 Based on the 
X-ray analysis and 1H NMR spectra, they proposed that the triazolium cations of 97 
would be tightly associated with the anion trough electrostatic interaction and two 
hydrogen bonds, i.e., a C(5)–H…anion and a suitably positioned amide N–H…anion, 
to form a structured ion pair. This well-defined 1,2,3-triazolium salt with anion-
recognition ability would catalyse the asymmetric alkylation reaction in a highly 
stereocontrolled manner. 
Chapter 2 
 
49 
 
Another good example of sp2-quaternized nitrogen cations is the methylene-bridged 
bis(imidazoline) derived 2-oxopyrimidinium salts which were synthesized by 
Sheshenev et al. in the year of 2013. 28 The new salts containing planar cationic 
nitrogen centres were successfully utilized as phase-transfer catalysts for asymmetric 
Michael reactions of tert-butyl glycinate benzophenone Schiff base with vinyl ketone 
and chalcone derivatives in excellent levels of diastereo- and enantiocontrol (Scheme 
2.11). It provides a new structurally unique motif for the development of phase-
transfer catalyst. 
Scheme 2.11 Chiral oxopyrimidinium PTC for Michael addition. 
Our group has developed bicyclic guanidine 99 as chiral Brønsted base catalyst for 
enantioselective reactions over the past several years,29 but one drawback of 99 is that 
the reaction scope is limited to activated nucleophiles. In order to enhancing the 
basicity of this guanidine catalyst, novel structurally pentanidines 100 containing five 
nitrogen atoms in conjugation were designed with the hypothesis that this conjugation 
may render it more basic than guanidine and then lead a superbase (Figure 2.5). 
However, the performance of pentanidines 100 as Brønsted base catalyst in reactions 
                                                     
29 Leow, D. S.; Lin, S. S.; Chittimalla, S. K.; Fu, X.; Tan, C. H. Angew. Chem., Int. Ed. 2008, 
47, 5641-5645.; Fu, X.; Loh, W. T.; Zhang, Y.; Chen, T.; Ma, T.; Liu, H. J.; Wang, J. M.; Tan, 
C. H. Angew. Chem., Int. Ed. 2009, 48, 7387-7390.; Jiang, Z. Y.; Pan, Y. H.; Zhao, Y. J.; Ma, 
T.; Lee, R.; Yang, Y. Y.; Huang, K. W.; Wong, M. W.; Tan, C. H. Angew. Chem., Int. Ed. 
2009, 48, 3627-3631.; Liu, H. J.; Leow, D.; Huang, K. W.; Tan, C. H. J. Am. Chem. Soc. 
2009, 131, 7212-7213. 
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is very bad in both of activity (slower reaction rate) and enantioselective induction in 
comparison with the original bicyclic guanidine 99. The bad controlling of chiral 
environment of pentanidines 100 may be due to the less steric hindrance in one side of 
it and then free rotation of it. Therefore, the full alkylated salt C2-symmetric 
pentanidiums 101 which is a new type of phase-transfer catalysts with sp2-quaternized 
ammonium active centre was synthesized and their applications in asymmetric 
reaction were conducted.  
 
Figure 2.5 The development of guanidine catalysts. 
For instance, this pentanidium salt 101a was successfully applied in catalytic 
enantioselective conjugate addition of tert-butyl glycinate-benzophenone Schiff base 
to various a, β-unsaturated acceptors, including vinyl ketones, acrylates and chalcones 
(Scheme 2.12).30  The reaction between Schiff base and chalcones gave only one 
diastereomers with excellent yield (83%-97%) and ee (85%-97%). A successful gram-
scale experiment at a low catalyst loading of 0.03 mol % indicates the potential for 
                                                     
30 Ma, T.; Fu, X. A.; Kee, C. W.; Zong, L. L.; Pan, Y. H.; Huang, K. W.; Tan, C. H. J. Am. 
Chem. Soc. 2011, 133, 2828-2831. 
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practical application of the methodology and this opens a road for large scale 
synthesis of chiral amino acid derivatives.  
Scheme 2.12 Pentanidium 101a-catalyzed Michael conjugate addition. 
Interestingly, pentanidium 101b also provided excellent stereocontrol in the 
reductant-free α-hydroxylation of 3-substituted-2-oxindoles using molecular oxygen 
as the green and cheap oxidant (Scheme 2.13).31 This reaction was demonstrated to be 
a two-step reaction: an enantioselective formation of hydroperoxide oxindole 
followed by kinetic resolution of the hydroperoxide oxindole. 
Scheme 2.13 Pentanidium 101b-catalyzed hydroxylation reaction. 
Also as an extension of developing guanidinium as novel phase transfer catalysts, 
several bis-guanidiniums such as 102 bearing two positively-charged sp2-quaternized 
ammonium centres were creatively designed and synthesized and their performances 
were preliminarily tested in many asymmetric reactions. The preliminary results in the 
potassium permanganate-mediated oxidation and some alkylation reaction 
                                                     
31 Yang, Y. Y.; Moinodeen, F.; Chin, W.; Ma, T.; Jiang, Z. Y.; Tan, C. H. Org. Lett. 2012, 14, 
4762-4765. 
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demonstrated their high efficiency as novel and promising phase transfer catalysts. In 
comparison with pentanidiums, the bis-guanidiniums are structurally different and 
also easier to obtain in shorter synthetic route. In next section the synthesis of both 
pentanidiums and bis-guanidiniums will be introduced and some structurally features 
will also be presented. 
2.2.2. Synthesis of Pentanidiums 
Biguanides can function as oral antihyperglycemic drug for treatment of diabetes 
mellitus or prediabetes and also be used as antimalarial drugs.   Early 1966, Bauer 
synthesized octamethylbiguanide perchlorate 103 as the most highly substituted 
biguanide (Figure 2.6).32 In 2004, Pleschke’s Group developed a new generation of 
catalyst CNC+ 104 which could be easily synthesized by coupling of 2-chloro-1,3- 
dimethylimidazolinium chloride (DMC) with tetramethyl guanidine (TMG) under 
basic condition. 33 CNC+Cl- 104 performed as an excellent and efficient phase-transfer 
catalyst for the halogen-exchange reactions in which chloro- and bromoaromatics 
react with a fluoride source to yield the corresponding fluoroarenes. 
 
Figure 2.6 Most highly substituted biguanides. 
                                                     
32 Bauer, V. J.; Safir, S. R. J. Med. Chem. 1966, 9, 980-981. 
33  Pleschke, A.; Marhold, A.; Schneider, M.; Kolomeitsev, A.; Roschenthaler, G. N. J. 
Fluorine Chem. 2004, 125, 1031-1038. 
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For chiral modification of CNC+, the easiest approach is the utilization of chiral 
diamines as building block. For the resulting chiral biguanide, our group described it 
as a chiral pentanidium salt. Chiral pentanidiums 101 can be obtained in several steps 
from commercially available (S,S)-diphenyl-diaminoethane and other commonly 
available and inexpensive reagents. For the four-methylated pentanidium 101a, it was 
synthesized in five steps from commercial available chiral diamine 105 with good 
chemical yield (Scheme 2.14).   
 
Scheme 2.14 Synthesis of four-methylated pentanidium salt 101a. 
However, during the expansion of reaction scope except the reported Michael 
conjugated addition, structurally brief pentanidium 101a only can give low to 
moderate stereocontrol. Considering that peripheral environment of the nitrogen is of 
crucial importance to catalysts’ stereocontrolling ability based on previous 
experiences in optimization of alkaloid derived PTC and Maruoka’s spiro PTC, so 
we started to design and synthesize various pentanidiums salts by varying some 
features. According to our previous synthesis of 101a, generally the pentanidium salt 
101 can be achieved through the coupling between the imidazolium salt part and the 
guanidine part (Scheme 2.15). The synthesis of these two components and the final 
coupling conditions are depicted in the following paragraphs. 
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Scheme 2.15 General route to chiral pentanidium salt 101. 
Usually, the imidazoline salts are in situ generated when treating the corresponding 
urea or thiourea by oxalyl chloride in anhydrous conditions (Scheme 2.14). Moreover, 
it must be emphasized that the imidazoline salts should be freshly synthesized and 
used for next step immediately or stored under inert atmospheres due to their high 
sensitivity to moisture. Only N-methyl urea 107 can be activated by oxalyl chloride to 
give imidazolium salts. For other substituted-groups on nitrogen, usually thioureas 
rather than ureas are required to achieve enough reactivity with oxalyl chloride. 
Treatment of urea 111 with Lawesson's reagent in refluxing xylene will provide the 
thiourea compound 112 in high yield (Scheme 2.16). The substituted urea 111 can be 
obtained through either alkylation of the naked urea 106 or by treating the 
monoalkylated diamine 110 with triphosgene in biphasic condition in quantitative 
yield. There are two ways for the synthesis of monoalkylated diamine 110. One is the 
direct alkylation of free diamine 105 with sterically hindered aryl methylbromide in 
the presence of base; the other is the first amide formation then followed reduction 
with diborane, because small aryl methylbromide or alkyl iodide with higher 
reactivity will lead to multi-alkylated diamine as the byproduct.  
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Scheme 2.16 Synthesis of various ureas and thioureas. 
Compared with the synthesis of imidazoline salts part, it is easier to obtain the 
guanidiniums 112 association with one HBr molecule from the mono-alkyated 
diamine 110 by treating with cyanobromide in refluxing MeCN medium (Scheme 
2.17). The guanidinium 113 can change to the corresponding guanidine by the loss of 
HBr under basic condition. 
                             
Scheme 2.17 Synthesis of various guanidiniums.  
In the final coupling step, firstly the dry imidazolium salt was dissolve in dry 
acetonitrile under nitrogen atmosphere, and subsequently the guanidine generated 
from guanidinium 113 and organic base triethyl amine were added through syringe at 
room temperature. The reaction mixture was allowed to reflux for 12 hours and the 
final pentanidium salts was obtained with good yield (28%-80%) after column 
chromatography (Scheme 2.18). 
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Scheme 2.18 Synthesis of various pentanidium salts. 
With the above-mentioned synthetic procedures, various pentanidium salts were 
obtained. For example, pentanidiums 101a-h with different N-alkylation groups by 
fine tuning the electric and steric properties and also involving the heteroaromatic 
rings were successfully achieved. Meanwhile, pentanidiums 101i-j with enhanced 
steric hindrance and enriched electric effects can also be obtained. To our surprise, the 
synthesis of more steric pentanidiums 101k-r bearing halogen atoms was realized and 
these catalysts may induce interesting features for pentanidium phase transfer 
catalysis (Figure 2.7). The structure of pentanidium salt 101r was confirmed by 
single-crystal X-ray diffraction analysis (Figure 2.8). 
                              
Figure 2.7 Pentanidiums obtained. 
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Figure 2.8 Single-crystal X-ray diffraction analysis of pentanidium 101r. 
2.2.3. Synthesis of Bis-guanidiniums 
Recently Ma and co-workers developed a series of newly designed binaphthyl-
modified bis-ammonium salt 114b (Scheme 2.19).34 For the Michael conjugate 
addition of 2-nitropropane to chalcones, usually the mono-ammonium phase-
transfer catalyst gave poor performance with low yield and disappointing ee values. 
                                                     
34 Hua, M. Q.; Cui, H. F.; Wang, L.; Nie, J.; Ma, J. A. Angew. Chem., Int. Ed. 2010, 49, 2772-
2776.; Hua, M. Q.; Wang, L.; Cui, H. F.; Nie, J.; Zhang, X. L.; Ma, J. A. Chem. Commun. 
2011, 47, 1631-1633. 
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Therefore, they surmised that bis-ammonium salt 114 with dicationic nature can 
exhibit dual activation of both the nucleophile and the electrophile synergistically 
for this challenging reaction. As a result of high activity and stereoselectivity, bis-
ammonium salts 114 represent a promising new generation of chiral phase-transfer 
catalysts for asymmetric syntheisis. Interestingly, reversal of enantioselectivity 
was observed by fine-tuning the conformational flexibility of bis-ammonium salt 
PTC such as 114a and 114b from a same chirality source. 
Scheme 2.19 New bis-ammonium phase-transfer catalysts. 
During the preparation of various pentanidiums 101, we found that the 
guanidine generated from the guanidinium 112 which has similar polarity to 
pentanidiums cannot be consumed completely, so this will cause little 
inconveniences in the final purification process. Inspired by the work form Ma 
group, the bis-guanidinium such as 102 was designed as a novel phase-transfer 
catalyst derived from guanidine group as well as pentanidiums (Scheme 2.20). 
One of the advantages is the use of the commercially available secondary diamines  
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Scheme 2.20 General route to bis-guanidinium salts. 
as the coupling partner for the imidazolium salts instead of the synthesized 
guanidinium 112. Furthermore, the bis-guanidinium can be easily obtained by 
simple silica gel column chromatography within short time. Piperazine and 
bipiperidines were chose as the coupling partner and the linkers for bis-
guanidinium salts.  
Scheme 2.21 Synthesis of various bis- guanidinium salts. 
Likewise, the imidazoline salt was in situ generated from the corresponding urea 
or thiourea and after the removal of toluene it was used directly in the final 
coupling reaction with less than 0.5 equivalent linkers (0.3 equiv) (Scheme 2.21). 
The use of excess imidazoline salts is aiming to avoid the generation of mono- 
guanidiniums. Usually, the solid diamines were added to the flask with dry 
imidazolium salt under inert atmosphere, and subsequently dry MeCN as solvent 
and triethylamine as the base were injected. The resulting mixture was allowed to 
reflux for overnight and after evaporation, the residue was subjected to column 
chromatography to afford the bis-guanidinium phase-transfer catalyst in good 
yield (45%-78%). Followed the above-mentioned procedure, bis-guanidiniums 
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102a-f with various linkers and structural features can be easily obtained in good 
yield (Figure 2.9). The structure of bis-guanidinium salt 102d was confirmed by 
single-crystal X-ray diffraction analysis (Figure 2.10).  
Figure 2.9 Bis-guanidiniums obtained. 
 
Figure 2.10 Single-crystal X-ray diffraction analysis of bis-guanidinium 102d. 
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In summary, the recent development of phase transfer catalyst and also the 
emerging concepts in this field were briefly introduced. The cationic phase-transfer 
catalyst containing guanidinium moiety which was designed in our group also was 
summarized. In particular, the dicationic bis-guanidinium phase-transfer catalyst was 
firstly designed and prepared. The catalytic ability of these novel catalysts was ready 
to be examined in various asymmetric reactions, and the results would be reported in 
due course. 
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Synthesis of Chiral Sulfoxides via Pentanidiums Catalyzed 
Enantioselective Alkylation of Sulfenate Anions 
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3.1. Optimization  of the Alkylation Reaction of Sulfenate Anions 
Inspired by the pioneering work of Perrio, and Poli, Madec (Chapter 1. Section 
1.3.2), we intended to apply our pentanidiums as chiral cationic phase transfer 
catalysts into the asymmetric synthesis of sulfoxides from active sulfenate anion 
nucleophiles. Initially, β-phenylsulfinyl ester 115a was chosen as the test sulfenate 
anion precursor and applied to the benzylation by reacting with benzyl bromide. The 
reaction was conducted at -20 °C in toluene with 5 equivalent (equiv) of electrophile 
(BnBr), 10 equiv. CsOH•H2O solid and 1 mol % pentanidium as the chiral phase 
transfer catalyst. The result is shown in Table 3.1. 
Pentanidium 101a with bulky N-alkylation groups has been successfully applied 
into the oxygen-mediated oxidation of 3-substituted 2-oxoindole and afforded the 
chiral 3-hydroxy 2-oxoindole products with good yield and excellent 
enantioselectivity. Therefore, its catalytic ability was ready to be examined. However, 
it can only furnish unsatisfied ee value (21% ee, Table 3.1, entry 1). Attempts to 
modify pentanidiums by tuning the electronic and steric effects (Table 3.1, entries 2-6) 
did not result in significant improvement of enantioselectivity. Especially, 
pentanidium 101e bearing pyridyl group led to almost racemic product (Table 3.1, 
entry 5). Pentanidium 101f with more steric hindrance (R1=CH(Ph)2) could not induce 
higher ee value (Table 3.1, entry 6). However, as demonstrated in Table 1, 
pentanidium 101i   with C2-symmetic structure and more sterically encumbered R
1, R2 
groups can result in a slight increase in enantioselectivity (27% ee, Table 3.1, entry 7). 
With the catalyst 101i, then the reaction parameters were screened, including the base, 
solvent, dilution and temperature. It was found that weaker bases such as Cs2CO3, 
K2CO3, Na2CO3, and K3PO4 could not promote the reaction to occur and other metal 
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hydroxides with different state (solid or aqueous solution) could not result in any 
improvement of enantioselectivity. Variation of reaction dilution and solvents showed 
no dramatic increase in ee value. Disappointingly, further lowering temperature could 
not give obvious improvements on enantioselectivity but led to extremely slow 
reaction (Table 3.1, entry 8). 
Table 3.1 Initial screening of pentanidiums for benzylation of phenyl sulfenate aniona  
 
entry catalyst R1 Time(h) ee (%)b 
1 101a 4-Cl-C6H4CH2 2 21 
2 101b 4-F-C6H4CH2 2 23 
3 101c 4-OMe-C6H4CH2 4 21 
4 101d 4-Ph-C6H4CH2 3 20 
5 101e pyridin-2-ylmethyl 24 4 
6 101f CH(Ph)2 2 21 
7 101i 3,5-(tBu)2C6H3CH2 4 27 
8c 101i 3,5-(tBu)2C6H3CH2 48 35 
a Reactions were performed by using 115a (0.02 mmol), and benzyl bromide (0.1 mmol) in 
the presence of 1 mol % of pentanidiums and CsOH•H2O (10 equiv.) in toluene (0.4 mL). 
b 
Determined by HPLC analysis. c This reaction was conducted at -60 °C. 
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Due to the low enantioselectivity in the benzylation of phenyl sulfenate anion, we 
tried to screen new substrates such as 115b containing a hetero-aromatic ring 
thiophene which is a bioisostere of phenyl group (Table 3.2). It is known that 
thiophene derivatives1  are one of the important heteroaromatic compounds which 
have been used prevalently in functional materials and pharmaceutical2 due to their 
distinct electronic properties and biological activities (Figure 3.1). 
 
Figure 3.1 Drugs and bioactive molecules incorporating thiophene unit. 
 In the preliminary study, the benzylation between in situ generated 2-thienyl 
sulfenate anion from 115b and benzyl bromide in the presence of pentanidium 101i 
was chosen as the model for reaction optimization. As shown in Table 3.2, the 
substrate 115b can undergo retro-Michael reaction smoothly to generate the 2-thienyl  
                                                     
1 Chemistry of Heterocyclic Compounds: Thiophene and Its Derivatives,Vol. 44, Parts 1-5.; 
Gronowitz, S., Ed.; Wiley: New York, USA., 1985–1992.; Gronowitz, S.; Hörnfeldt, A. B. 
Thiophenes; Elsevier: Oxford, U.K., 2004. 
2 Nakamura, S.; Kondo, M.; Goto, K.; Nakamura, M.; Tsuda, Y.; Shishido, K. Heterocycles 
1996, 43, 2747-2755.; Andersen, K. E.; Braestrup, C.; Gronwald, F. C.; Jorgensen, A. S.; 
Nielsen, E. B.; Sonnewald, U.; Sorensen, P. O.; Suzdak, P. D.; Knutsen, L. J. S. J. Med. Chem. 
1993, 36, 1716-1725.; Meotti, F. C.; Silva, D. O.; Dos Santos, A. R.; Zeni, G.; Rocha, J. B.; 
Nogueira, C. W. Environ. Toxicol. Pharmacol. 2003, 15, 37-44.; McAllister, L. A.; Hixon, M. 
S.; Kennedy, J. P.; Dickerson, T. J.; Janda, K. D. J. Am. Chem. Soc. 2006, 128, 4176-4177.; 
Bey, E.; Marchais-Oberwinkler, S.; Negri, M.; Kruchten, P.; Oster, A.; Klein, T.; Spadaro, A.; 
Werth, R.; Frotscher, M.; Birk, B.; Hartmann, R. W. J. Med. Chem. 2009, 52, 6724-6743. 
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Table 3.2 Optimization in benzylation of 2-thienyl sulfenate aniona  
 
entry solvent Base(x equiv.) Temperature(°C ) time(h) b ee(%)c 
1 Toluene CsOH•H2O(10) -20 12 26 
2 Toluene 50% CsOH(10) -20 12 37 
3 Toluene 50% CsOH (10) -30 10 42 
4 Toluene 50% CsOH(10) -40 12 42 
5 Toluene 50% CsOH(10) -60 48 54 
6 Toluene 50% CsOH(20) -60 48 58 
7 Toluene 67% CsOH(20) -60 48 59 
8 Toluene 77% CsOH(20) -60 48 53 
9 MTBE 67% CsOH(20) -60 48 60 
10d CPME 67% CsOH(20) -60 48 61 
11 CPME 67% CsOH(20) -80 48 61 
a Reactions were performed by using 115b (0.02 mmol), and benzyl bromide (0.1 mmol) in 
the presence of 1 mol % of pentanidiums 101i in toluene (0.4 mL). b This reaction was 
monitored by TLC.  c Determined by HPLC analysis. d CPME= cyclopentyl methyl ether. 
sulfenate anions followed by benzylation to afford the sulfoxide 116ba. Initially, the 
solid CsOH•H2O was used as the base to promote the retro-Michael reaction (Table 
3.2 entry 1). However, it is a bit inconvenient to weight such highly hydroscopic base. 
Therefore, a solution of CsOH (50% wt) was tested. To our delight, such alternative is 
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not detrimental but beneficial to the improvement of enantioselectivity (Table 3.2, 
entry 2). The effect of temperature was examined (Table 3.2, entries 3-6) and finally 
an acceptable ee value of 58% was obtained at -60°C. Then the dilution of aqueous 
CsOH base was adjusted and finally 20 equiv of 67% CsOH base was chosen as the 
optimal choice (Table 3.2, entry 7). The variation of solvent realized the identification 
of cyclopentyl methyl ether (CPME) as the most suitable solvent and the sulfoxide 
116ba can be obtained in 61% ee value (Table 3.2, entry 10). Further lowing 
temperature to -80 °C could not give better results (Table 3.2, entry 11). 
With these results in hand, the influence of precursors 115b-115g activated by 
different electron-withdrawing groups (EWG) was next examined (Table 3.3, entries 
1-6). As shown in Table 3.3, the β-sulfinyl methyl ester 115b (EWG = CO2Me) was 
still the appropriate precursor in terms of reactivity and enantioselectivity (Table 3.3, 
entry 1). Attempts to use other β-sulfinyl esters did not lead to any improvements 
improvement (Table 3.3, entries 2-4). In particular, β-sulfinyl tert-butyl ester 115d 
(EWG = CO2
tBu) was mostly recovered without undergoing the reaction (Table 3.3, 
entry 3). To a large extent, this may ascribe to steric effects and different acidity of 
the α-hydrogen attached to the carbon adjacent to the EWG activating group. The β-
sulfinyl nitrile 115g (EWG = CN) also gave similar results (Table 3.3, entry 6), while 
the sulfinyl sulfone 115f (EWG = SO2Ph) led to a slow reaction with low yield and 
poor enantioselectivity (Table 3.3, entry 5). Overall only moderate results were 
obtained by using pentanidium 101i. Therefore, further structural modification of 
pentanidiums was carried on in order to increase their capability of stereocontrol. 
Pentanidium 101j with bulky and electron rich N-alkylation group (R1=R2=3,5-
(tBu)2-4-OMe-C6H3CH2) only led to slow reaction rate and low level of 
enantioselectivity(Table 3.3, entry 7). To our delight, the modification of pentanidium 
Chapter 3 
68 
 
by the addition of halogens to ortho-position of the benzyl group led to an increase in 
enantioselectivity relative to the pentanidium 101i (Table 3.3, entries 8-14). 
Eventually, it was found that iodinated pentanidium 101n is the best catalyst, 
providing sulfoxide 116ba with excellent enantioselectivity (91% ee). In contrast, the 
commercially available phase-transfer catalyst such as Cinchonidinium salt 69 and 
Maruoka’s catalyst were also tested and low enantioselectivity was obtained (Table 
3.4, below 15% ee). 
Table 3.3 Screening of different precursors and pentanidiumsa  
 
entry Catalyst 115 [EWG] yield (%)b ee (%)c 
1 101i 115b [CO2Me] 76 61 
2 101i 115c [CO2Et] 39 61 
3 101i 115d [CO2
tBu] trace 45 
4 101i 115e [CO2Ph] 39 58 
5 101i 115f [SO2Ph] 29 37 
6 101i 115g [CN] 73 57 
7 101j 115b [CO2Me] 68 40 
8 101o 115b [CO2Me] 70 75 
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9 101p 115b [CO2Me] 73 75 
10 101q 115b [CO2Me] 75 81 
11 101l 115b [CO2Me] 67 79 
12 101m 115b [CO2Me] 72 81 
13d 101m 115b [CO2Me] 86 88 
14d 101n 115b [CO2Me] 72 91 
a aReactions were performed by using 115b (0.02 mmol) and benzyl bromide (0.024 mmol) 
in the presence of 1 mol % of pentanidiums in CPME (0.4 mL). bYield of the isolated product. 
cDetermined by HPLC analysis. dThis reaction was conducted at -70 °C with saturated  CsOH 
solution (24 L) in a solvent mixture of CPME (0.2 mL)/Et2O (0.6 mL). 
Table 3.4 Benzylation of 2-thienyl sulfenate anion catalyzed by commercially 
available phase-transfer catalystsa 
 
entrya base solvent temperature 
(C) 
time 
(h) 
yield 
(%)b 
ee 
(%)c 
1d,e 33% NaOH   
(10 equiv.) 
Toluene/CH2Cl2(7:3) 
(0.25 mL) 
rt 1.5 73 15 
2e 67% CsOH 
(10 equiv.) 
CPME(0.4 mL) rt 0.5 82 10 
3e Saturated 
CsOH 
(20 equiv.) 
CPME(0.4 mL) -60 28 86 9 
4d,f 33% NaOH Toluene/CH2Cl2(7:3) 
(0.25 mL) 
rt 12 45 1 
5f 33% NaOH 
(10 equiv.) 
Toluene(0.25 mL) rt 12 9 3 
6f 67% CsOH 
(10 equiv.) 
CPME(0.4 mL) rt 2 50 3 
7f 67% CsOH 
(20 equiv.) 
CPME(0.4 mL) -60 48 70 1 
a Reactions were performed by using 115b (0.02 mmol), and benzyl bromide (0.024 mmol) 
in the presence of 10 mol % of phase-transfer catalysts. b Isolated yield. c Determined by 
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HPLC analysis using Chiralcel OD-H column. d The reaction was performed under the 
condition mentioned in reference 7c. e Cinchonidinium salt 69 was used as the phase-
transfer catalyst. f Commercially available Maruoka Catalysts was used as the phase-
transfer catalyst. 
 
3.2. Substrate Scope of the  Halogenated Pentanidium Phase-
Transfer Catalyst 
With the optimal condition on hand, the reaction scope was next examined by using 
a series of alkyl halides as electrophiles (Table 3.5). In the presence of 1 mol % 
iodinated pentanidium 101n and base, the alkylation of in situ generated 2-thienyl 
sulfenate anion with various alkyl bromides afforded the corresponding sulfoxides 
116ba-f in good yields and enantioselectivities. With benzyl bromide derivatives, the 
presence of electron-withdrawing and electron-donating substituents of the phenyl 
rings was tolerated (Table 3.5, entries 1-6). It should be noted that benzyl bromides 
caused erosion of enantioselectivity in the previous report of a related reaction by 
Perrio group.3The construction of stereogenic sulfoxides 116bg-i bearing allylic and 
propargylic substituents could also be achieved in a similar manner (Table 3.5, entries 
7-9). However, the nucleophilic displacement of alkyl iodides by sulfenate anions 
provided the sulfoxide 116bj-l with moderate enantioselectivity (77-81% ee, Table 
3.5, entries 10-12). These results indicated that both alkyl and benzyl groups can be 
installed using this methodology. For specific benzyl bromide derivatives with 
electron-withdrawing substituents (entries 3-4) and alkyl iodides (entries 10-12), 
brominated pentanidium 101m provided sulfoxides with marginally better 
enantioselectivities.  
                                                     
3 Gelat, F.; Gaumont, A.-C.; Perrio, S. J. Sulfur Chem. 2013, 1-9.; Gelat, F.; Jayashankaran, J.; 
Lohier, J. F.; Gaumont, A. C.; Perrio, S. Org. Lett. 2011, 13, 3170-3173. 
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Table 3.5 Asymmetric alkylation of 2-thienyl sulfenate anion catalyzed with iodo-
pentanidium 101na 
 
entry R1 Product time(h) yield (%)
b ee (%)c 
1 PhCH2 116ba 12 87 92 
2 4-MeC6H4CH2 116bb 12 88 94 
3 4-ClC6H4CH2 116bc 12 84 90
d 
4 4-CF3C6H4CH2 116bd 12 83 94
d 
5 3-MeOC6H4CH2 116be 12 84 90 
6 2-naphthylCH2 116bf 12 84 92 
7  116bg 36 82 92 
8  116bh 21 79 92 
9  116bi 21 77 82 
10e Me 116bj 40 65 77d 
11e CH3CH2CH2 116bk 28 66 81d 
12e CH3(CH2)6CH2 116bl 20 69 81
d 
aReactions were performed by using 2a (0.06 mmol) and alkyl bromides or iodides (0.072 
mmol) in the presence of 1 mol % of pentanidium 1d in a solvent mixture of CPME (0.6 mL) 
and Et2O (1.8 mL) and saturated CsOH (72 L). 
bYield of the isolated product. cDetermined 
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by HPLC analysis. dData was obtained in the present of 1 mol% of brominated pentanidium 
101m.  e2.5 equivalents of alkyl iodides was used; sulfoxides are volatile under vacuum 
pump. 
The scope of this reaction was further examined under the optimized condition by 
using various β-heteroaryl and aryl sulfinyl esters (115h-115q) as sulfenate anion 
precursors and benzyl bromide derivatives as the electrophile (Scheme 3.1). These 
sulfinyl esters were easily prepared from corresponding mercaptans using literature 
procedures. They participated in the reaction efficiently to provide the anticipated 
sulfoxides in high yield with good to excellent enantioselectivity. The methyl 
substituted 2-thienyl sulfinyl esters (115h-115j) was transformed to the corresponding 
highly enantioenriched sulfoxides (116ha-116ja) bearing thiophene unit. Interestingly, 
the reaction between the sulfenate generated from sulfinyl ester 115h and m-xylylene 
dibromide can deliver the bis-sulfoxide 116hg in reasonable yield (62%, dl/meso = 
4.45:1) and excellent enantioselectivity (>99% ee). Besides, the sulfoxides (116ka-
116lf) involving benzothiophene rings also can be obtained with similar 
enantioselectivity. The sulfenate anions containing furyl, benzofuryl, pyridyl moieties 
also can be efficiently released in relatively shorter reaction time and smoothly 
converted into the sulfoxides (116ma-116pb). However, only a moderated level of 
enantioselectivity (65%-81% ee) was achieved under the optimized reaction 
conditions. Generally, the normal aryl and alkyl sulfinyl esters led a slower reaction 
with the benzyl reagent and resulted in the sulfoxides only in poor enantioselectivity 
(Table 3.6, <60% ee); nevertheless, 3,5-dimethyl substituted phenyl sulfenate anion 
can react with the electron-deficient benzyl bromides and afford the products in high 
yield and excellent enantioselectivity (116qa-116qb). For specific electrophile such 
as 4-chlorobenzyl bromide and 4-trifluromethylbenzyl bromide, brominated 
pentanidium 101m provided the corresponding sulfoxides (116lc,116ld, 
116mb,116pb,116qb) with marginally better enantioselectivities.  
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Scheme 3.1 Substrate scope of pentanidium-catalyzed alkylation to enantioenriched 
heterocyclic sulfoxides a, b, c 
a Reactions were performed by using 115 (0.06 mmol), and alkyl bromide (0.072 mmol) in the 
presence of 1 mol % of pentanidium 1d in a solvent mixture of CPME (0.6 mL) and Et2O (1.2 
mL). b Yield of the isolated product. c Enantiomeric excess (ee) value determined by HPLC 
analysis. d Diastereomeric dl/meso ratio = 4.45:1 determined by 1H NMR analysis. e The 
reaction was conducted at -40 C. f Data was obtained in the presence of  brominated 
pentanidium 101m. The absolute configuration was assigned to R by analogy to 116la. 
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The absolute configuration of compound 116la was determined by X-ray analysis 
to be R (Figure 3.2). Consequently, absolute configurations of all others compounds 
shown in Table 3.4 and Table 3.5 were assigned to be R by analogy. Furthermore, to 
investigate the practical use of pentanidium phase-transfer catalyst, we conducted the 
reaction with 1 mmol substrate 115l in the presence of 0.25 mol % 101l with 1.2 
equiv benzyl bromide and 20 equiv saturated CsOH in Et2O (20 mL) at -60 °C. The 
sulfoxide 116la can be isolated in 85% yield with 92% ee within 24 h. 
Figure 3.2 X-ray structure of 116la 
Table 3.6 Pentanidium catalyzed benzylation of sulfenate anionsa 
        
Entry R4 catalyst Temperature(°C ) solvent ee(%)b 
1 Ph 101i -60 CPME 35 
2 
 
101k -40 CPME 45 
3 
 
101k -40 CPME 39 
4 
 
101k -40 CPME 43 
5 
 
101l -60 CPME 35 
6 
 
101k -40 CPME 59 
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7 
 
101k -40 CPME 53 
8 
 
101l -40 CPME 35 
9 
 
101l -40 CPME 7 
10 
 
101l -60 toluene 34 
11 
 
101l -60 toluene 33 
12 
 
101l -60 CPME 31 
13 
 
101k -40 CPME 39 
14 
 
101i -40 toluene 27 
15 
 
101l -40 toluene 51 
a Reactions were performed by using 115 (0.02 mmol), and benzyl bromide (0.024 mmol) in 
the presence of 1 mol % of pentanidiums in solvent (0.04 ml). b Determined by HPLC 
analysis. 
Besides, we also try to extend the substrate to 115r containing benzimidazole 
moiety. The preliminary results obtained by using brominated pentanidium 101m 
were summarized in Table 3.7. Although the results were not so promising, it strongly 
demonstrated the feasibility of current strategy by using our pentanidium phase 
transfer catalyst. Moreover, fine tuning of the reaction paremeters can lead to an 
increase of enantioselectivity (entries 2-3). Further extension of substrate scope is 
currently in progress. 
Table 3.7 Preliminary results of alkylation of sulfenate anion generated from 115ra 
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entry R5 Yield (%)
b ee (%)c 
1 Ph 78% 47 
2 4-MeC6H4 75% 70 
3 4-MeC6H4 99% 90
d 
4 4-ClC6H4 82% 60 
5 4-CF3C6H4 65% 57 
6 4-MeOC6H4 67% 67 
7 
 
54% 45 
a Reactions were performed by using 115r (0.02 mmol), and alkyl bromide (0.024 mmol) in 
the presence of 1 mol % of brominated pentanidium 101m in CPME (0.04 mL). b Yield of the 
isolated product. c Enantiomeric excess (ee) value determined by HPLC analysis. d Data was 
obtained by using 115r (0.06 mmol), and alkyl bromide (0.072 mmol) in the presence of 1 
mol % of brominated pentanidium 101m in a solvent mixture of CPME (0.6 mL) and Et2O 
(1.2 mL) and saturated CsOH (72 L)..  
3.3. Experimental mechanistic study  
Although a brief mechanistic description of the reaction pathway has been 
proposed, additional experiments were carried out under present reaction system in 
order to obtain a comprehensive insight into the reaction mechanism (Table 3.8). 
When the reaction was performed in the presence of phase-transfer catalyst but in 
the absence of aryl halides, β-sulfinyl methyl ester 115b produced thiophene sulfenate 
117ba instead of the usual sulfoxide product 116ba (Table 3.8, entry 1). In the 
absence of phase-transfer catalyst, β-sulfinyl methyl ester 115b also underwent the 
retro-Michael process under basic conditions to give rise to 2-thienyl sulfenate anion  
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Table 3.8 Mechanistic insights to alkylation of sulfenate aniona 
 
entry catalyst X time(h) product 
yield 
(%)b 
ee (%)c 
1 101i - 24 117ba 40 - 
2d - Br 1 - - - 
4 101i Cl 48 117ba 27 - 
5 101l Cl 24 
116ba:117ba 
(1:2)e 
9 83 
6 101m Cl 24 116ba 15 91 
7 101n Cl 1 116ba 29 90 
       
a 
Reactions were performed by using 115b (0.02 mmol) and benzyl halides (0.024 mmol) in the 
presence of 1 mol % of pentanidiums in CPME (0.4 mL) and saturated CsOH (24 L). b Yield of the 
isolated product. c Determined by HPLC analysis. d The substrate 115b decomposed under basic 
conditions without phase-transfer catalysts. e The ratio was determined by 1H NMR analysis. 
intermediate which will undergo alkaline hydrolysis (Table 3.8, entry 2; Scheme 3.2, 
path c).4 Using non-halogenated pentanidium 101i as the catalyst and benzyl chloride, 
a less active electrophile, the result was similar to entry 1 (entry 3), and thiophene 
sulfenate 117ba was formed instead of possible O- alkylation product.5 This can be 
ascribed to the ambident nucleophilic feature of sulfenate anion, which led to oxygen-
Michael addition of the sulfenate anion to methyl acrylate released during the retro-
Michael process (Scheme 3.2, path b).6  However, it is noteworthy that sulfoxide 
116ba can be formed when halogenated pentanidiums were used as catalysts with 
                                                     
4 O'Donnell, J. S.; Schwan, A. L. J. Sulfur Chem. 2004, 25, 183-211. 
5 Caupene, C.; Boudou, C.; Perrio, S.; Metzner, P. J. Org. Chem. 2005, 70, 2812-2815. 
6 Hogg, D. R.; Robertson, A. J. Chem. Soc., Perkin Trans. 1 1979, 1125-1128.; Kiełbasiński, P.;    
Żurawiński, R.; Orabowicz, J.; Mikołajczyk, M. Tetrahedron 1988, 44, 6687-6692. 
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benzyl chloride (Table 3.8, entries 4-6; Scheme 3.2, path a). These results indicate the 
ability of halogenated pentanidiums to activate the electrophile as well as the 
sulfenate anion nucleophile. 
These results allowed us to draw the following conclusions: a) background reaction 
was observed; b) the electrophilicity decreases in the order of benzyl bromide> 
methyl acrylate> benzyl chloride; c) benzyl halides should react preferentially with 
the “soft” nucleophilic center, the sulfur atom, to give the sulfoxide, while methyl 
acrylate might act a hard electrophile to react with the “harder” nucleophilic center, 
the oxygen atom of sulfenate anion; d) in all cases, no oxygen-alkylation product was 
found at all; e) halogenated pentanidium 101l-n  might have additional interaction 
with the benzyl halides electrophiles. 
Based on these observations, a plausible catalytic cycle was proposed (Scheme 
3.2). 7  The inorganic base can promote the deprotonation of 115b to give the 
corresponding caesium enolate, which leads to the generation of sulfenate anion and 
the release of methyl acrylate via a retro-Michael process even without phase-transfer 
catalyst. In the presence of chiral cationic phase transfer catalyst, after the cation-
exchange and retro-Michael process, a chiral ion pair A of sulfenate anion and 
catalyst will be formed. It can readily react with electrophile RX (X= Br) to afford the 
desired sulfoxide product 116ba (Scheme 3.2, path a). However, in the absence of 
electrophile RX, or in the presence of less active electrophiles, this ion pair will 
undergo oxygen-Michael addition to methyl acrylate to give compound 117ba. In 
contrast, the in situ generated sulfenate anion will be hydrolyzed under basic 
conditions without phase-transfer catalyst. A possible transition-state model was 
                                                     
7  Rabinovitz, M.; Cohen, Y.; Halpern, M. Angew. Chem., Int. Ed. 1986, 25, 960-970.; 
Denmark, S. E.; Weintraub, R. C.; Gould, N. D. J. Am. Chem. Soc. 2012, 134, 13415-13429. 
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tentatively proposed which involved simultaneously activation/stabilization of the 
nucleophiles and electrophiles by ion-pairing and halogen bonding interactions8. 
Scheme 3.2 Plausible Catalytic Cycle. 
In summary, we have described a highly enantioselective alkylation of the in situ- 
generated hetero-aryl and aryl sulfenate anions providing various enantioenriched 
sulfoxides. Current methodology is of high efficiency and the reaction can be scaled 
up at very low catalyst loading (0.25 mol %) without the loss of enantioselectivity. 
These sulfoxide adducts might be of importance as chiral ligands, chiral 
organocatalyst 9 or bioactive molecules. Further exploration of the reaction scope and 
chiral pentanidium in other asymmetric carbon-heteroatom bond formation is 
currently in progress in our laboratory. 
                                                     
8 Serpell, C. J.; Kilah, N. L.; Costa, P. J.; Felix, V.; Beer, P. D. Angew. Chem., Int. Ed. 2010, 
49, 5322-5326.; Kilah, N. L.; Wise, M. D.; Serpell, C. J.; Thompson, A. L.; White, N. G.; 
Christensen, K. E.; Beer, P. D. J. Am. Chem. Soc. 2010, 132, 11893-11895.; Caballero, A.; 
White, N. G.; Beer, P. D. Angew. Chem., Int. Ed. 2011, 50, 1845-1848.; Evans, N. H.; Serpell, 
C. J.; Beer, P. D. Angew. Chem., Int. Ed. 2011, 50, 2507-2510.; Walter, S. M.; Kniep, F.; 
Herdtweck, E.; Huber, S. M. Angew. Chem., Int. Ed. 2011, 50, 7187-7191.; Caballero, A.; 
Zapata, F.; White, N. G.; Costa, P. J.; Felix, V.; Beer, P. D. Angew. Chem., Int. Ed. 2012, 51, 
1876-1880.; Gilday, L. C.; Lang, T.; Caballero, A.; Costa, P. J.; Felix, V.; Beer, P. D. Angew. 
Chem., Int. Ed. 2013, 52, 4356-4360.; Kniep, F.; Jungbauer, S. H.; Zhang, Q.; Walter, S. M.; 
Schindler, S.; Schnapperelle, I.; Herdtweck, E.; Huber, S. M. Angew. Chem., Int. Ed. 2013, 52, 
7028-7032. 
9  Furukawa, N.; Ogawa, S.; Kawai, T.; Oae, S. Journal of the Chemical Society-Perkin 
Transactions 1 1984, 1833-1838.; Fujihara, H.; Imaoka, K.; Furukawa, N.; Oae, S. Journal of 
the Chemical Society, Perkin Transactions 1 1986, 333.; Kobayashi, S.; Ogawa, C.; Konishi, 
H.; Sugiura, M. J. Am. Chem. Soc. 2003, 125, 6610-6611.; Ichikawa, E.; Suzuki, M.; Yabu, 
K.; Albert, M.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 2004, 126, 11808-11809.; Reyes-
Rangel, G.; Bandala, Y.; Garcia-Flores, F.; Juaristi, E. Chirality 2013, 25, 529-540. 
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4.1. General Information 
General 1H and 13C NMR spectra were recorded on Bruker AV-300 (300 MHz), 
Bruker Avance III 400 (400MHz) (100 MHz) spectrometer, 500 MHz Bruker DRX 
NMR spectrometer or AMX500 (500MHz) spectrometer. Chemical shifts are 
recorded as δ in units of parts per million (ppm). The residual solvent peak was used 
as an internal reference. 19F NMR was performed on a Bruker Avance III 400 
(400MHz) spectrometer. Low resolution mass spectra (LRMS) were obtained on the 
ThermoFinnigan PolarisQ MS and ThermoFinnigan LCQ Fleet MS; High resolution 
mass spectra (HRMS) were obtained on the Q-Tof Premier mass spectrometer 
(Waters Corporation). LRMS and HRMS were reported in units of mass of charge 
ratio (m/z). Enantiomeric excess values were determined by HPLC analysis on 
Shimadzu LC-20AT and LC-2010CHT HPLC workstations. Optical rotations were 
measured in CHCl3 using a 1 mL cell with a 1 dm path length on a Jasco P-1030 
polarimeter with a sodium lamp of wavelength 589 nm and reported as follows: [𝑎]𝐷
𝑟𝑡 
(c = g/100 mL, solvent). Melting points (mp) were measured in OptiMelt MPA100 
equipment and uncorrected. X-ray crystallography analysis was performed on Bruker 
X8 APEX X-ray diffractionmeter. Flash chromatography separations were performed 
on Merck 60 (0.040-0.063mm) mesh silica gel. Analytical thin-layer chromatography 
(TLC) was performed on Merck 60 F254 silica gel plates. Visualization was 
performed using a UV lamp or potassium permanganate stain. 
Materials THF were distilled over sodium/benzophenone under N2 atmosphere. 
Toluene, Acetonitrile and Dichloromethane were distilled over CaH2 under N2 
atmosphere. The mercaptans were purchased from commercial suppliers or 
synthesized according to the literature procedures and used directly without further 
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purification. Other reagents and solvents were commercial grade and were used as 
supplied without further purification, unless otherwise stated. Experiments involving 
moisture and/or air sensitive components were performed under a positive pressure of 
nitrogen in oven-dried glassware equipped with a rubber septum inlet. All compounds 
synthesized were stored in a -30 oC freezer. 
4.2. Experimental procedures 
4.2.1. Preparation and Characterizations of Chiral Pentanidium Salts 
 
Representative procedure for chlorination or bromination of arene1,2 A mixture 
of 3,5-di-tert-butyltoluene(5.0 g, 24.4 mmol, 1.0 equiv), FeCl3 (0.78 g, 4.9 mmol, 0.2 
equiv) and NBS (4.56 g, 25.6 mmol, 1.05 equiv) in dry CH3CN (50 mL) was stirred at 
82 °C for 12 h, and the resulting solution was cooled to room temperature and then 
evaporated. The crude product was purified by silica gel column chromatography 
(hexane) to give the colorless oil 2-bromo-1,5-di-tert-butyl-3-methylbenzene (6.83 g, 
24.0 mmol, 98% yield). 
 
                                                     
1Kawamura, K.; Fukuzawa, H.; Hayashi, M. Bull. Chem. Soc. Jpn.2011, 84, 640-647. 
2Tanemura, K.; Suzuki, T.; Nishida, Y.; Satsumabayashi, K.; Horaguchi, T. Chem. Lett.2003, 
32, 932-933. 
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Representative procedure for iodination of arene3 To a solution of 3,5-di-tert-  
butyl toluene (4.08 g, 20 mmol, 1.0 equiv) in MeCN (100 mL) were added I2 (3.8 g, 
15.0 mmol, 0.75 equiv) and Selectfluor (5.3 g, 15.0 mmol, 0.75 equiv) and the 
reaction mixture was stirred at 60 °C for 12 h. The solvent was removed under 
reduced pressure and the crude mixture was dissolved in CH2Cl2 (100 mL). Insoluble 
material was filtered off, and then the filtrate was washed with aqueous 10 % 
Na2S2O3•5H2O (100 mL) and H2O (100 mL), and dried (Na2SO4). The solvent was 
evaporated, and the crude product were purified by flash chromatography over silica 
gel (hexane), followed by distillation under reduced pressure (colourless oil, 3.21 g, 
74% isolated yield) with the recovery of 3,4-di-tert-butyltoluene (1.4 g, 6.86 mmol). 
 
Syntheses of 1-(bromomethyl)-3,5-di-tert-butyl-2-iodobenze4: To a stirred solution 
of 1,5-di-tert-butyl-2-iodo-3-methylbenzene (4.17 g, 12.6 mmol, 1.0 equiv.) in H2SO4 
(6.86 mL), AcOH (21 mL), and Ac2O (46 mL) was slowly added KMnO4 (4.98 g, 
31.5 mmol, 2.5 equiv.) at 40 °C over a period of 4 h and the mixture was stirred for 1 
day at the same temperature. The mixture was poured into H2O and extracted with 
Et2O. The ethereal layer was washed with 10% NaOH solution and brine, dried over 
anhydrous Na2SO4, and the solvent was removed under reduced pressure. The residue 
was chromatographed through a column of silica gel using hexane-CH2Cl2 (2:1) as the 
                                                     
3Stavber, S.; Kralj, P.; Zupan, M. Synthesis-Stuttgart2002, 1513-1518. 
4 Hirai, K.; Bessho, K.; Kitagawa, T.; Tomioka, H. J. Phys. Org. Chem. 2010, 23, 347-356; Sperandio, 
D.; Hansen, H. J. Helv. Chim. Acta 1995, 78, 765-771. 
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eluent to give 3,5-di-tert-butyl-2-iodobenzyl acetate(1.51 g, 3.90 mmol) as a yellow 
viscous liquid in 31% crude yield.  
To a stirred solution of this acetate (1.51 g, 3.90 mmol 1.0 equiv.) in MeOH (20 mL) 
was added K2CO3 (270 mg, 1.95 mmol, 0.5 equiv.) and the mixture was stirred at 
room temperature for 3 h. The reaction mixture was quenched by the addition of 2 M 
hydrochloric acid. The mixture was extracted with ether, and the organic solution was 
washed with brine, dried over anhydrous Na2SO4, and the solvent was removed under 
reduced pressure. The residue was subjected to flash chromatography (silica gel, 
hexane-ethyl acetate 20:1-5:1) afford the product to give (3,5-di-tert-butyl-2-
iodophenyl)methanol (1.24 g, 3.58 mmol) as a white solid in 92% yield. 
(3,5-di-tert-butyl-2-iodophenyl)methanol (984 mg, 2.84 mmol, 1.0 equiv.) was 
suspended in a vigorously stirred solution of glacial AcOH (5.7 mL) and HBr (48% 
wt in H2O, 1.54 mL, 10 equiv.). The suspension was heated up to 100 °C for 1 h. 
Then the mixture was cooled to room temperature and poured onice-water and stirred 
again for 10 min. The mixture was extracted with ether, and the organic solution was 
washed with brine, dried over anhydrous Na2SO4, and the solvent was removed under 
reduced pressure. The residue was subjected to flash chromatography using hexane as 
an eluent to afford the product 1-(bromomethyl)-3,5-di-tert-butyl-2-iodobenzene(1.0 
g, 2.45 mmol) as colourless oil in 87% yield. 
 
Representative procedure for synthesis of monoalkyaled diamines 110 by 
amidation\reduction To a mixture of 105 (1.06 g, 5.0 mmol, 1.0 equiv) and Et3N 
(1.74 mL, 12.5 mmol, 2.5 equiv) in dry CH2Cl2 (20 mL) was added 4-chloro benzoyl 
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chloride (1.3 mL, 10.25 mmol, 2.05 equiv) dropwise at 0 °C and the solution was 
vigorously stirred for the appropriate time as monitored by thin-layer chromatography 
(TLC).Then the reaction mixture was quenched by addition of water. The aqueous 
was extracted with CH2Cl2 (50 mL × 3). The combined organic phase was washed 
with water, saturated NaHCO3 solution and brine, dried over anhydrous Na2SO4, and 
evaporated in vacuo. The crude amide product was used directly in next stop with 
further purification. Thus, to a suspension of the crude amide in dry THF (50 mL) was 
slowly added BH3•Me2S (6.25 mL, 12.5 mmol, 2.5 equiv) at 0 °C. After reflux for 8 
h, the reaction was cooled to 0 °C and quenched by the slow addition of MeOH (10 
mL). After 15 min, 6N HCl (5 mL) was added at 0 °C and refluxed for 1 h. The 
reaction mixture was cooled to 0°C and basified with 4N NaOH. The reaction mixture 
was extracted with CH2Cl2 (50 mL × 3), dried (Na2SO4) and concentrated under 
vacuo. Further chromatographic purification afforded the desired compound 110 (1.75 
g, 76% yield). 
Representative procedure for the synthesis of chiral pentanidium salts (take the 
pentanidium 101l as an example) 
 
Step 1: To a solution of chiral diamine A (1.23 g, 5.8 mmol, 1.0 equiv) and K2CO3 
(1.77 g, 12.8 mmol, 2.2 equiv) in MeCN (15 mL), was added 2-bromo-3,5-di-tert-
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butylbenzyl bromide (4.30 g, 11.9 mmol, 2.05 equiv) by using a syringe pump during 
1 h, and then the reaction mixture was stirred for 24 h at room temperature (monitored 
by TLC). After diamine A was completely consumed, reaction was quenched by 
water (20 mL) and extracted with CH2Cl2 (30 mL × 3). The combined organic layer 
was washed by brine and dried by Na2SO4 and the solvent was removed under 
reduced pressure. Compound B was obtained by flash chromatography (silica gel, 
hexane-ethyl acetate 50:1-30:1), as a white solid, 3.55 g, 79% yield. 
Step 2: A 50 ml flask was charged with 1.0 mL CH2Cl2, compound B (522 mg, 0.67 
mmol, 1.0 equiv), and K2CO3 (205 mg, 1.48 mmol, 2.2 equiv) in 1.5 mL H2O. The 
resulting mixture was stirred vigorously at 0 oC, followed by the dropwise addition of 
an anhydrous CH2Cl2 solution of triphosgene (1.0 M, 67 mg, 0.22 mmol, 0.33 equiv). 
After the addition, the mixture was warmed to rt and further stirred for 2 h to 
complete the reaction. The reaction mixture was then extracted with CH2Cl2 (5 mL × 
3). The combined organic layer was washed by brine and dried by Na2SO4. Solvent 
was removed under reduced pressure. Compound C was obtained by flash 
chromatography (silica gel, hexane-ethyl acetate 50:1-30:1), as a white solid, 515 mg, 
95% yield. 
Step 3: To a solution of compound C (515 mg, 0.64 mmol, 1.0 equiv) in 3.0 mL o-
xylene was added Lawesson’s reagent (518 mg, 1.28 mmol, 2.0 equiv) under nitrogen 
atmosphere. Then the whole solution was heated to 145 oC for 24 h and cooled to rt. 
Upon the completion of compound C on TLC, the whole solution was directly loaded 
on a column, use gravity to drain all the o-xylene and generally use Hexane/EA 
(100:1-20:1) to flush out the D as pale-yellow foam, 508 mg, 96% yield. 
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Step 4: A 100 mL RBF was charged with a solution of D (508 mg, 0.62 mmol, 1.0 
equiv) in toluene (3 mL) with a condenser under N2 atmosphere. (COCl)2 (0.43 mL, 
4.97 mmol, 8.0 equiv) was added via syringe in one portion. The mixture was 
refluxed overnight until D was completely reacted. Toluene was removed under 
reduced pressure and solid imidazoline salt was obtained for the next step without 
any purification. (Imidazoline salt is air and moisture sensitive, which should be 
stored under nitrogen atmosphere or vacuum.) 
Step 5: To a solution of B (775 mg, 1 mmol, 1.0 equiv) in dry MeCN (5 mL) under 
nitrogen atmosphere was added BrCN (106 mg, 1 mmol, 1.0 equiv). And the whole 
solution was heated to reflux for 12 h and cool to rt, solvent was removed under 
reduced pressure and compound E was obtained by flash chromatography (silica gel, 
DCM-Methanol 100:1-30:1), as a white hygroscopic powder, 703 mg, 87% yield. 
Step 6:The imidazoline salt was dissolved in dry MeCN (3 mL) under nitrogen 
atmosphere, and then compound E (204 mg, 0.25 mmol, 0.4 equiv) was added, 
followed by the addition of Et3N (0.26 mL, 1.86 mmol, 3.0 equiv). Then the whole 
solution was heated to reflux for 12 h and cooled to rt. Add 1M HCl (20 mL) to the 
reaction solution and the mixture was extracted by CH2Cl2 (10 mL × 3). The 
combined organic layer was dried by Na2SO4. Solvent was removed under reduced 
pressure and PTC was obtained by flash chromatography (silica gel, DCM-Methanol 
100:1-20:1), as a beige powder, 315 mg, 78% yield. 
 
1,5-di-tert-butyl-2-chloro-3-methylbenzene Colourless oil; 80% yield; 1H NMR 
(400 MHz, CDCl3) δ 7.35 (d, J = 2.4 Hz, 1H), 7.15 (d, J = 2.3 Hz, 1H), 2.42 (s, 3H), 
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1.53 (s, 9H), 1.33 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 148.49, 145.79, 137.15, 
131.09, 125.93, 122.57, 36.52, 34.53, 31.36, 29.90, 21.99; LRMS (EI) m/z 238.1 [M] +. 
 
1-(bromomethyl)-3,5-di-tert-butyl-2-chlorobenzene Colourless oil; 93% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.45 (d, J = 2.4 Hz, 1H), 7.31 (d, J = 2.4 Hz, 1H), 4.66 (s, 
2H), 1.51 (s, 9H), 1.31 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 149.37, 146.88, 
136.24, 131.06, 126.28, 125.70, 36.74, 34.70, 33.21, 31.25, 29.87. 
 
2-bromo-1, 5-di-tert-butyl-3-methylbenzene  Colourless oil; 98% yield; 1HNMR 
(400 MHz, CDCl3) δ 7.33 (d, J = 2.5 Hz, 1H), 7.13 (d, J = 2.4 Hz, 1H), 2.44 (s, 3H), 
1.54 (s, 9H), 1.30 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 149.18, 147.36, 139.22, 
125.94, 122.91, 122.61, 77.32, 77.00, 76.68, 37.28, 34.56, 31.29, 30.10, 25.65; LRMS 
(EI) m/z 283.1 [M] +.  
 
2-bromo-1-(bromomethyl)-3,5-di-tert-butylbenzene1 Colourless oil; 83% yield; 1H 
NMR (300 MHz, CDCl3) δ 7.45 (d, J = 2.5 Hz, 1H), 7.33 (d, J = 2.5 Hz, 1H), 4.72 (s, 
2H), 1.55 (s, 9H), 1.32 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 150.08, 148.48, 138.11, 
126.47, 125.97, 122.13, 77.42, 77.00, 76.58, 37.53, 36.78, 34.72, 31.19, 30.11; 
 
                                                     
1Kawamura, K.; Fukuzawa, H.; Hayashi, M. Bull. Chem. Soc. Jpn.2011, 84, 640-647. 
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1,5-di-tert-butyl-2-iodo-3-methylbenzene Colourless oil; 74% yield; 1H NMR (400 
MHz, CDCl3) δ 7.29 (d, J = 2.4 Hz, 1H), 7.16 (d, J = 2.2 Hz, 1H), 2.53 (s, 3H), 1.61 
(s, 9H), 1.31 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 150.27, 150.15, 142.97, 124.93, 
122.55, 100.01, 37.80, 34.54, 32.64, 31.23, 30.42; LRMS (EI) m/z 330.0 [M] +.  
 
(3,5-di-tert-butyl-2-iodophenyl)methanol5 White solid; 92% yield; mp: 89.9-91.0 °C; 
1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 2.5 Hz, 1H), 7.35 (d, J = 2.5 Hz, 1H), 4.76 
(d, J = 6.4 Hz, 2H), 2.28 (t, J = 6.6 Hz, 1H), 1.61 (s, 9H), 1.33 (s, 9H); 13C NMR (100 
MHz, CDCl3) δ 150.87, 150.31, 143.86, 124.70, 124.20, 96.61, 72.28, 37.86, 34.76, 
31.23, 30.44. 
 
1-(bromomethyl)-3,5-di-tert-butyl-2-iodobenzene Colourless oil; 87% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.5 Hz, 1H), 7.36 (d, J = 2.5 Hz, 1H), 4.79 (s, 
2H), 1.60 (s, 9H), 1.31 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 151.45, 151.07, 
141.56, 125.75, 125.54, 98.71, 43.80, 38.09, 34.70, 31.14, 30.48. 
 
(1S,2S)-N1,N2-dibenzhydryl-1,2-diphenylethane-1,2-diamine(110a) Yellow oil; 70% 
yield; 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.22 (m, 14H), 7.22 – 7.16 (m, 6H), 7.16 
                                                     
5Hirai, K.; Bessho, K.; Kitagawa, T.; Tomioka, H. J. Phys. Org. Chem.2010, 23, 347-356. 
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– 7.10 (m, 6H), 7.01 – 6.94 (m, 4H), 4.54 (s, 2H), 3.65 (s, 2H), 2.72 (s, 2H), 1.54 (s, 
2H); 13C NMR (125 MHz, CDCl3) δ 144.88, 143.33, 140.97, 128.44, 128.27, 128.10, 
127.89, 127.79, 127.18, 126.89, 126.87, 126.74, 65.83, 63.31; HRMS (ESI) calcd for 
C40H36N2 m/z [M+1]
 +:545.2957; found: 545.2952. 
 
(1S,2S)-N1,N2-bis(3,5-di-tert-butylbenzyl)-1,2-diphenylethane-1,2 diamine(110b) 
White solid; 83% yield; mp: 109.7-111.1 °C; [𝑎]𝐷
22= + 6.4 (c 0.64, CHCl3);
 1H NMR 
(400 MHz, CDCl3) δ 7.28 (t, J = 1.7 Hz, 2H), 7.16 (dd, J = 6.2, 4.5 Hz, 6H), 7.06 (dd, 
J = 9.4, 1.8 Hz, 8H), 3.73 (s, 2H), 3.63 (d, J = 13.0 Hz, 2H), 3.49 (d, J = 13.0 Hz, 2H), 
1.29 (s, 36H); 13C NMR (100 MHz, CDCl3) δ 150.53, 141.48, 139.62, 128.08, 127.87, 
126.80, 122.39, 120.73, 68.44, 52.08, 34.73, 31.48; HRMS (ESI) calcd for C44H60N2 
m/z [M+1] +:617.4835; found:617.4835. 
 
(1S,2S)-N1,N2-bis(3,5-di-tert-butyl-2-fluorobenzyl)-1,2-diphenylethane-1,2-
diamine(110c) colorless oil; 85% yield; 1H NMR (400 MHz, CDCl3) δ 7.20 – 7.10 (m, 
8H), 7.08 – 6.99 (m, 6H), 3.75 (d, J = 13.4 Hz, 2H), 3.69 (s, 2H), 3.53 (d, J = 13.5 Hz, 
2H), 2.39 (s, 2H),  1.34 (s, 18H), 1.28 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 
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159.52, 157.07, 145.46, 135.71, 135.59, 127.99, 127.91, 126.87, 125.14, 125.09, 
122.68, 122.64, 68.40, 45.89, 45.84, 34.45, 34.41, 34.39, 31.55, 30.06, 30.02; 19F 
NMR (376 MHz, CDCl3) δ -121.16; HRMS (ESI) calcd for C44H58F2N2 m/z 
[M+1]+:653.4646; found:653.4649. 
 
(1S,2S)-N1,N2-bis(3,5-di-tert-butyl-2-chlorobenzyl)-1,2-diphenylethane-1,2 
diamine(110d) Colourless oil; 78% yield; [𝑎]𝐷
22= + 20.3 (c 1.24, CHCl3);
 1H NMR 
(400 MHz, CDCl3) δ 7.33 (d, J = 2.4 Hz, 2H), 7.20 -7.12 (m, 6H), 7.09 (d, J = 1.8 Hz, 
2H), 7.07 (dd, J = 4.1, 1.9 Hz, 4H), 3.79 (d, J = 13.6 Hz, 2H), 3.66 (s, 2H), 3.56 (d, J 
= 13.6 Hz, 2H), 2.64 (s, 2H), 1.45 (s, 18H), 1.26 (s, 18H); 13C NMR (100 MHz, 
CDCl3) δ 148.41, 145.89, 141.21, 138.61, 130.64, 128.02, 127.91, 126.84, 125.72, 
123.53, 68.41, 50.84, 36.51, 34.59, 31.33, 29.96; HRMS (ESI) calcd for C44H58Cl2N2 
m/z [M+1]+:685.4055; found:685.4050. 
 
(1S,2S)-N1,N2-bis(2-bromo-3,5-di-tert-butylbenzyl)-1,2-diphenylethane-1,2- 
diamine (110e) White hygroscopic foam; 79% yield; [𝑎]𝐷
22= –22.1 (c 1.8, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 7.38 (d, J = 2.5 Hz, 2H), 7.24-7.11 (m, 10H), 7.08 (d, J = 
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2.5 Hz, 2H), 3.84 (d, J = 13.6 Hz, 2H), 3.71 (s, 2H), 3.63 (d, J = 13.6 Hz, 2H), 2.72 (s, 
2H), 1.53 (s, 18H), 1.30 (s, 18H);13C NMR (100 MHz, CDCl3) δ 149.00, 147.33, 
141.10, 140.31, 128.01, 127.92, 126.84, 126.07, 123.94, 121.85,68.22, 53.60, 37.27, 
34.57, 31.26, 30.17; HRMS (ESI) calcd for C44H58Br2N2 m/z [M+1]
 +:775.3025; 
found:775.3007. 
 
(1S,2S)-N1,N2-bis(3,5-di-tert-butyl-2-iodobenzyl)-1,2-diphenylethane-1,2-
diamine(110f) White foam; 94% yield; [𝑎]𝐷
22= +18.2 (c 1.72, CHCl3);
  1H NMR (400 
MHz, CDCl3) δ 7.33 (d, J = 2.3 Hz, 2H), 7.16 (dt, J = 13.7, 4.9 Hz, 10H), 7.00 (d, J = 
2.3 Hz, 2H), 3.79 (d, J = 13.5 Hz, 2H), 3.69 (s, 2H), 3.63 (d, J = 13.5 Hz, 2H), 2.74 (s, 
2H), 1.55 (s, 18H), 1.25 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 150.19, 149.94, 
143.63, 141.14, 128.16, 127.98, 126.88, 125.60, 123.85, 98.67, 68.12, 58.98, 37.85, 
34.55, 31.23, 30.55; HRMS (ESI) calcd for C44H58I2N2 m/z [M+1]
 +:869.2768; found: 
869.2767. 
 
(4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-one(111a) 
White solid; >99% yield; mp: 144.5-146.3 °C; [𝑎]𝐷
22= – 53.7 (c 1.2, CHCl3); 1H NMR 
Chapter 4 
 
93 
 
(400 MHz, CDCl3) δ 7.25 (ddt, J = 8.8, 3.5, 1.7 Hz, 8H), 7.01 – 6.96 (m, 4H), 6.96 (d, 
J = 1.7 Hz, 4H), 5.12 (d, J = 14.5 Hz, 2H), 3.99 (s, 2H), 3.62 (d, J = 14.5 Hz, 2H), 
1.28 (s, 36H); 13C NMR (100 MHz, CDCl3) δ 159.85, 150.82, 139.41, 135.70, 128.66, 
128.14, 127.27, 122.98, 121.07, 65.34, 46.30, 34.70, 31.41; HRMS (ESI) calcd for 
C45H58N2O m/z [M+1]
 +:643.4627; found:643.4631. 
 
(4S,5S)-1,3-bis(3,5-di-tert-butyl-2-chlorobenzyl)-4,5-diphenylimidazolidin-2 
one(111b) White solid; 78% yield; mp:100.2-101.3 °C; [𝑎]𝐷
22= –77.8 (c 0.6, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 2.3 Hz, 2H), 7.27-7.18 (m, 6H), 7.03 (dd, J 
= 7.3, 2.0 Hz, 4H), 6.85 (d, J = 2.3 Hz, 2H), 5.11 (d, J = 14.8 Hz, 2H), 4.02 (d, J = 
14.8 Hz, 2H), 3.94 (s, 2H), 1.45 (s, 18H), 1.19 (s, 18H); 13C NMR (100 MHz, CDCl3) 
δ 159.30, 148.42, 146.19, 139.92, 134.81, 130.69, 128.71, 128.06, 127.08, 126.24, 
124.18, 66.09, 45.42, 36.52, 34.49, 31.21, 29.8; HRMS (ESI) calcd for C45H56Cl2N2O 
m/z [M+1] +:711.3848; found:711.3849. 
 
(4S,5S)-1,3-bis(2-bromo-3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-one 
(111c) Colorless oil; 95% yield; [𝑎]𝐷
22= –69.8 (c 1.57, CHCl3); 1H NMR (400 MHz, 
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CDCl3) δ 7.39-7.18 (m, 8H), 7.07 (dd, J = 6.4, 3.1 Hz, 4H), 6.82 (d, J = 2.4 Hz, 2H), 
5.13 (d, J = 14.8 Hz, 2H), 4.09 (d, J = 14.8 Hz, 2H), 3.96 (s, 2H), 1.50 (s, 18H), 1.18 
(s, 18H); 13C NMR (100 MHz, CDCl3) δ 159.23, 149.05, 147.74, 139.92, 136.60, 
128.75, 128.06, 127.07, 126.39, 124.59, 121.60, 66.08, 48.23, 37.32, 34.50, 31.15, 
30.04; HRMS (ESI) calcd for C45H56Br2N2O m/z [M+1]
 +:801.2817; found:801.2822. 
 
(4S,5S)-1,3-bis(4-fluorobenzyl)-4,5-diphenylimidazolidine-2-thione(112a) White 
foam; 84% yield; 1H NMR (300 MHz, CDCl3) δ 7.40 – 7.27 (m, 6H), 7.26 – 7.14 (m, 
4H), 7.05 – 6.79 (m, 8H), 5.79 (d, J = 14.8 Hz, 2H), 4.27 (s, 2H), 3.79 (d, J = 14.8 Hz, 
2H); 13C NMR (75 MHz, CDCl3) δ 182.57, 163.93, 160.66, 137.89, 131.77, 131.73, 
130.25, 130.14, 129.21, 128.87, 126.96, 115.57, 115.28, 69.26, 48.18;19F NMR (282 
MHz, CDCl3) δ -38.44; HRMS (ESI) calcd for C29H24F2N2S m/z [M+1] +:471.1707; 
found: 471.1713. 
 
(4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidine-2-thione(112b) 
Pale yellow foam; >99% yield; [𝑎]𝐷
22= – 152.10 (c 0.95, CHCl3);1H NMR (400 MHz, 
CDCl3) δ 7.32-7.24 (m, 8H), 7.01 (d, J = 1.6 Hz, 4H), 6.97 (dd, J = 7.7, 1.6 Hz, 4H), 
5.88 (d, J = 14.6 Hz, 2H), 4.24 (s, 2H), 3.74 (d, J = 14.6 Hz, 2H), 1.27 (s, 36H); 13C 
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NMR (100 MHz, CDCl3) δ 182.08, 150.96, 139.18, 135.14, 129.02, 128.57, 127.06, 
122.88, 121.40, 68.73, 49.72, 34.75, 31.45; HRMS (ESI) calcd for C45H58N2S m/z 
[M+1] +:659.4399; found:659.4401. 
 
(4S,5S)-1,3-bis(3,5-di-tert-butyl-4-methoxybenzyl)-4,5-diphenylimidazolidine-2-
thione(112c) White foam; 89% yield; 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.22 (m, 
8H), 7.05 (s, 4H), 6.95 (dd, J = 7.6, 1.6 Hz, 4H), 5.72 (d, J = 14.5 Hz, 2H), 4.25 (s, 
2H), 3.72 (d, J = 14.5 Hz, 2H), 3.63 (s, 6H), 1.36 (s, 36H); 13C NMR (100 MHz, 
CDCl3) δ 173.19, 158.87, 143.65, 139.16, 129.97, 129.00, 128.57, 127.01, 126.98, 
68.99, 64.14, 49.41, 35.64, 32.09; HRMS (ESI) calcd for C47H62N2O2S m/z [M+1]
 
+:719.4610; found: 719.4621. 
 
(4S,5S)-1,3-bis(3,5-di-tert-butyl-2-fluorobenzyl)-4,5-diphenylimidazolidine-2-
thione(112d) pale yellow foam; quantitative yield; 1H NMR (400 MHz, CDCl3) δ 
7.33 – 7.22 (m, 6H), 7.17 (dd, J = 7.5, 2.5 Hz, 2H), 7.12 (dd, J = 6.2, 2.4 Hz, 2H), 
6.99 (dd, J = 7.7, 1.5 Hz, 4H), 5.72 (d, J = 14.7 Hz, 2H), 4.26 (s, 2H), 4.02 (d, J = 
14.7 Hz, 2H), 1.31 (s, 18H), 1.26 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 181.92, 
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159.36, 156.89, 145.87, 145.83, 139.36, 136.10, 135.98, 129.02, 128.54, 126.82, 
125.79, 125.75, 123.66, 123.61, 122.56, 122.40, 69.22, 43.64, 43.58, 34.45, 34.41, 
31.50, 29.94, 29.90; 19F NMR (377 MHz, CDCl3) δ -119.55; HRMS (ESI) calcd for 
C45H56F2N2S m/z [M+1]
+:695.4211; found:695.4205. 
 
(4S,5S)-1,3-bis(3,5-di-tert-butyl-2-chlorobenzyl)-4,5-diphenylimidazolidine-2-
thione(112e) Colourless oil; 78% yield; [𝑎]𝐷
22= –164.64 (c 2.2, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 7.33 (d, J = 2.3 Hz, 2H), 7.29 (dd, J = 5.0, 1.6 Hz, 6H), 7.06 (dd, J = 
6.3, 2.8 Hz, 4H), 6.98 (d, J = 2.2 Hz, 2H), 5.79 (d, J = 14.9 Hz, 2H), 4.23 (d, J = 16.6 
Hz, 4H), 1.44 (s, 18H), 1.22 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 182.51, 148.57, 
146.29, 139.36, 134.30, 130.69, 129.02, 128.44, 126.81, 126.02, 124.39, 69.52, 48.62, 
36.52, 34.52, 31.23, 29.78; HRMS (ESI) calcd for C45H56Cl2N2S m/z [M+1]
 
+:727.3620; found:727.3620. 
 
(4S,5S)-1,3-bis(2-bromo-3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidine-2-
thione (112f) Pale yellow foam;  96% yield; [𝑎]𝐷
22= –145.0 (c 2.02, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 7.33 (d, J = 2.4 Hz, 2H), 7.31-7.26 (m, 6H), 7.14-7.02 (m, 4H), 
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6.95 (d, J = 2.4 Hz, 2H), 5.77 (d, J = 15.0 Hz, 2H), 4.32 (d, J = 15.0 Hz, 2H), 4.22 (s, 
2H), 1.47 (s, 18H), 1.20 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 182.65, 149.23, 
147.83, 139.32, 136.11, 129.09, 128.48, 126.86, 126.07, 124.83, 121.59, 69.58, 51.49, 
37.36, 34.58, 31.22, 30.04; HRMS (ESI) calcd for C45H56Br2N2S m/z [M+1]
 
+:817.2589; found:817.2587. 
 
(4S,5S)-1,3-bis(2-bromo-3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidine-2-
thione(112g): A 5 mL flask was charged with 1.5 mL CH2Cl2, (1S,2S)-N1,N2-
bis(3,5-di-tert-butyl-2-iodobenzyl)-1,2-diphenylethane-1,2-diamine 110f (305 mg, 
0.35 mmol, 1.0 equiv.) and K2CO3 (106 mg, 0.77 mmol, 2.2 equiv.) in 1.5 mL H2O. 
The resulting mixture was stirred vigorously at 0 oC, followed by the dropwise 
addition of an anhydrous CH2Cl2 solution of thiophosgene (1.0 M, 29.6 μL, 0.39 
mmol, 1.1 equiv.). After the addition, the mixture was warmed to room temperature 
and further stirred for 2 h to complete the reaction. The reaction mixture was then 
extracted with CH2Cl2 (5 mL × 3). The combined organic layer was washed by brine 
and dried by Na2SO4. After removal of solvent under reduced pressure, the residue 
was subjected to flash chromatography (silica gel, hexane-ethyl acetate 50:1-30:1) to 
afford the product as colorless oil in 91% yield; [𝑎]𝐷
22= –126.4 (c 0.36, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 7.30 (dd, J = 4.2, 2.3 Hz, 4H), 7.10 (dd, J = 6.5, 3.0 Hz, 
2H), 6.91 (d, J = 2.4 Hz, 1H), 5.74 (d, J = 15.1 Hz, 1H), 4.43 (d, J = 15.2 Hz, 1H), 
4.22 (s, 1H), 1.51 (s, 8H), 1.19 (s, 8H); 13C NMR (100 MHz, CDCl3) δ 182.99, 150.63, 
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150.14, 139.35, 139.21, 129.13, 128.45, 126.94, 125.28, 124.65, 97.89, 69.64, 57.23, 
37.90, 34.52, 31.15, 30.40; IR: 2964, 2870, 1633, 1556, 1487, 1454, 1396, 1361, 1280, 
1234, 1165, 1001, 731 cm-1; HRMS (ESI) calcd for C45H56I2N2S m/z [M+H]
 +: 
911.2332; found: 911.2335. 
 
(3aS,7aS)-1,3-bis(3,5-di-tert-butylbenzyl)hexahydro-1H-benzo[d]imidazole-
2(3H)-thione(112h) Pale yellow oil; 59% yield;  [𝑎]𝐷
22= –104.6 (c 1.27, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 7.34 – 7.19 (m, 6H), 5.03 – 4.86 (m, 4H), 2.85 (d, J = 7.4 
Hz, 2H), 1.95 (d, J = 8.7 Hz, 2H), 1.72 (d, J = 6.2 Hz, 4H), 1.31 (s, 36H), 1.19 (d, J = 
6.5 Hz, 4H); 13C NMR (100 MHz, CDCl3) δ 187.52, 150.67, 136.12, 122.34, 120.92, 
64.81, 50.60, 34.74, 31.49, 28.81, 24.15; HRMS (ESI) calcd for C37H56N2S m/z [M+1]
 
+:561.4242; found: 561.4240. 
 
(4S,5S)-1,3-dibenzhydryl-4,5-diphenylimidazolidin-2-iminehydrobromide(113a) 
Brown oil; 27% yield; 1H NMR (500 MHz, CDCl3) δ 7.32 (s, 5H), 7.22 (dt, J = 6.8, 
4.7 Hz, 5H), 7.18 – 7.11 (m, 3H), 6.90 (d, J = 6.8 Hz, 2H), 6.51 (s, 1H), 4.57 (s, 1H); 
13C NMR (125 MHz, CDCl3) δ 158.78, 138.32, 136.73, 135.41, 129.49, 129.08, 
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129.04, 128.70, 128.66, 128.54, 128.23, 126.52, 70.61, 63.95; HRMS (ESI) calcd for 
C41H36BrN3 m/z [M-Br
-] +:570.2909; found: 570.2906. 
 
(4S,5S)-1-(3,4-di-tert-butylbenzyl)-3-(3,5-di-tert-butylbenzyl)-4,5-
diphenylimidazolidin-2-imine hydrobromide(113b) White foam; 98% yield; [𝑎]𝐷
22= 
– 125.3 (c 1.37, CHCl3); 1H NMR (400 MHz, CDCl3) δ 9.29 (s, 2H), 7.37-7.23 (m, 
8H), 6.97 (d, J = 1.6 Hz, 4H), 6.95-6.89 (m, 4H), 5.76 (d, J = 15.0 Hz, 2H), 4.25 (s, 
2H), 3.89 (d, J = 14.9 Hz, 2H), 1.26 (s, 36H); 13C NMR (100 MHz, CDCl3) δ 156.35, 
151.24, 137.16, 132.47, 129.24, 129.17, 126.92, 123.37, 122.03, 68.24, 49.25, 34.74, 
31.40; HRMS (ESI) calcd for C45H60BrN3 m/z [M-Br
-] +:642.4787; found:642.4781.  
 
(4S,5S)-1,3-bis(3,5-di-tert-butyl-4-methoxybenzyl)-4,5-diphenylimidazolidin-2-
imine hydrobromide(113c) Pale yellow foam; >99% yield; 1H NMR (400 MHz, 
CDCl3) δ 9.28 (s, 2H), 7.31 (dt, J = 14.1, 6.9 Hz, 6H), 7.01 (s, 4H), 6.93 (d, J = 7.5 
Hz, 4H), 5.65 (d, J = 14.9 Hz, 2H), 4.30 (s, 2H), 3.88 (d, J = 15.0 Hz, 2H), 3.63 (s, 
6H), 1.35 (s, 36H); 13C NMR (100 MHz, CDCl3) δ 159.44, 156.53, 144.02, 137.18, 
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129.30, 129.21, 127.52, 127.39, 126.83, 68.56, 64.21, 48.97, 35.69, 32.06; HRMS 
(ESI) calcd for C47H64BrN3O2 m/z [M-Br
-] +:702.4999; found: 702.5000. 
 
(4S,5S)-1,3-bis(3,5-di-tert-butyl-2-fluorobenzyl)-4,5-diphenylimidazolidin-2-
iminium bromide(113d) white foam; 98% yield; 1H NMR (400 MHz, CDCl3) δ 9.28 (s, 
2H), 7.33 – 7.27 (m, 2H), 7.25 (d, J = 7.8 Hz, 4H), 7.23 – 7.16 (m, 2H), 6.95 (dd, J = 6.2, 2.4 
Hz, 2H), 6.93 – 6.87 (m, 4H), 5.75 (d, J = 15.0 Hz, 2H), 4.19 (s, 2H), 4.08 (d, J = 15.0 Hz, 
2H), 1.34 (s, 18H), 1.22 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 159.51, 157.04, 156.16, 
146.19, 146.15, 137.42, 136.27, 136.16, 129.12, 129.02, 126.87, 126.79, 126.75, 124.53, 
124.47, 120.20, 120.03, 68.81, 44.27, 44.23, 34.44, 34.41, 34.38, 31.42, 29.94, 29.91;  19F 
NMR (376 MHz, CDCl3) δ -118.83; HRMS (ESI) calcd for C45H58BrF2N3 m/z [M-Br-
]+:685.4055; found:685.4050. 
 
 
(4S,5S)-1,3-bis(3,5-di-tert-butyl-2-chlorobenzyl)-4,5-diphenylimidazolidin-2-
imine hydrobromide(113e) White solid; 78% yield; mp:167.1-168.8 °C; [𝑎]𝐷
22= –
44.9 (c 2.6, CHCl3);
 1H NMR (400 MHz, CDCl3) δ 9.19 (s, 2H), 7.35 (d, J = 2.3 Hz, 
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2H), 7.33 – 7.20 (m, 8H), 6.98 (d, J = 6.9 Hz, 4H), 5.89 (d, J = 14.6 Hz, 2H), 4.15 (d, 
J = 14.7 Hz, 2H), 3.96 (s, 2H), 1.52 (s, 18H), 1.10 (s, 18H); 13C NMR (100 MHz, 
CDCl3) δ 156.32, 148.71, 146.73, 137.57, 131.53, 131.16, 129.15, 128.98, 128.09, 
127.07, 125.37, 68.73, 49.69, 36.62, 34.41, 31.03, 29.81; HRMS (ESI) calcd for 
C45H58BrCl2N3 m/z [M-Br
-] +:710.4008; found: 710.3995.  
 
(4S,5S)-1-(2-bromo-3,4-di-tert-butylbenzyl)-3-(2-bromo-3,5-di-tert-butylbenzyl)-
4,5-diphenylimidazolidin-2-imine hydrobromide(113f) White hygroscopic powder; 
87% yield; [𝑎]𝐷
22= –96.2 (c 0.42, CHCl3);  1H NMR (400 MHz, CDCl3) δ 9.26 (s, 2H), 
7.34 (d, J = 2.3 Hz, 2H), 7.32-7.23 (m, 6H), 7.02 (d, J = 6.7 Hz, 4H), 6.44 (d, J = 2.3 
Hz, 2H), 5.92 (d, J = 14.5 Hz, 2H), 4.25 (d, J = 14.6 Hz, 2H), 3.93 (s, 2H), 1.55 (s, 
18H), 1.06 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 156.34, 149.25, 148.25, 137.61, 
133.28, 129.16, 128.92, 128.61, 127.07, 125.72, 122.20, 68.73, 52.28, 37.37, 34.37, 
30.93, 29.99; HRMS (ESI) calcd for C45H58Br3N3 m/z [M-Br
-] +:801.2817; 
found:801.2822. 
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(4S,5S)-1,3-bis(3,5-di-tert-butyl-2-iodobenzyl)-4,5-diphenylimidazolidin-2-imine 
hydrobromide(113g) Pale yellow foam; >99% yield; [𝑎]𝐷
22= –89.3 (c 1.36, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 9.23 (s, 2H), 7.36 – 7.16 (m, 8H), 7.07 (dd, J = 11.4, 
5.7 Hz, 4H), 6.43 (d, J = 2.1 Hz, 2H), 5.72 (d, J = 14.5 Hz, 2H), 4.53 (d, J = 14.6 Hz, 
2H), 3.95 (s, 2H), 1.53 (s, 18H), 1.03 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 156.90, 
151.12, 150.04, 137.66, 136.69, 129.14, 128.80, 127.96, 127.03, 125.29, 98.85, 69.14, 
57.09, 37.85, 34.31, 30.88, 30.33; HRMS (ESI) calcd for C45H58BrI2N3 m/z [M-Br
-] 
+:894.2720; found: 894.2723. 
Pentanidiums 
 
(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-
ylidene)amino)-1,3-bis(4-chlorobenzyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-
ium chloride(101a) Pale brown powder; 53% yield; mp:139.7-141.4 °C; [𝑎]𝐷
22= –
80.1 (c 0.3, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.32 (d, J = 8.6 Hz, 6H), 7.30 – 
7.23 (m, 8H), 7.19 (d, J = 8.3 Hz, 4H), 7.07 – 6.94 (m, 12H), 6.89 (d, J = 1.5 Hz,  4H), 
5.04 (dd, J = 21.4, 15.2 Hz, 4H), 4.63 (s, 2H), 4.58 (s, 2H), 4.23 (dd, J = 15.1, 11.5 
Hz, 4H), 1.20 (s, 36H); 13C NMR (125 MHz, CDCl3) δ 157.11, 156.65, 151.82, 
136.49, 135.15, 134.58, 132.26, 131.87, 129.68, 129.65, 129.61, 129.50, 129.42, 
129.32, 127.36, 127.13, 122.71, 122.25, 68.83, 68.66, 49.21, 47.88, 34.67, 31.20; 
HRMS (ESI) calcd for C74H82Cl3N5 m/z [M–Cl-]+: 1110.5942; found: 1110.5904. 
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(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-
ylidene)amino)-1,3-bis(4-fluorobenzyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-
ium chloride(101b) Pale yellow powder; 72% yield; mp: 120.8-121.9 °C; [𝑎]𝐷
22= –
88.9 (c 0.5, CHCl3);
1H NMR (300 MHz, CDCl3) δ 7.38 – 7.31 (m, 6H), 7.26 (ddd, J = 
8.2, 5.7, 2.2 Hz, 8H), 7.05 – 6.95 (m, 8H), 6.94 – 6.84 (m, 12H), 4.98 (dd, J = 22.0, 
15.0 Hz, 4H), 4.57 (s, 2H), 4.45 (s, 2H), 4.15 (dd, J = 15.0, 6.5 Hz, 4H), 1.18 (s, 36H); 
13C NMR (75 MHz, CDCl3) δ 164.21, 160.91, 157.09, 156.66, 151.85, 136.49, 135.37, 
132.25, 130.28, 130.17, 129.64, 129.62, 129.48, 129.42, 129.10, 129.06, 127.22, 
127.10, 122.69, 122.22, 116.29, 116.00, 68.68, 68.63, 49.16, 47.84, 34.67, 31.18; 19F 
NMR (282 MHz, CDCl3) δ -36.14; HRMS (ESI) calcd for C74H82ClF2N5 m/z [M–Cl-] 
+:1078.6533; found: 1078.6574. 
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(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-
ylidene)amino)-1,3-bis(4-methoxybenzyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-
3-ium chloride(101c) Pale yellow foam; 75% yield; [𝑎]𝐷
22= –115.3 (c 0.4, CHCl3); 1H 
NMR (300 MHz, CDCl3) δ 7.42 – 7.27 (m, 14H), 7.03 – 6.89 (m, 8H), 6.87 (d, J = 1.6 
Hz, 8H), 6.77 (d, J = 8.7 Hz, 4H), 4.98 (dd, J = 22.1, 14.9 Hz, 4H), 4.50 (s, 2H), 4.39 
(s, 2H), 4.02 (dd, J = 45.7, 14.9 Hz, 4H), 3.76 (s, 6H), 1.19 (s, 36H); 13C NMR (75 
MHz, CDCl3) δ 159.95, 158.30, 156.99, 156.56, 151.99, 136.75, 135.73, 132.04, 
129.75, 129.68, 129.64, 129.56, 127.19, 126.99, 124.71, 122.85, 122.32, 114.74, 
68.37, 68.17, 55.38, 49.05, 47.68, 34.73, 31.22; HRMS (ESI) calcd for 
C76H88ClN5O2 m/z [M–Cl-]+: 1102.6933; found: 1102.6914.  
 
(4S,5S)-1,3-bis([1,1'-biphenyl]-4-ylmethyl)-2-(((4S,5S)-1,3-bis(3,5-di-tert-
butylbenzyl)-4,5-diphenylimidazolidin-2-ylidene)amino)-4,5-diphenyl-4,5-
dihydro-1H-imidazol-3-ium chloride(101d) Pale brown oil; 56% yield; [𝑎]𝐷
22= –
69.1 (c 0.2, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.52 – 7.47 (m, 8H), 7.43 (t, J = 
7.6 Hz, 4H), 7.36 (dt, J = 6.6, 4.4 Hz, 8H), 7.30 (dd, J = 13.1, 7.3 Hz, 8H), 7.16 (d, J 
= 8.1 Hz, 4H), 6.99 (dd, J = 15.4, 7.3 Hz, 8H), 6.90 (d, J = 1.4 Hz, 4H), 5.06 (dd, J = 
14.9, 5.3 Hz, 4H), 4.56 (s, 2H), 4.55 (s, 2H), 4.15 (dd, J = 15.0, 6.3 Hz, 4H), 1.17 (s, 
36H); 13C NMR (125 MHz, CDCl3) δ 157.18, 156.68, 151.96, 150.69, 145.30, 141.82, 
139.77, 136.68, 135.59, 132.10, 129.75, 129.59, 129.55, 128.92, 128.73, 127.94, 
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127.84, 127.36, 127.10, 126.90, 122.83, 122.39, 68.54, 68.47, 49.21, 48.08, 34.74, 
31.24; HRMS (ESI) calcd for C86H92ClN5 m/z [M–Cl-] +:1194.7347; found: 1194.7348. 
 
(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-
ylidene)amino)-4,5-diphenyl-1,3-bis(pyridin-2-ylmethyl)-4,5-dihydro-1H-
imidazol-3-ium(101e) Brown foam; 28% yield; 1H NMR (300 MHz, CDCl3) δ 8.34 
(d, J = 4.2 Hz, 2H), 7.80 (td, J = 7.7, 1.6 Hz, 2H), 7.35 (dd, J = 8.4, 3.2 Hz, 10H), 
7.25 – 7.16 (m, 10H), 6.89 (dd, J = 10.7, 4.4 Hz, 6H), 6.68 (d, J = 1.6 Hz, 4H), 5.20 
(d, J = 14.3 Hz, 4H), 4.62 (s, 2H), 4.31 (s, 2H), 4.07 (dd, J = 26.4, 15.4 Hz, 4H), 1.13 
(s, 36H); 13C NMR (75 MHz, CDCl3) δ 159.29, 157.59, 153.33, 151.23, 149.98, 
137.70, 136.72, 136.60, 132.85, 129.50, 129.41, 129.20, 127.73, 127.34, 123.41, 
123.01, 122.87, 122.32, 122.01, 69.63, 68.35, 49.39, 48.29, 34.58, 31.23; HRMS (ESI) 
calcd for C72H82ClN7 m/z [M–Cl-] +:1044.6626; found: 1044.6676.  
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(4S,5S)-1,3-dibenzhydryl-2-(((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-
diphenylimidazolidin-2-ylidene)amino)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-
ium chloride(101f) Beige powder; 45% yield; mp: 155.8-156.7 °C; [𝑎]𝐷
22= +17.9 (c 
0.5, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.36 (m, 6H), 7.34 (t, J = 1.6 Hz, 
2H), 7.26 (t, J = 7.5 Hz, 2H), 7.20 (dt, J = 3.4, 2.6 Hz, 6H), 7.17 – 7.12 (m, 6H), 7.10 
(t, J = 7.7 Hz, 4H), 7.05 (t, J = 7.7 Hz, 4H), 6.94 (d, J = 7.6 Hz, 4H), 6.71 (dd, J = 5.7, 
1.3 Hz, 8H), 6.69 – 6.64 (m, 4H), 6.31 (s, 2H), 4.69 (s, 2H), 4.43 (d, J = 14.7 Hz, 2H), 
4.37 (s, 2H), 4.00 (d, J = 14.7 Hz, 2H), 1.20 (s, 36H); 13C NMR (125 MHz, CDCl3) δ 
158.24, 156.25, 151.91, 138.12, 136.96, 136.03, 135.74, 131.71, 129.50, 129.33, 
129.19, 129.13, 128.98, 128.61, 128.55, 128.42, 127.02, 126.72, 122.85, 122.32, 
70.09, 68.78, 65.31, 49.36, 34.76, 31.32; HRMS (ESI) calcd for C86H92ClN5 m/z [M–
Cl-] +:1194.7347; found: 1194.7328. 
 
(4S,5S)-2-(((4S,5S)-1,3-bis(4-chlorobenzyl)-4,5-diphenylimidazolidin-2-ylidene) 
amino)-1,3-bis(4-chlorobenzyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium 
chloride(101g) Beige powder; 80% yield; mp:153.2-153.9 °C; [𝑎]𝐷
22= –79.0 (c 0.4, 
CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.17 (m, 20H), 7.03 (t, J = 8.3 Hz, 
16H), 4.95 (d, J = 15.6 Hz, 4H), 4.74 (s, 4H), 4.27 (d, J = 15.6 Hz, 4H); 13C NMR 
(125 MHz, CDCl3) δ 156.81, 135.05, 134.13, 132.40, 129.49, 129.40, 129.29, 129.00, 
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127.57, 69.30, 48.00; HRMS (ESI) calcd for C58H48Cl5N5 m/z [M–Cl-] +:954.2658; 
found: 954.2677.  
 
(4S,5S)-2-(((4S,5S)-1,3-bis(2-bromobenzyl)-4,5-diphenylimidazolidin-2-ylidene) 
amino)-1,3-bis(2-bromobenzyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium 
chloride(101h) Brown powder; 80% yield; mp:128.2-129.7 °C; [𝑎]𝐷
22= –2.9 (c 0.5, 
CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.43 (m, 4H), 7.32 – 7.20 (m, 12H), 
7.18 – 7.08 (m, 12H), 7.02 (d, J = 6.6 Hz, 8H), 4.94 (d, J = 15.0 Hz, 4H), 4.64 (d, J = 
15.0 Hz, 4H), 4.64 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 157.60, 135.44, 133.13, 
132.32, 131.31, 130.23, 129.43, 129.31, 127.87, 127.51, 123.78, 70.09, 49.49; HRMS 
(ESI) calcd for C58H48Br4ClN5 m/z [M-Cl
-] +:1134.0602; found: 1134.0607. 
 
(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2 
ylidene)amino)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenyl-4,5-dihydro-1H-
imidazol-3-ium chloride(101i) Brown foam; 53% yield; [𝑎]𝐷
22 = –89.0 (c 1.05, 
CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.38 (t, J = 7.4 Hz, 1H), 7.33-7.24 (m, 3H), 
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6.92-6.88 (m, 2H), 6.86 (d, J = 1.6 Hz, 2H), 5.20 (d, J = 14.8 Hz, 1H), 4.40 (s, 1H), 
4.11 (d, J = 14.8 Hz, 1H), 1.11 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 157.24, 
151.99, 136.27, 131.53, 129.78, 129.51, 127.13, 123.17, 122.39, 68.04, 49.17, 34.66, 
31.15; HRMS (ESI) calcd for C90H116ClN5 m/z [M–Cl-] +:1266.9231; found:1266.9229. 
 
(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butyl-4-methoxybenzyl)-4,5 
diphenylimidazolidin-2-ylidene)amino)-1,3-bis(3,5-di-tert-butyl-4-
methoxybenzyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium chloride(101j) 
Beige powder; 68% yield; mp: 142.0-143.6 °C; [𝑎]𝐷
22= –61.0 (c 0.4, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 7.36 (d, J = 7.4 Hz, 4H), 7.28 (dd, J = 12.2, 4.9 Hz, 8H), 6.90 (s, 
8H), 6.88 (d, J = 7.2 Hz, 8H), 5.10 (d, J = 14.7 Hz, 4H), 4.40 (s, 4H), 4.10 (d, J = 14.7 
Hz, 4H), 3.58 (s, 12H), 1.21 (s, 72H); 13C NMR (100 MHz, CDCl3) δ 159.96, 157.52, 
144.80, 136.20, 129.76, 129.49, 127.08, 126.73, 126.33, 68.30, 64.27, 49.17, 35.60, 
31.74; HRMS (ESI) calcd for C94H124ClN5O4 m/z [M-Cl
-] +:1386.9653; found: 
1386.9647. 
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(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butyl-2-fluorobenzyl)-4,5-
diphenylimidazolidin-2-ylidene)amino)-1,3-bis(3,5-di-tert-butyl-2-fluorobenzyl)-
4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium chloride(101k) pale yellow foam; 97% 
yield; 1H NMR (400 MHz, CDCl3) δ 7.33 (t, J = 7.4 Hz, 4H), 7.27 – 7.18 (m, 12H), 6.88 (d, J 
= 7.3 Hz, 8H), 6.63 (d, J = 3.6 Hz, 4H), 5.31 (d, J = 14.4 Hz, 4H), 4.27 (s, 4H), 4.09 (d, J = 
14.5 Hz, 4H), 1.19 (s, 36H), 1.13 (s, 36H); 13C NMR (100 MHz, CDCl3) δ 159.44, 156.98, 
156.87, 146.71, 136.66, 136.55, 136.46, 129.57, 129.36, 127.08, 126.19, 125.36, 119.14, 
118.98, 68.45, 44.59, 34.39, 31.24, 29.83; 19F NMR (376 MHz, CDCl3) δ -119.69; HRMS 
(ESI) calcd for C90H112ClF4N5 m/z [M-Cl
-] +:1338.8854; found: 1338.8850. 
 
(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butyl-2-chlorobenzyl)-4,5-
diphenylimidazolidin-2-ylidene)amino)-1,3-bis(3,5-di-tert-butyl-2-chlorobenzyl)-
4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium chloride(101l) Pale yellow powder; 
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71% yield; mp:178.5-180.3 °C; [𝑎]𝐷
22= +5.3 (c 1.14, CHCl3);
 1H NMR (400 MHz, 
CDCl3) δ 7.37 (d, J = 2.1 Hz, 4H), 7.33 – 7.27 (m, 1H), 7.21 (t, J = 7.5 Hz, 8H), 6.94 
(d, J = 7.3 Hz, 8H), 6.78 (d, J = 2.1 Hz, 1H), 5.02 (d, J = 14.4 Hz, 4H), 4.62 (d, J = 
14.4 Hz, 4H), 4.36 (s, 4H), 1.45 (s, 36H), 1.09 (s, 36H); 13C NMR (100 MHz, CDCl3) 
δ 157.93, 149.50, 147.08, 136.38, 131.21, 130.36, 129.46, 129.34, 127.07, 126.45, 
125.92, 70.01, 49.30, 36.63, 34.55, 31.06, 29.73; HRMS (ESI) calcd for C90H112Cl5N5 
m/z [M-Cl-] +:1402.7672; found: 1402.7646. 
 
(4S,5S)-2-(((4S,5S)-1,3-bis(2-bromo-3,5-di-tert-butylbenzyl)-4,5 
diphenylimidazolidin-2-ylidene)amino)-1,3-bis(2-bromo-3,5-di-tert-butylbenzyl)-
4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium chloride (101m) Beige powder; 78% 
yield; mp:200.1-200.5 °C; [𝑎]𝐷
22= + 14.4 (c 1.43, CHCl3); 
1H NMR (400 MHz, CDCl3) 
δ 7.36 (d, J = 2.1 Hz, 4H), 7.29 (d, J = 7.4 Hz, 4H), 7.21 (t, J = 7.4 Hz, 8H), 6.96 (d, J 
= 7.3 Hz, 8H), 6.80 (d, J = 2.1 Hz, 4H), 5.00 (d, J = 14.4 Hz, 4H), 4.74 (d, J = 14.4 
Hz, 4H), 4.41 (s, 4H), 1.48 (s, 36H), 1.07 (s, 36H); 13C NMR (100 MHz, CDCl3) δ 
158.19, 150.05, 148.52, 136.21, 132.95, 129.38, 129.31, 127.10, 126.65, 126.19, 
121.46, 77.32, 52.22, 37.39, 34.55, 31.01, 29.91, 17.41; HRMS (ESI) calcd for 
C90H112Br4ClN5 m/z [M-Cl
-]+:1582.5610; found:1582.5624. 
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(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butyl-2-iodobenzyl)-4,5-
diphenylimidazolidin-2-ylidene)amino)-1,3-bis(3,5-di-tert-butyl-2-iodobenzyl)-
4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium chloride(101n) Brown powder; 27% 
yield; mp:195.2-196.7 °C; [𝑎]𝐷
22= –9.4 (c 0.35, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ 7.32 (d, J = 2.2 Hz, 4H), 7.28 (d, J = 7.4 Hz, 4H), 7.22 (t, J = 7.4 Hz, 8H), 6.99 (d, J 
= 7.3 Hz, 8H), 6.76 (d, J = 2.1 Hz, 4H), 5.04 (d, J = 14.4 Hz, 4H), 4.87 (d, J = 14.4 
Hz, 4H), 4.48 (s, 4H), 1.55 (d, 36H), 1.03 (s, 36H); 13C NMR (100 MHz, CDCl3) δ 
158.23, 151.64, 150.91, 136.17, 136.02, 129.46, 129.40, 127.11, 126.01, 125.86, 
98.62, 70.45, 57.99, 38.00, 34.50, 30.99, 30.32; IR: 2964, 2870, 1651, 1556, 1504, 
1454, 1361, 1201, 1165, 1001, 731 cm-1; HRMS (ESI) calcd for C90H112ClI4N5 m/z 
[M-Cl-] +: 1770.5097; found: 1770.5073. 
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(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-
ylidene)amino)-1,3-bis(3,5-di-tert-butyl-2-chlorobenzyl)-4,5-diphenyl-4,5-
dihydro-1H-imidazol-3-ium chloride(101o) Beige powder; 80% yield; mp:253.7-
254.2 °C; [𝑎]𝐷
22= –66.7 (c 2.53, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.33 
(m, 6H), 7.30 (d, J = 7.7 Hz, 4H), 7.28 (d, J = 1.8 Hz, 2H), 7.18 (t, J = 7.5 Hz, 4H), 
7.02 – 6.97 (m, 4H), 6.94 (d, J = 1.6 Hz, 4H), 6.83 (d, J = 7.2 Hz, 4H), 6.57 (d, J = 
2.3 Hz, 2H), 5.19 (d, J = 14.7 Hz, 2H), 5.03 (d, J = 14.0 Hz, 2H), 4.47 (s, 2H), 4.32 (d, 
J = 14.1 Hz, 2H), 4.20 (d, J = 14.6 Hz, 2H), 4.13 (s, 2H), 1.40 (s, 18H), 1.19 (s, 36H), 
1.05 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 157.32, 156.89, 151.90, 149.56, 147.10, 
136.80, 136.42, 131.96, 130.50, 130.28, 129.73, 129.49, 129.40, 129.28, 127.12, 
127.08, 126.83, 126.14, 122.94, 122.39, 69.13, 68.26, 49.28, 48.95, 36.55, 34.72, 
34.43, 31.22, 30.92, 29.66; HRMS (ESI) calcd for C90H114Cl3N5 m/z [M-Cl
-] 
+:1334.8451; found: 1334.8455. 
 
(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-
ylidene)amino)-1,3-bis(2-bromo-3,5-di-tert-butylbenzyl)-4,5-diphenyl-4,5-
dihydro-1H-imidazol-3-ium chloride(101p) Beige powder; 38% yield; mp:251.6-
252.3 °C; [𝑎]𝐷
22= –47.0 (c 1.3, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.34 (m, 
6H), 7.31 (d, J = 7.7 Hz, 4H), 7.28 (d, J = 3.2 Hz, 2H), 7.19 (t, J = 7.5 Hz, 4H), 7.01 
(d, J = 7.2 Hz, 4H), 6.97 (d, J = 1.6 Hz, 4H), 6.86 (d, J = 7.2 Hz, 4H), 6.56 (d, J = 2.3 
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Hz, 2H), 5.23 (d, J = 14.7 Hz, 2H), 5.03 (d, J = 14.0 Hz, 2H), 4.48 (s, 2H), 4.44 (d, J 
= 14.0 Hz, 2H), 4.22 (d, J = 14.7 Hz, 2H), 4.17 (s, 2H), 1.45 (s, 18H), 1.21 (s, 36H), 
1.03 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 157.53, 156.87, 152.01, 150.15, 148.69, 
136.87, 136.44, 132.29, 132.01, 129.79, 129.55, 129.38, 129.28, 127.38, 127.16, 
126.88, 126.47, 123.03, 122.51, 121.58, 69.45, 68.33, 52.08, 49.01, 37.37, 34.79, 
34.46, 31.28, 30.90, 29.90; HRMS (ESI) calcd for C90H114Br2ClN5 m/z [M-Cl
-] 
+:1424.7421; found:1424.7434. 
 
(4S,5S)-2-(((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-
ylidene)amino)-1,3-bis(3,5-di-tert-butyl-2-iodobenzyl)-4,5-diphenyl-4,5-dihydro-
1H-imidazol-3-ium chloride(101q) Brown foam; 58% yield; [𝑎]𝐷
22= –27.2 (c 0.3, 
CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.37 (dd, J = 14.1, 6.7 Hz, 4H), 7.33 – 7.28 
(m, 6H), 7.28 – 7.23 (m, 2H), 7.18 (t, J = 7.5 Hz, 4H), 7.00 (d, J = 7.2 Hz, 4H), 6.97 
(d, J = 1.6 Hz, 4H), 6.87 (d, J = 7.3 Hz, 4H), 6.59 (d, J = 2.2 Hz, 2H), 5.26 (d, J = 
14.7 Hz, 2H), 4.99 (d, J = 14.1 Hz, 2H), 4.68 (d, J = 14.2 Hz, 2H), 4.49 (s, 2H), 4.29(s, 
2H), 4.27 (d, J = 16.9 Hz, 2H), 1.50 (s, 18H), 1.19 (s, 36H), 0.99 (s, 18H); 13C NMR 
(100 MHz, CDCl3) δ 157.92, 157.04, 152.08, 151.61, 150.91, 136.81, 136.18, 135.65, 
131.99, 129.84, 129.60, 129.39, 129.29, 127.23, 126.99, 126.41, 126.08, 123.14, 
122.59, 98.60, 70.00, 68.47, 57.50, 49.20, 37.97, 34.83, 34.42, 31.33, 30.90, 30.29; 
HRMS (ESI) calcd for C90H114ClI2N5 m/z [M-Cl
-] +:1518.7164; found: 1518.7141. 
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(4S,5S)-2-(((4S,5S)-1,3-bis(2-bromo-3,5-di-tert-butylbenzyl)-4,5-
diphenylimidazolidin-2-ylidene)amino)-1,3-bis(3,5-di-tert-butyl-2-iodobenzyl)-
4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium chloride(101r) Brown powder; 40% 
yield; mp:151.3-152.8 °C; [𝑎]𝐷
22= +22.1 (c 0.4, CHCl3);
 1H NMR (400 MHz, CDCl3) 
δ 7.37 (d, J = 2.3 Hz, 2H), 7.31 (d, J = 2.3 Hz, 2H), 7.27 (d, J = 4.1 Hz, 2H), 7.24 (d, 
J = 4.6 Hz, 2H), 7.23 – 7.15 (m, 8H), 6.96 (t, J = 8.2 Hz, 8H), 6.78 – 6.75 (m, 4H), 
5.05 (d, J = 14.4 Hz, 2H), 4.98 (d, J = 14.4 Hz, 2H), 4.87 (d, J = 14.4 Hz, 2H), 4.71 (d, 
J = 14.4 Hz, 2H), 4.45 (s, 2H), 4.41 (s, 2H), 1.53 (s, 18H), 1.48 (s, 18H), 1.06 (s, 
18H), 1.05 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 158.32, 158.06, 151.53, 150.81, 
150.12, 148.71, 136.23, 136.08, 135.97, 132.83, 129.49, 129.38, 129.28, 127.05, 
126.45, 126.32, 125.90, 121.48, 98.44, 70.48, 70.12, 57.91, 52.30, 37.95, 37.40, 34.54, 
34.46, 30.99, 30.95, 30.25, 29.91; HRMS (ESI) calcd for C90H112Br2I2ClN5 m/z [M-
Cl-] +:1676.5354; found: 1676.5347. 
4.2.2. Preparation and Characterizations of Chiral Bis-guanidium Salts 
Representative procedure for the synthesis of chiral bis-guanidium salts (take the 
bis-guanidium102b as an example)  
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A 25 mL RBF was charged with a solution of thiourea (1.59 g, 2.41 mmol, 1.0 equiv) 
in toluene (8 mL) with a condenser under N2 atmosphere. (COCl)2 (1.66 mL, 19.3 
mmol, 8.0 equiv) was added via syringe in one portion. The mixture was refluxed for 
24 h until D was completely reacted. Toluene was removed under reduced pressure 
and solid imidazoline salt was obtained for the next step without any purification. 
(Imidazoline salts air and moisture sensitive, which should be stored under nitrogen 
atmosphere or vacuum).The imidazoline salt was dissolved in dry MeCN (2 mL) 
under nitrogen atmosphere, and then piperazine (62 mg, 0.72 mmol, 0.3 equiv) was 
added, followed by the addition of Et3N (1 mL, 7.23 mmol, 3.0 equiv). Then the 
whole solution was heated to reflux for 12 h and cool to rt. Add 1M HCl (20 mL) to 
the reaction solution and the mixture was extracted by CH2Cl2 (20 mL × 3). The 
combined organic layer was dried by Na2SO4. Solvent was removed under reduced 
pressure and bisguanidium salt 102b was obtained by flash chromatography (silica 
gel, DCM-Methanol 100:1-30:1), as a beige powder, 695 mg, 68% yield. 
Bis-guanidiums: 
 
1,4-bis((4S,5S)-1,3-dimethyl-4,5-diphenylimidazolidin-2-ylidene)piperazine-1,4-
diium chloride(102a) White solid; 45% yield; mp:265.8 °C (decomposed); [𝑎]𝐷
22= 
+134.5 (c 1.22, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.33 (m, 12H), 7.28 – 
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7.16 (m, 8H), 4.66 (d, J = 9.4 Hz, 4H), 4.50 (s, 4H), 4.12 (d, J = 9.4 Hz, 4H), 3.23 (s, 
12H); 13C NMR (100 MHz, CDCl3) δ 164.23, 135.52, 129.52, 126.99, 75.21, 47.93, 
37.30; HRMS (ESI) calcd for C38H44Cl2N6 m/z [M-2Cl
-]2+:292.1814; found: 292.1816.  
 
1,4-bis((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-
ylidene) piperazine-1,4-diium chloride (102b) Beige solid; 68% yield; mp:204.4 °C 
(decomposed); [𝑎]𝐷
22= –33.9 (c 1.07, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.30 (dd, 
J = 5.0, 1.5 Hz, 12H), 7.20 (s, 4H), 7.05 (dd, J = 6.5, 2.8 Hz, 8H), 6.96 (d, J = 1.5 Hz, 
8H), 5.19 (d, J = 14.7 Hz, 4H), 4.82 (d, J = 14.7 Hz, 4H), 4.73 (d, J = 9.5 Hz, 4H), 
4.48 (d, J = 9.5 Hz, 4H), 4.32 (s, 1H), 1.14 (s, 72H); 13C NMR (100 MHz, CDCl3) δ 
162.68, 151.30, 137.67, 131.89, 129.58, 129.16, 126.51, 123.37, 122.26, 70.39, 54.52, 
48.99, 34.69, 31.37, 31.28; HRMS (ESI) calcd for C94H124Cl2N6 m/z [M-2Cl
-
]2+:668.4944; found: 668.4941. 
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1,4-bis((4S,5S)-1,3-bis(3,5-di-tert-butyl-4-methoxybenzyl)-4,5-
diphenylimidazolidin-2-ylidene)piperazine-1,4-diium chloride(102c) Beige solid; 
56% yield; mp:207.5 °C (decomposed); [𝑎]𝐷
22= –17.8 (c 1.5, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 7.35 – 7.26 (m, 3H), 7.01 (dd, J = 7.3, 2.0 Hz, 2H), 6.98 (s, 2H), 5.21 
(d, J = 14.3 Hz, 1H), 4.88 (d, J = 9.5 Hz, 1H), 4.73 (d, J = 14.3 Hz, 1H), 4.56 (d, J = 
9.6 Hz, 1H), 4.29 (s, 1H), 3.52 (s, 3H), 1.23 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 
162.31, 159.64, 144.08, 137.84, 129.62, 129.16, 127.81, 126.38, 126.19, 70.13, 64.20, 
54.28, 48.97, 35.62, 31.90; HRMS (ESI) calcd for C98H132Cl2N6O4 m/z [M-2Cl
-] 
2+:728.5155; found: 728.5157. 
 
1,4-bis((3aS,7aS)-1,3-bis(3,5-di-tert-butylbenzyl)hexahydro-1H-
benzo[d]imidazol-2(3H)-ylidene)piperazine-1,4-diiumchloride(102d) White solid; 
78% yield; mp:286.29 °C(decomposed); [𝑎]𝐷
22= +57.2 (c 1.41, CHCl3); 
1H NMR (400 
MHz, CDCl3) δ 7.23 (s, 4H), 7.10 (s, 8H), 5.34 (d, J = 17.9 Hz, 4H), 4.41 (d, J = 17.8 
Hz, 4H), 4.00 – 3.75 (m, 4H), 3.91 (s, 4H), 3.34 (ddd, J = 158.6, 77.0, 11.0 Hz, 12H), 
1.89 (dd, J = 51.8, 9.9 Hz, 8H), 1.22 (s, 72H); 13C NMR (100 MHz, CDCl3) δ 169.37, 
151.44, 134.67, 121.47, 119.87, 69.38, 54.29, 48.31, 34.85, 31.48, 29.29, 23.94; 
HRMS (ESI) calcd for C78H120Cl2N6 m/z [M-2Cl
-]2+:570.4787; found: 570.4777. 
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1,1'-bis((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-
ylidene)-[4,4'-bipiperidine]-1,1'-diium chloride(102e) Pale yellow solid; 61% yield; 
mp:187.6-188.5 °C; [𝑎]𝐷
22= –22.4(c 0.58, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.27 
(dt, J = 12.0, 2.8 Hz, 16H), 6.94 (d, J = 6.0 Hz, 8H), 6.86 (d, J = 1.6 Hz, 8H), 4.92 (d, 
J = 14.8 Hz, 4H), 4.38 (d, J = 16.7 Hz, 4H), 4.36(s, 4H),  4.07 (dd, J = 37.4, 12.4 Hz, 
4H), 3.85 (dt, J = 24.6, 11.1 Hz, 4H), 2.29 (d, J = 8.0 Hz, 2H), 2.09 (d, J = 13.5 Hz, 
4H), 1.81 (s, 4H), 1.19 (s, 72H);13C NMR (100 MHz, CDCl3) δ 162.96, 151.76, 
137.25, 132.00, 129.49, 129.23, 126.59, 122.75, 119.95, 77.32, 77.00, 76.68, 69.76, 
53.51, 50.79, 50.64, 39.07, 34.76, 31.29, 29.99, 29.06; HRMS (ESI) calcd for 
C100H134Cl2N6 m/z [M-2Cl
-]2+:709.5227; found: 709.5241.  
 
(S,S)-4,4'-(propane-1,3-diyl)bis(1-((4S,5S)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-
diphenylimidazolidin-2-ylidene)piperidin-1-ium) chloride(101f) Pale yellow solid; 
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65% yield; mp:156.1-157.6 °C; [𝑎]𝐷
22= –19.2(c 1.86, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 7.31 (s, 4H), 7.29 – 7.18 (m, 12H), 6.95 (d, J = 6.5 Hz, 8H), 6.88 (d, J = 1.4 
Hz, 8H), 4.93 (d, J = 15.1 Hz, 4H), 4.41 (s, 4H), 4.35 (d, J = 15.1 Hz, 4H), 3.90 (ddd, 
J = 42.2, 28.8, 12.3 Hz, 8H), 2.30 – 1.92 (m, 8H), 1.64 – 1.46 (m, 4H), 1.42 (dd, J = 
16.6, 8.0 Hz, 4H), 1.21 (s, 72H); 13C NMR (100 MHz, CDCl3) δ 163.21, 151.81, 
137.04, 132.22, 129.43, 129.24, 126.78, 122.70, 122.63, 69.88, 53.35, 51.02, 50.76, 
36.01, 34.78, 34.50, 32.61, 31.90, 31.30, 23.19; HRMS (ESI) calcd for C103H140Cl2N6 
m/z [M-2Cl-]2+:730.6039; found: 730.6033.  
4.2.3. Synthesis of Starting Materials for Asymmetric Alkylation of Sulfenate 
Anions 
Preparation of heteroaromatic thiols Benzo[b]thiophene-2-thiol and 3-
methylbenzo[b]thiophene-2-thiol6, 3-methyl-thiophene-2-thiol, 5-methylthiophene-2-
thiol and 3,5-dimethylthiophene-2-thiol7, furan-2-thiol and benzofuran-2-thiol8were 
prepared according to the literature procedures and used directly in next steps without 
further purifications. 
 
5-methoxy-1-methyl-1H-benzo[d]imidazole-2-thiol 9 A mixture of 4-methoxy-N1-
methylbenzene-1,2-diamine (2.25 g, 11.6 mmol, 1.0 equiv), Et3N (3.23 mL, 23.2 
                                                     
6 Chong, J. A. et al. Compounds for modulating TRPV3 function. U.S. Patent 20070213321, 
September 13, 2007.b) Anisimov, A. V.; Babaitsev, V. S.; Kolosova, T. A.; Viktorova, Y. A. 
Khim. Geterotsikl.Soedin.1982, 1335-1337. 
7 Zhong, B. H. et al. Acyclic nucleoside phosphonate derivative and its pharmaceutical use. 
Faming Zhuanli Shenqing, 101293899, 29 Oct 2008 
8 Wiles, J. A.; Phadke, A. S.; Bradbury, B. J.; Pucci, M. J.; Thanassi, J. A.; Deshpande, M. J. 
Med. Chem.2011, 54, 3418-3425. 
9 Nomoto, Y.; Takai, H.; Hirata, T.; Teranishi, M.; Ohno, T.; Kubo, K. Chem. Pharm. Bull. 
(Tokyo)1990, 38, 3014-3019. 
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mmol, 2.0 equiv) and CS2 (4.2 mL, 69.6mmol, 6.0 equiv) in EtOH (60 mL) was 
stirred for overnight at room temperature(monitored by TLC). Then, the reaction 
mixture was concentrated under reduced pressure and the resulted residue was 
subjected to flash chromatography to afford the desired compounds as a beige solid, 
in 90% yield. 1H NMR (400 MHz, CDCl3) δ 11.44 (s, 1H), 7.03 (d, J = 9.5 Hz, 1H), 
6.82 (dd, J = 6.9, 2.3 Hz, 2H), 3.82 (s, 3H), 3.74 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 167.53, 157.06, 131.22, 127.66, 110.72, 109.53, 94.99, 55.95, 30.55. 
Preparation of sulfanyl precursors 
Sulfanyl Precursors were prepared according to the literature procedures (Method A, 
B, C) and used directly in next steps without further purifications. 
 
Method A: General procedure for Michael addition of electron-deficient olefins 
with thiols10 
Et3N (5 mol %) was added to a solution of thiol 118(0.5mmol) and electron-deficient 
olefin 119a (0.5 mmol) in THF (0.1 mL) at 0 oC. The resulting reaction mixture was 
                                                                                                                                                        
 
10 Haynes, R. K.; Vonwiller, S. C.; Stokes, J. P.; Merlino, L. M. Aust. J. Chem.1988, 41, 881-
895.b)Caupene, C.; Boudou, C.; Perrio, S.; Metzner, P. J. Org. Chem.2005, 70, 2812-2815.c) 
Gelat, F.; Jayashankaran, J.; Lohier, J. F.; Gaumont, A. C.; Perrio, S. Org. Lett.2011, 13, 
3170-3173.d)HUANG, Q. P. G. R. D., 10555 Science Center DriveSan Diego, California, 
92121, US), RUI, Eugene, Yuanjin (Pfizer Global Research & Development, 10555 Science 
Center DriveSan Diego, California, 92121, US); PFIZER INC. (235 East 42nd Street, New 
York, New York, 10017, US),HUANG, Qinhua (Pfizer Global Research & Development, 
10555 Science Center DriveSan Diego, California, 92121, US),RUI, Eugene, Yuanjin (Pfizer 
Global Research & Development, 10555 Science Center DriveSan Diego, California, 92121, 
US): 2009. 
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stirred for appropriate time at room temperature (monitored by TLC). After removing 
solvent under reduced pressure, the crude residue was used in next step without 
further purification. 
 
Method B11 
Methyl 3-bromopropanoate 119b (133 µL, 1.2 mmol, 1.2 equiv) was added dropwise 
to a solution of 2-mercaptopyridine 118p (111 mg, 1 mmol, 1.0 equiv) and Et3N (209 
µL, 1.5 mmol, 1.5 equiv) in CH3CN (0.2 mL) at room temperature. Then the mixture 
was stirred for 24 h at 82 oC. After the removal of solvent under reduced procure, the 
resulting residue was purified by flash chromatography to afford the desired 
compound 120p as pale yellow oil in 76% yield. 1H NMR (400 MHz, CDCl3) δ 8.42 
(d, J = 4.2 Hz, 1H), 7.49 (td, J = 7.8, 1.8 Hz, 1H), 7.17 (d, J = 8.1 Hz, 1H), 6.99 (ddd, 
J = 7.2, 5.0, 0.7 Hz, 1H), 3.69 (s, 3H), 3.44 (t, J = 7.1 Hz, 2H), 2.79 (t, J = 7.1 Hz, 
2H); 13C NMR (100 MHz, CDCl3) δ 172.46, 158.05, 149.09, 136.24, 122.52, 119.53, 
51.73, 34.42, 25.01. 
 
Method C10 
                                                     
11Furukawa, N.; Takahashi, F.; Kawai, T.; Kishimoto, K.; Ogawa, S.; Oae, S. Phosphorous 
and Sulfur and the Related Elements1983, 16, 167-180. 
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Methyl 3-bromopropanoate 119b (1.37 mL, 12.5 mmol, 1.2 equiv) was added 
dropwise to a solution of 5-methoxy-1-methyl-1H-benzo[d]imidazole-2-thiol118r 
(2.03 g, 10.4 mmol, 1.0 equiv) in MeOH (10 mL) at room temperature. Then the 
mixture was stirred for 24 h at 82 oC. After the removal of solvent under reduced 
procure, the resulting residue was purified by flash chromatography to afford the 
desired compound 120r as a red sold in quantitative yield. 1H NMR (400 MHz, 
CDCl3) δ 7.16 (d, J = 2.3 Hz, 1H), 7.09 (d, J = 8.7 Hz, 1H), 6.84 (dd, J = 8.7, 2.4 Hz, 
1H), 3.83 (s, 3H), 3.69 (s, 3H), 3.61 (s, 3H), 3.57 (t, J = 6.8 Hz, 2H), 2.90 (t, J = 6.8 
Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 172.12, 155.92, 151.06, 144.03, 131.39, 
111.37, 108.70, 101.09, 55.75, 51.74, 34.41, 29.98, 27.22. 
Synthesis and characterizations of sulfinyl precursors12 
 
General procedure for sulfides oxidation to sulfoxides To a 2M solution of sulfide 
120a-q (2 mmol) in 2,2,2-trifluoroethanol (TFE) (1.0 mL) at 0 °C, H2O2 (35% wt in 
water, 160 µL, 1.8 mmol, 1.8 equiv) was added dropwise. The reaction mixture was 
allowed to warm to room temperature and stirred for appropriate time (monitor by 
TLC). Solid sodium sulfite (1.8 mmol, 1.8 equiv) was added then the reaction mixture 
was stirred for 30 min. The resulting mixture was filtered on celite, dried over MgSO4, 
filtered and evaporated under reduced pressure. The crude product was then purified 
by column chromatography on silica gel to afford the pure anticipated sulfoxide 115a-
q. For the oxidation of sulfanyl 120r to sulfoxide 115r, additional ammonium 
                                                     
12Begue, J. P.; Bonnet-Delpon, D.; Crousse, B. Synlett 2004, 18-29. 
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molybdate tetrahydrate (5 mol %) was added as a catalyst to promote this 
transformation. 
 
Methyl 3-(phenylsulfinyl)propanoate(115a) Colourless oil; 93% yield; 1H NMR 
(400 MHz, CDCl3) δ 7.65 – 7.59 (m, 2H), 7.57 – 7.46 (m, 3H), 3.66 (s, 3H), 3.23 (ddd, 
J = 13.4, 8.4, 6.8 Hz, 1H), 3.03 – 2.93 (m, 1H), 2.84 (ddd, J = 17.2, 8.3, 6.8 Hz, 1H), 
2.55 (ddd, J = 17.2, 8.4, 5.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 171.60, 142.92, 
131.17, 129.30, 124.05, 52.08, 51.10, 25.97; HRMS (ESI) calcd for C10H12O3S m/z 
[M+1] +:213.0585; found:213.0587. 
 
Methyl 3-(thiophen-2-ylsulfinyl)propanoate(115b) Colourless oil; 93% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.80-7.73 (m, 1H), 7.52 (dd, J = 5.1, 3.0 Hz, 1H), 7.22 (dd, 
J = 5.1, 1.0 Hz, 1H), 3.68 (s, 3H), 3.26 (ddd, J = 13.5, 8.2, 7.0 Hz, 1H), 3.15-3.03 (m, 
1H), 2.89-2.76 (m, 1H), 2.62 (ddd, J = 17.3, 8.2, 6.1 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 171.58, 142.35, 128.63, 126.26, 122.80, 52.15, 50.50, 26.08; HRMS (ESI) 
calcd for C8H10O3S2 m/z [M+1]
+: 219.0150; found: 219.0147. 
 
Ethyl 3-(thiophen-2-ylsulfinyl)propanoate(115c) Colourless oil; 83% yield; 1H 
NMR (400 MHz, CDCl3)  δ 7.66 (dd, J = 5.0, 0.7 Hz, 1H), 7.46 (dd, J = 3.6, 0.8 Hz, 
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1H), 7.13 (dd, J = 4.7, 3.9 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.37 – 3.17 (m, 2H), 2.81 
(dt, J = 17.2, 7.5 Hz, 1H), 2.73 – 2.53 (m, 1H), 1.25 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 170.82, 145.05, 131.17, 129.67, 127.48, 61.18, 52.59, 26.99, 14.08; HRMS 
(ESI) calcd for C9H12O3S2 m/z [M+1]
 +:233.0306; found: 233.0305. 
 
tert-butyl 3-(thiophen-2-ylsulfinyl)propanoate(115d) Colourless oil; 82% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.65 (dd, J = 5.0, 1.1 Hz, 1H), 7.46 (dd, J = 3.6, 1.1 Hz, 
1H), 7.13 (dd, J = 4.9, 3.7 Hz, 1H), 3.24 (t, J = 7.3 Hz, 2H), 2.73 (dt, J = 17.2, 7.5 Hz, 
1H), 2.57 (dt, J = 17.2, 7.2 Hz, 1H), 1.44 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 
169.99, 145.31, 131.06, 129.57, 127.46, 81.64, 52.93, 28.16, 27.99; HRMS (ESI) 
calcd for C11H16O3S2 m/z [M+1]
 +:261.0619; found:261.0627. 
 
phenyl 3-(thiophen-2-ylsulfinyl)propanoate(115e) Colourless oil; 74% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.69 (d, J = 4.9 Hz, 1H), 7.51 d, J = 3.6 Hz, 1H), 7.38 (t, J 
= 7.8 Hz, 2H), 7.24 (dd, J = 12.4, 4.8 Hz, 1H), 7.19-7.12 (m, 1H), 7.07 (d, J = 8.0 Hz, 
2H), 3.49-3.25 (m, 2H), 3.19-3.04 (m, 1H), 3.01-2.86 (m, 1H); 13C NMR (100 MHz, 
CDCl3) δ 169.53, 150.38, 144.90, 131.26, 129.67, 129.44, 127.60, 126.06, 121.28, 
52.31, 27.05; HRMS (ESI) calcd for C13H12O3S2 m/z [M+1]
 +:281.0306; 
found:281.0300. 
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2-((2-(phenylsulfonyl)ethyl)sulfinyl)thiophene(115f) White solid; 82% yield; 
mp:121.9-122.7 °C; 1H NMR (400 MHz, CDCl3) δ 7.95-7.84 (m, 2H), 7.69 (dt, J = 
4.9, 4.2 Hz, 2H), 7.59 (t, J = 7.7 Hz, 2H), 7.43 (dd, J = 3.7, 1.1 Hz, 1H), 7.15 (dd, J = 
4.9, 3.8 Hz, 1H), 3.57-3.46 (m, 1H), 3.40 (ddd, J = 14.1, 8.5, 2.9 Hz, 1H), 3.36-3.30 
(m, 1H), 3.29-3.19 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 143.83, 138.46, 134.30, 
131.68, 129.74, 129.58, 128.05, 127.81, 49.53, 48.82; HRMS (ESI) calcd for 
C12H12O3S3 m/z [M+1]
 +:301.0027; found:301.0042. 
 
3-(thiophen-2-ylsulfinyl)propanenitrile(115g) Colourless oil; 90% yield;  1H NMR 
(400 MHz, CDCl3) δ 7.71 (dd, J = 5.0, 1.2 Hz, 1H), 7.50 (dd, J = 3.7, 1.2 Hz, 1H), 
7.17 (dd, J = 5.0, 3.7 Hz, 1H), 3.35 – 3.12 (m, 2H), 2.89 (ddd, J = 17.3, 8.1, 7.0 Hz, 
1H), 2.69 (ddd, J = 17.3, 8.4, 6.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 143.22, 
131.91, 130.13, 127.86, 116.87, 51.81, 10.51; HRMS (ESI) calcd for C7H7NOS2 m/z 
[M+1] +:186.0047; found:186.0044. 
 
Methyl 3-((3-methylthiophen-2-yl)sulfinyl)propanoate(115h) Orange oil; 62% 
yield; 1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 5.0 Hz, 1H), 6.90 (d, J = 5.0 Hz, 1H), 
3.70 (s, 3H), 3.47 – 3.04 (m, 2H), 2.95 – 2.54 (m, 2H), 2.38 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 171.36, 141.49, 138.84, 130.46, 130.39, 52.19, 51.67, 27.20, 14.40; 
HRMS (ESI) calcd for C9H12O3S2 m/z [M+1]
 +: 233.0306; found: 233.0303. 
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Methyl 3-((5-methylthiophen-2-yl)sulfinyl)propanoate(115i) Colourless oil; 87% 
yield; 1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 3.6 Hz, 1H), 6.80-6.70 (m, 1H), 3.70 
(s, 3H), 3.37-3.17 (m, 2H), 2.88-2.73 (m, 1H), 2.73-2.58 (m, 1H), 2.55 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 171.34, 147.28, 141.30, 130.93, 125.71, 52.16, 52.14, 
27.08, 15.81; HRMS (ESI) calcd for C9H12O3S2 m/z [M+1]
 +:233.0306; 
found:233.0305. 
 
Methyl 3-((3,5-dimethylthiophen-2-yl)sulfinyl)propanoate(115j) Colourless oil; 53% 
yield; 1H NMR (400 MHz, CDCl3) δ 6.58 (s, 1H), 3.71 (s, 3H), 3.45 – 3.31 (m, 1H), 
3.23 (dt, J = 13.1, 7.5 Hz, 1H), 2.87 – 2.66 (m, 2H), 2.50 (s, 3H), 2.31 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 171.36, 145.93, 142.64, 135.50, 128.89, 52.12, 51.55, 
27.51, 15.80, 14.41; HRMS (ESI) calcd for C10H14O3S2 m/z [M+1]
 +:247.0463; 
found:247.0462. 
 
methyl 3-(benzo[b]thiophen-2-ylsulfinyl)propanoate(115k) Colourless oil; 80% 
yield;  1H NMR (400 MHz, CDCl3) δ 7.93-7.86 (m, 1H), 7.86-7.81 (m, 1H), 7.47-7.38 
(m, 2H), 7.26 (s, 1H), 3.68 (s, 3H), 3.45-3.35 (m, 1H), 3.35-3.25 (m, 1H), 2.88 (ddd, J 
= 17.3, 7.9, 7.1 Hz, 1H), 2.69 (ddd, J = 17.3, 8.2, 6.1 Hz, 1H) 13C NMR (100 MHz, 
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CDCl3) δ 171.31, 145.52, 141.35, 138.16, 126.62, 126.36, 125.27, 124.89, 122.82, 
52.20, 51.93, 26.50; HRMS (ESI) calcd for C12H12O3S2 m/z [M+1]
 +: 269.0306; found: 
269.0299. 
 
Methyl 3-((3-methylbenzo[b]thiophen-2-yl)sulfinyl)propanoate(115l) Pale yellow 
oil; 93% yield; 1H NMR (400 MHz, CDCl3) δ 7.92-7.85 (m, 1H), 7.82-7.71 (m, 1H), 
7.51-7.39 (m, 2H), 3.68 (s, 3H), 3.42 (ddd, J = 13.9, 7.5, 6.4 Hz, 1H), 3.31 (dt, J = 
13.2, 7.4 Hz, 1H), 2.86 (dt, J = 17.4, 7.4 Hz, 1H), 2.74 (ddd, J = 17.4, 7.6, 6.5 Hz, 
1H), 2.56 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.28, 140.43, 140.34, 139.37, 
135.98, 126.61, 124.85, 123.06, 122.89, 52.19, 51.53, 27.18, 12.73; HRMS (ESI) 
calcd for C13H14O3S2 m/z [M+1]
 +: 283.0463; found: 283.0457. 
 
methyl 3-(furan-2-ylsulfinyl)propanoate(111m) Colourless oil; 85% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.69-7.62 (m, 1H), 6.97 (dd, J = 3.5, 0.6 Hz, 1H), 6.52 (dd, 
J = 3.4, 1.8 Hz, 1H), 3.69 (s, 3H), 3.44 (dd, J = 7.8, 6.4 Hz, 1H), 3.38 (dd, J = 7.7, 7.2 
Hz, 1H), 2.79 (t, J = 7.5 Hz, 1H), 2.71 (dd, J = 7.8, 6.5 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 171.27, 151.07, 146.99, 116.40, 111.40, 52.13, 47.09, 26.61; HRMS (ESI) 
calcd for C8H10O4S m/z [M+1]
 +:203.0378; found:203.0375. 
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Methyl 3-((2-methylfuran-3-yl)sulfinyl)propanoate(115n) Orange oil; 71% yield; 
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.0 Hz, 1H), 6.66 (d, J = 2.0 Hz, 1H), 3.70 
(s, 3H), 3.35-3.20 (m, 1H), 3.19-3.04 (m, 1H), 2.84-2.61 (m, 2H), 2.44 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 171.40, 154.75, 142.64, 121.67, 106.60, 52.16, 49.51, 
27.38, 12.38; HRMS (ESI) calcd for C9H12O4S m/z [M+1]
 +:217.0535; found: 
217.0529. 
 
Methyl 3-(benzofuran-2-ylsulfinyl)propanoate(115o) Orange oil; 78% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.67 (d, J = 7.8 Hz, 1H), 7.56 (d, J = 8.3 Hz, 1H), 7.47 – 
7.38 (m, 1H), 7.37 – 7.29 (m, 2H), 3.67 (s, 3H), 3.50 (t, J = 7.3 Hz, 2H), 2.90 (dt, J = 
17.4, 7.4 Hz, 1H), 2.72 (dt, J = 17.4, 7.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
171.30, 156.58, 153.62, 126.95, 126.48, 123.98, 122.31, 112.23, 112.06, 52.21, 47.22, 
26.20; HRMS (ESI) calcd for C12H12O4S m/z [M+1]
 +:253.0535; found:253.0538. 
 
Methyl 3-(pyridin-2-ylsulfinyl)propanoate(115p) Pale yellow oil; 78% yield; 1H 
NMR (400 MHz, CDCl3) δ 8.62 (d, J = 4.5 Hz, 1H), 8.00-7.86 (m, 2H), 7.38 (ddd, J = 
6.9, 4.7, 1.7 Hz, 1H), 3.64 (s, 3H), 3.49 (ddd, J = 13.7, 9.2, 6.1 Hz, 1H), 3.19 (ddd, J 
= 13.7, 9.1, 5.9 Hz, 1H), 2.85 (ddd, J = 17.0, 9.1, 6.1 Hz, 1H), 2.44 (ddd, J = 17.0, 9.2, 
5.9 Hz, 1H);  13C NMR (100 MHz, CDCl3) δ 171.52, 163.72, 149.77, 137.86, 124.66, 
120.24, 52.04, 47.94, 25.47; HRMS (ESI) calcd for C9H11NO3S m/z [M+1]
 +:214.0538; 
found:214.0546. 
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Methyl 3-((3,5-dimethylphenyl)sulfinyl)propanoate(115q) Colourless oil; 
quantitative yield; 1H NMR (400 MHz, CDCl3) δ 7.20 (s, 1H), 7.11 (s, 0H), 3.67 (s, 
3H), 3.20 (ddd, J = 13.1, 8.7, 6.5 Hz, 1H), 3.01 – 2.76 (m, 2H), 2.55 (ddd, J = 17.0, 
8.7, 5.5 Hz, 1H), 2.38 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 171.76, 142.70, 139.33, 
132.91, 121.44, 52.06, 51.11, 26.12, 21.27; HRMS (ESI) calcd for C12H16O3S m/z 
[M+1] +:241.0898; found:241.0901. 
 
Methyl 3-((5-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl) sulfinyl)propanoate 
(115r)  Reddish oil; 1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 8.9 Hz, 1H), 7.23 (d, J 
= 2.3 Hz, 1H), 7.05 (dd, J = 8.9, 2.4 Hz, 1H), 4.08 (s, 3H), 3.86 (s, 3H), 3.82-3.70 (m, 
2H), 3.66 (s, 3H), 3.00 (m, 1H), 2.92-2.81 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 
171.38, 157.01, 150.16, 142.73, 131.53, 115.81, 110.35, 101.99, 55.73, 52.17, 47.45, 
30.93, 26.49; HRMS (ESI) calcd for C13H16N2O4S m/z [M+1]
 +: 297.0909; found: 
297.0919. 
 
Methyl 3-(p-tolylsulfinyl)propanoate Colourless oil; 80% yield; 1H NMR (400 MHz, 
CDCl3) δ 7.50 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 8.3 Hz, 2H), 3.66 (s, 3H), 3.20 (ddd, J 
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= 13.3, 8.6, 6.7 Hz, 1H), 2.95 (ddd, J = 14.0, 8.5, 5.7 Hz, 1H), 2.88 – 2.75 (m, 1H), 
2.54 (ddd, J = 17.1, 8.6, 5.7 Hz, 1H), 2.42 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
171.70, 141.68, 139.63, 129.99, 124.04, 52.09, 51.14, 26.00, 21.39; HRMS (ESI) 
calcd for C11H14O3S m/z [M+1]
 +:227.0742; found:227.0743. 
 
Methyl 3-((4-methoxyphenyl)sulfinyl)propanoate Colourless oil; 80% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.8 Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 3.86 (s, 
3H), 3.67 (s, 3H), 3.17 (ddd, J = 13.4, 8.5, 6.8 Hz, 1H), 3.04 – 2.87 (m, 1H), 2.86 – 
2.71 (m, 1H), 2.56 (ddd, J = 17.2, 8.5, 5.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
171.69, 162.11, 133.78, 125.92, 114.86, 55.54, 52.09, 51.33, 26.17; HRMS (ESI) 
calcd for C11H14O4S m/z [M+1]
 +:243.0691; found:243.0699. 
 
Methyl 3-((4-chlorophenyl)sulfinyl)propanoate White solid; 78% yield; mp:77.9-
78.3 °C; 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.54 (m, 2H), 7.53 – 7.48 (m, 2H), 
3.66 (s, 3H), 3.23 (ddd, J = 13.3, 8.2, 6.9 Hz, 1H), 3.15 – 3.14 (m, 0H), 2.94 (ddd, J = 
13.4, 8.0, 5.8 Hz, 1H), 2.83 (ddd, J = 17.2, 7.9, 7.0 Hz, 1H), 2.55 (ddd, J = 17.2, 8.2, 
5.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 171.48, 141.46, 137.43, 129.59, 125.45, 
52.17, 51.20, 25.82; HRMS (ESI) calcd for C10H11ClO3S m/z [M+1]
 +:247.0196; 
found:247.0195. 
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Methyl 3-((4-bromophenyl)sulfinyl)propanoate White solid; 78% yield; mp:56.0-
56.8 °C; 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.61 (m, 2H), 7.53 – 7.43 (m, 2H), 
3.66 (s, 3H), 3.23 (ddd, J = 13.3, 8.1, 6.9 Hz, 1H), 2.93 (ddd, J = 13.4, 8.0, 5.7 Hz, 
1H), 2.88 – 2.74 (m, 1H), 2.55 (ddd, J = 17.2, 8.2, 5.7 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 171.47, 142.08, 132.51, 125.65, 125.62, 52.17, 51.12, 25.80; HRMS (ESI) 
calcd for C10H11BrO3S m/z [M+1]
 +:290.9691; found: 290.9689. 
 
Methyl 3-(o-tolylsulfinyl)propanoate Pale Yellow oil; 83% yield; 1H NMR (400 
MHz, CDCl3) δ 7.86 (dd, J = 7.5, 1.6 Hz, 1H), 7.47 – 7.34 (m, 2H), 7.21 (d, J = 6.9 
Hz, 1H), 3.64 (s, 3H), 3.27 – 3.14 (m, 1H), 2.95 – 2.82 (m, 2H), 2.70 – 2.57 (m, 1H), 
2.40 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.75, 141.04, 134.53, 130.88, 130.79, 
127.05, 123.89, 52.04, 48.81, 25.94, 18.05; HRMS (ESI) calcd for C11H14O3S m/z 
[M+1] +:227.0742; found:227.0740. 
 
Methyl 3-((2-ethylphenyl)sulfinyl)propanoate Pale yellow oil; 90% yield; 1H NMR 
(400 MHz, CDCl3) δ 7.95 – 7.82 (m, 1H), 7.48 – 7.37 (m, 2H), 7.29 (d, J = 3.4 Hz, 
1H), 3.66 (s, 3H), 3.20 (ddd, J = 10.9, 7.7, 4.9 Hz, 1H), 2.97 – 2.85 (m, 2H), 2.79 (dd, 
J = 14.8, 7.4 Hz, 1H), 2.70 – 2.57 (m, 2H), 1.30 (t, J = 7.5 Hz, 3H); 13C NMR (100 
Chapter 4 
132 
 
MHz, CDCl3) δ 171.76, 161.18, 140.96, 140.83, 131.21, 128.84, 127.16, 123.87, 
52.06, 50.14, 26.23, 24.49, 15.04; HRMS (ESI) calcd for C12H16O3S m/z [M+1]
 
+:241.0898; found:241.0895. 
 
Methyl 3-((2-methoxyphenyl)sulfinyl)propanoate Pale yellow oil; 90% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.73 (dd, J = 7.7, 1.2 Hz, 1H), 7.49 – 7.40 (m, 1H), 7.17 (t, 
J = 7.5 Hz, 1H), 6.91 (d, J = 8.2 Hz, 1H), 3.88 (s, 3H), 3.60 (s, 3H), 3.42 – 3.30 (m, 
1H), 3.18 – 3.06 (m, 1H), 2.80 (ddd, J = 16.8, 8.9, 6.2 Hz, 1H), 2.50 (ddd, J = 17.0, 
9.0, 6.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 172.03, 155.11, 132.18, 129.72, 
125.73, 121.46, 110.58, 55.72, 51.92, 46.61, 25.38; HRMS (ESI) calcd for C10H14O4S 
m/z [M+1] +:243.0691; found: 243.0692. 
 
Methyl 2-((3-methoxy-3-oxopropyl)sulfinyl)benzoate Pale yellow solid; 85% yield; 
1H NMR (400 MHz, CDCl3) δ 8.20 (d, J = 7.9 Hz, 1H), 8.11 (d, J = 7.7 Hz, 1H), 7.86 
– 7.66 (m, 1H), 7.58 (t, J = 7.6 Hz, 1H), 3.96 (s, 2H), 3.61 (s, 3H), 3.50 (ddd, J = 13.4, 
9.1, 6.2 Hz, 1H), 3.10 (ddd, J = 13.4, 9.0, 6.1 Hz, 1H), 2.95 – 2.77 (m, 1H), 2.62 (ddd, 
J = 16.9, 9.1, 6.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 171.92, 165.68, 147.30, 
133.65, 131.02, 130.37, 126.90, 125.22, 52.71, 51.94, 49.61, 26.22; HRMS (ESI) 
calcd for C12H14O5S m/z [M+1]
 +:271.0640; found: 271.0659. 
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Methyl 3-((2,6-dimethylphenyl)sulfinyl)propanoate Colourless oil; 79% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.23 (t, J = 7.6 Hz, 1H), 7.06 (t, J = 10.0 Hz, 2H), 3.71 (s, 
3H), 3.47 (dt, J = 13.2, 6.6 Hz, 1H), 3.14 (dt, J = 13.2, 7.8 Hz, 1H), 2.84 (d, J = 7.3 
Hz, 2H), 2.58 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 171.58, 138.41, 137.60, 130.99, 
130.29, 52.13, 47.02, 28.15, 19.10; HRMS (ESI) calcd for C12H16O3S m/z [M+1]
 
+:241.0898; found: 241.0898. 
 
Methyl 3-(mesitylsulfinyl)propanoate Colourless oil; 72% yield; 1H NMR (400 
MHz, CDCl3) δ 6.86 (s, 2H), 3.70 (s, 3H), 3.45 (dt, J = 13.3, 6.7 Hz, 1H), 3.12 (dt, J = 
13.2, 7.8 Hz, 1H), 2.86 – 2.70 (m, 2H), 2.54 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 
171.61, 141.29, 138.38, 134.41, 131.01, 52.09, 47.13, 28.22, 20.98, 19.02; HRMS 
(ESI) calcd for C13H18O3S m/z [M+1]
 +:255.1055; found: 255.1069. 
 
Methyl 3-(benzo[d][1,3]dioxol-5-ylsulfinyl)propanoate Pale yellow oil; 78% yield; 
1H NMR (400 MHz, CDCl3) δ 7.11 (dd, J = 3.8, 1.6 Hz, 1H), 7.08 (d, J = 1.7 Hz, 1H), 
6.91 (d, J = 7.9 Hz, 1H), 6.05 (s, 2H), 3.67 (s, 3H), 3.16 (ddd, J = 13.4, 8.5, 6.8 Hz, 
1H), 3.04 – 2.89 (m, 1H), 2.79 (ddd, J = 17.2, 8.2, 6.9 Hz, 1H), 2.56 (ddd, J = 17.2, 
8.4, 5.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 171.57, 150.46, 148.79, 135.69, 
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118.99, 108.80, 104.25, 101.98, 52.12, 51.41, 26.16; HRMS (ESI) calcd for 
C11H12O5S m/z [M+1]
 +:257.0484; found:257.0489. 
 
Methyl 3-(naphthalen-1-ylsulfinyl)propanoate White solid; 95% yield; mp:75.2-
76.8 °C; 1H NMR (400 MHz, CDCl3) δ 8.10 (dd, J = 7.2, 1.1 Hz, 1H), 8.07 – 8.06 (m, 
0H), 8.03 – 7.87 (m, 3H), 7.66 (dd, J = 8.1, 7.4 Hz, 1H), 7.63 – 7.51 (m, 2H), 3.64 (s, 
3H), 3.46 (dd, J = 7.5, 5.9 Hz, 1H), 3.09 – 2.84 (m, 2H), 2.65 – 2.43 (m, 1H); 13C 
NMR (100 MHz, CDCl3) δ 171.73, 138.58, 133.50, 131.38, 129.04, 128.72, 127.42, 
126.77, 125.45, 123.11, 121.54, 52.03, 49.58, 26.11; HRMS (ESI) calcd for 
C14H14O3S m/z [M+1]
 +:263.0742; found:263.0745. 
 
Methyl 3-(cyclohexylsulfinyl)propanoate Brown oil; 81% yield; 1H NMR (400 
MHz, CDCl3) δ 3.72 (s, 3H), 3.11 – 2.93 (m, 1H), 2.91 – 2.75 (m, 3H), 2.58 (tt, J = 
11.4, 3.5 Hz, 1H), 2.13 (d, J = 12.8 Hz, 1H), 2.01 – 1.81 (m, 3H), 1.72 (d, J = 11.1 Hz, 
1H), 1.56 – 1.15 (m, 5H); 13C NMR (100 MHz, CDCl3) δ 172.03, 59.50, 52.15, 43.66, 
27.19, 26.21, 25.48, 25.34, 25.10, 25.03; HRMS (ESI) calcd for C10H18O3S m/z [M+1]
 
+:219.1055; found: 219.1055. 
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Methyl 3-(tert-butylsulfinyl)propanoate Yellow oil; 51% yield; 1H NMR (400 MHz, 
CDCl3) δ 3.72 (s, 3H), 2.92 – 2.77 (m, 3H), 2.73 – 2.58 (m, 1H), 1.27 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 172.10, 53.29, 52.11, 40.65, 28.08, 22.74; HRMS (ESI) 
calcd for C8H16O3S m/z [M+1]
 +:193.0898; found:193.0898. 
4.2.4. Experimental Procedures for Asymmetric Alkylation of Sulenate Anions 
and Characterizations of Sulfoxide Products 
General procedure for pentanidium 101n catalysed asymmetric alkylation of in 
situ generated sulfenate anions. 
A 5 mL RBF was charged with a solution of methyl 3-(thiophen-2-
ylsulfinyl)propanoate 115b (13.1 mg, 0.06 mmol, 1.0 equiv.), benzyl bromide (8.6 L, 
0.072 mmol, 1.2 equiv.) and pentanidium 101n (1.1 mg, 0.0006 mmol, 1 mol %) in a 
solvent mixture of CPME (0.6 mL) and Et2O (1.8 mL). The reaction mixture was 
stirred at -70 °C for 30 min, and then saturated CsOH (72 L, 1.2 mmol, 20.0 equiv.) 
was added by syringe in one portion. The reaction mixture was stirred at -70 °C and 
monitored by TLC. After 115b was completely consumed, reaction was quenched by 
at 0 °C by addition of 1M aqueous HCl solution (1.5 mL) and extracted with CH2Cl2 
(3 mL × 3). The combined organic layer was washed by brine and dried by Na2SO4, 
filtered and concentrated. The sulfoxide 116ba was obtained by flash chromatography 
(silica gel, hexane-ethyl acetate 10:1-2:1), as colorless oil, 12.3 mg, 87% yield. 
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Large-scale experiment for synthesis of sulfoxide 6q: A 50 mL RBF was charged 
with a solution of methyl 3-((3-methylbenzo[b]thiophen-2-yl)sulfinyl)propanoate 115l 
(282 mg, 1 mmol, 1.0 equiv.), benzyl bromide (143 L, 1.2 mmol, 1.2 equiv.) and 
pentanidium 101n (4.4 mg, 0.0025 mmol, 0.25 mol %) in Et2O (20 mL). The reaction 
mixture was vigorously stirred at -60 °C for 30 min and then saturated CsOH (1.2 mL, 
20 mmol, 20.0 equiv.) was added by syringe in one portion. The reaction mixture was 
stirred at -60 °C and monitored by TLC. After 115l was completely consumed within 
18 h, the reaction was quenched by at 0 °C by addition of 1 M aqueous HCl solution 
(30 mL) and extracted with Et2O (50 mL × 3). The combined organic layer was 
washed by brine and dried by Na2SO4, filtered and concentrated. The sulfoxide 116la 
was obtained by flash chromatography (silica gel, hexane-ethyl acetate 10:1-2:1), as a 
white solid (245 mg, 85% yield) with 91% ee. 
 
(R)-2-(benzylsulfinyl)thiophene(116ba) Colorless oil; 87% yield; 1H NMR (400 
MHz, CDCl3) δ 7.62 (d, J = 4.8 Hz, 1H), 7.36 – 7.19 (m, 3H), 7.16 – 6.96 (m, 4H), 
4.36 (d, J = 12.4 Hz, 1H), 4.14 (d, J = 12.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
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144.94, 130.98, 130.19, 129.66, 129.24, 128.65, 128.42, 127.12, 65.07; IR: 1045 cm-1; 
HRMS (ESI) calcd for C11H10OS2 m/z [M+H]
 +: 223.0251; found: 223.0255; [𝑎]𝐷
22= –
86.7 (c 0.85, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 90/10, 1.0 mL/min, 
230 nm, 22°C), 20.7 (major), 29.1 min, 92% ee. 
 
(R)-2-((4-methylbenzyl)sulfinyl)thiophene(116bb) Colorless oil. 88% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.61 (dd, J = 4.9, 1.1 Hz, 1H), 7.13 (dd, J = 3.6, 1.1 Hz, 
1H), 7.08 (d, J = 7.8 Hz, 2H), 7.03 (dd, J = 4.9, 3.7 Hz, 1H), 6.97 (d, J = 7.9 Hz, 2H), 
4.32 (d, J = 12.5 Hz, 1H), 4.11 (d, J = 12.5 Hz, 1H), 2.32 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 145.16, 138.31, 130.88, 130.07, 129.66, 129.35, 127.09, 126.13, 
64.84, 21.16; IR: 2918, 1907, 1514, 1401, 1224, 1087, 1045, 1001 cm-1; HRMS (ESI) 
calcd for C12H12OS2 m/z [M+H]
 +: 237.0408; found: 237.0418; [𝑎]𝐷
22= –106.7 (c 1.06, 
CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 
22°C), 18.4 (major), 23.7 min, 94% ee. 
 
(R)-2-((4-chlorobenzyl)sulfinyl)thiophene(116bc) White solid; 84% yield; mp:96.0-
97.5 °C; 1H NMR (400 MHz, CDCl3) δ 7.63 (dd, J = 5.0, 1.2 Hz, 1H), 7.30 – 7.19 (m, 
2H), 7.16 (dd, J = 3.7, 1.2 Hz, 1H), 7.05 (dd, J = 5.0, 3.7 Hz, 1H), 7.03 – 6.98 (m, 2H), 
4.26 (d, J = 12.6 Hz, 1H), 4.13 (d, J = 12.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
144.53, 134.62, 131.47, 131.17, 129.71, 128.83, 127.65, 127.23, 64.03; IR: 2972, 
1489, 1401, 1224, 1087, 1045, 1033 cm-1; HRMS (ESI) calcd for C11H9ClOS2 m/z 
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[M+H] +: 256.9862; found: 256.9875; [𝑎]𝐷
22= –56.9 (c 1.24, CHCl3); HPLC analysis: 
Chiralcel OD-H (Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 22°C), 22.1 (major), 30.1 
min, 90% ee. 
 
(R)-2-((4-(trifluoromethyl)benzyl)sulfinyl)thiophene(116bd)  White solid; 83% 
yield; mp:161.9-163.1 °C; 1H NMR (400 MHz, CDCl3) δ 7.64 (dd, J = 5.0, 1.2 Hz, 
1H), 7.55 (d, J = 8.1 Hz, 2H), 7.21 (d, J = 8.1 Hz, 2H), 7.18 (dd, J = 3.7, 1.2 Hz, 1H), 
7.06 (dd, J = 4.9, 3.7 Hz, 1H), 4.32 (d, J = 12.6 Hz, 1H), 4.22 (d, J = 12.5 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 144.38, 133.23, 131.33, 130.56, 130.49, 129.72, 
127.31, 125.52 (q, J = 3.7 Hz), 122.55, 64.21; 19F NMR (376 MHz, CDCl3) δ -62.70; 
IR: 3049, 1417, 1126, 1066, 1047, 750 cm-1; HRMS (ESI) calcd for C12H9F3OS2 m/z 
[M+H] +: 291.0125; found: 291.0115; [𝑎]𝐷
22= –106.5 (c 1.13, CHCl3); HPLC analysis: 
Chiralcel OD-H (Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 22°C), 28.7 (major), 24.2 
min, 93% ee. 
 
(R)-2-((3-methoxybenzyl)sulfinyl)thiophene(116be) Colourless oil; 84% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.62 (d, J = 5.0 Hz, 1H), 7.19 (t, J = 7.9 Hz, 1H), 7.15 (d, 
J = 3.6 Hz, 1H), 7.07 – 6.99 (m, 1H), 6.84 (dd, J = 8.3, 2.4 Hz, 1H), 6.69 (d, J = 7.5 
Hz, 1H), 6.59 (s, 1H), 4.34 (d, J = 12.4 Hz, 1H), 4.10 (d, J = 12.4 Hz, 1H), 3.73 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 159.68, 145.04, 131.00, 130.63, 129.73, 129.65, 
127.13, 122.47, 115.29, 114.35, 65.18, 55.19; IR: 1600, 1489, 1153, 1041, 788 cm-1; 
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HRMS (ESI) calcd for C12H12O2S2 m/z [M+H]
 +: 253.0357; found: 253.0356; [𝑎]𝐷
22= –
91.5 (c 1.07, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 90/10, 1.0 mL/min, 
230 nm, 22°C), 25.3 (major), 36.9 min, 90% ee. 
 
(R)-2-((naphthalen-2-ylmethyl)sulfinyl)thiophene(116bf) Beige powder; 84% yield; 
mp:93.9-94.8 °C; 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.78 (m, 1H), 7.75 (t, J = 5.4 
Hz, 2H), 7.62 (dd, J = 5.0, 1.2 Hz, 1H), 7.56 (s, 1H), 7.52 – 7.43 (m, 2H), 7.18 (dd, J 
= 8.4, 1.6 Hz, 1H), 7.11 (dd, J = 3.6, 1.2 Hz, 1H), 7.00 (dd, J = 4.9, 3.7 Hz, 1H), 4.52 
(d, J = 12.4 Hz, 1H), 4.31 (d, J = 12.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 144.94, 
133.17, 132.98, 131.04, 129.76, 129.71, 128.38, 127.86, 127.67, 127.42, 127.14, 
126.69, 126.45, 126.39, 65.36; IR: 2983, 1508, 1419, 1406, 1224, 1045, 821 cm-1; 
HRMS (ESI) calcd for C15H12OS2 m/z [M+H]
 +: 273.0408; found: 273.0410; [𝑎]𝐷
22= –
110.4 (c 1.32, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 90/10, 1.0 
mL/min, 230 nm, 22°C), 30.5 (major), 41.3 min, 92% ee. 
 
(R)-2-(allylsulfinyl)thiophene(116bg) Pale yellow oil; 82% yield; 1H NMR (400 
MHz, CDCl3) δ 7.65 (dd, J = 5.0, 1.2 Hz, 1H), 7.43 (dd, J = 3.7, 1.2 Hz, 1H), 7.12 (dd, 
J = 5.0, 3.7 Hz, 1H), 5.71 (ddt, J = 17.6, 10.2, 7.5 Hz, 1H), 5.37 (d, J = 10.2 Hz, 1H), 
5.29 (dd, J = 17.0, 1.2 Hz, 1H), 3.79 (dd, J = 12.6, 7.4 Hz, 1H), 3.70 (dd, J = 12.4, 7.4 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 145.00, 131.08, 129.82, 127.22, 125.21, 
124.23, 62.08; IR: 3082, 1635, 1404, 1222, 1039, 933, 850, 711 cm-1; HRMS (ESI) 
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calcd for C7H8OS2 m/z [M+H]
 +: 173.0095; found: 173.0101; [𝑎]𝐷
22= +39.1 (c 0.45, 
CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 90/10, 1.0 mL/min, 254 nm, 
22°C), 13.7 (major), 16.6 min, 92% ee. 
 
(R)-2-((2-methylallyl)sulfinyl)thiophene(116bh) Pale yellow oil; 79% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.65 (dd, J = 5.0, 1.1 Hz, 1H), 7.43 (dd, J = 3.6, 1.1 Hz, 
1H), 7.11 (dd, J = 4.9, 3.7 Hz, 1H), 5.08 – 4.98 (m, 1H), 4.88 (s, 1H), 3.82 (d, J = 
12.2 Hz, 1H), 3.58 (d, J = 12.3 Hz, 1H), 1.81 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
145.81, 134.65, 130.98, 129.71, 127.18, 118.98, 67.65, 22.79; IR: 3080, 2972, 2912, 
1649, 1448, 1404, 1377, 1224, 1045, 902, 850, 715 cm-1; HRMS (ESI) calcd for 
C8H10OS2 m/z [M+H]
 +: 187.0251; found: 187.0257; [𝑎]𝐷
22= +34.3(c 0.72, CHCl3); 
HPLC analysis: Chiralcel OD-H (Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 22°C), 11.6 
(major), 14.2 min, 92% ee. 
 
(R)-2-(but-2-yn-1-ylsulfinyl)thiophene(116bi) Pale yellow oil; 77% yield; 1H NMR 
(400 MHz, CDCl3) δ 7.67 (d, J = 5.0 Hz, 1H), 7.52 (d, J = 3.6 Hz, 1H), 7.17 – 7.10 (m, 
1H), 3.90 – 3.63 (m, 2H), 1.82 (t, J = 2.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
145.01, 131.38, 130.04, 127.10, 85.26, 67.59, 49.46, 3.74; IR: 3080, 2902, 2235, 1404, 
1224, 1047, 1001, 850, 713 cm-1; HRMS (ESI) calcd for C8H8OS2 m/z [M+H]
 +: 
185.0095; found: 185.0098; [𝑎]𝐷
22= –103.3 (c 0.58, CHCl3); HPLC analysis: Chiralcel 
AD-H (Hex/IPA = 90/10, 1.0 mL/min, 254 nm, 22°C), 11.6, 14.1(major) min, 82% ee. 
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(R)-2-(methylsulfinyl)thiophene(116bj) Colourless oil; 65% yield; 1H NMR (400 
MHz, CDCl3) δ 7.65 (dd, J = 5.0, 1.1 Hz, 1H), 7.49 (dd, J = 3.6, 1.1 Hz, 1H), 7.12 (dd, 
J = 4.9, 3.7 Hz, 1H), 2.93 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 130.74, 129.19, 
127.42, 44.55; IR: 1406, 1033, 954, 717 cm-1; HRMS (ESI) calcd for C5H6OS2 m/z 
[M+H] +: 146.9938; found: 146.9944; [𝑎]𝐷
22= +38.7 (c 0.15, CHCl3); HPLC analysis: 
Chiralcel OD-H (Hex/IPA = 95/5, 1.0 mL/min, 254 nm, 22°C), 34.1 (major), 38.2 min, 
77% ee. 
 
(R)-2-(propylsulfinyl)thiophene(116bk) pale yellow oil; 66% yield; 1H NMR (400 
MHz, CDCl3) δ 7.65 (dd, J = 5.0, 1.2 Hz, 1H), 7.47 (dd, J = 3.7, 1.2 Hz, 1H), 7.12 (dd, 
J = 5.0, 3.7 Hz, 1H), 3.12 (dt, J = 12.8, 7.3 Hz, 1H), 2.91 (dt, J = 12.8, 7.7 Hz, 1H), 
1.84 – 1.67 (m, 2H), 1.08 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 130.88, 
129.67, 127.32, 60.22, 16.50, 13.18; IR: 1458, 1404, 1226, 1026, 848, 717 cm-1; 
HRMS (ESI) calcd for C7H10OS2 m/z [M+H]
 +: 175.0251; found: 175.0257; [𝑎]𝐷
22= 
+60.5 (c 0.18, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 95/5, 1.0 mL/min, 
230 nm, 22°C), 19.8 (major), 23.0 min, 81% ee.  
 
(R)-2-(octylsulfinyl)thiophene(116bl)  pale yellow oil; 69% yield; 1H NMR (400 
MHz, CDCl3) δ 7.65 (dd, J = 5.0, 1.2 Hz, 1H), 7.47 (dd, J = 3.6, 1.2 Hz, 1H), 7.12 (dd, 
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J = 5.0, 3.7 Hz, 1H), 3.11 (ddd, J = 12.9, 8.5, 6.4 Hz, 1H), 2.94 (ddd, J = 12.8, 8.6, 
7.1 Hz, 1H), 1.81 – 1.58 (m, 2H), 1.43 (dd, J = 12.7, 5.9 Hz, 2H), 1.36 – 1.15 (m, 8H), 
0.87 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 130.87, 129.69, 127.31, 
58.35, 31.68, 29.09, 28.95, 28.58, 22.74, 22.57, 14.04; IR: 2924, 2854, 1458, 1404, 
1226, 1049, 848, 717 cm-1; HRMS (ESI) calcd for C12H20OS2 m/z [M+H]
 +: 245.1034; 
found: 245.1020; [𝑎]𝐷
22= +34.7 (c 0.32, CHCl3); HPLC analysis: Chiralcel OD-H 
(Hex/IPA = 95/5, 1.0 mL/min, 230 nm, 22°C), 13.2 (major), 15.9 min, 81% ee. 
 
(R)-2-(benzylsulfinyl)-3-methylthiophene(116ha) White solid; 85% yield; mp:63.1-
63.9 °C; 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 5.0 Hz, 1H), 7.31 – 7.20 (m, 3H), 
7.02 (dd, J = 7.9, 1.4 Hz, 2H), 6.75 (d, J = 5.0 Hz, 1H), 4.47 (d, J = 12.1 Hz, 1H), 
4.11 (d, J = 12.1 Hz, 1H), 1.80 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 142.22, 138.50, 
130.36, 130.19, 129.83, 129.14, 128.62, 128.38, 64.64, 13.83; IR: 2983, 1465, 1419, 
1045, 750 cm-1; HRMS (ESI) calcd for C12H12OS2 m/z [M+H]
 +: 237.0408; found: 
237.0408; [𝑎]𝐷
22= –129.5 (c 1.3, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 
90/10, 1.0 mL/min, 230 nm, 22°C), 20.6 (major), 30.4 min, 92% ee. 
 
(R)-3-methyl-2-((4-methylbenzyl)sulfinyl)thiophene(116hb) Colourless oil; 86% 
yield; 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 5.0 Hz, 1H), 7.05 (d, J = 7.8 Hz, 2H), 
6.91 (d, J = 8.0 Hz, 2H), 6.76 (d, J = 5.0 Hz, 1H), 4.44 (d, J = 12.1 Hz, 1H), 4.08 (d, J 
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= 12.1 Hz, 1H), 2.31 (s, 3H), 1.82 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 142.23, 
138.61, 138.29, 130.30, 130.08, 129.84, 129.30, 126.01, 64.32, 21.15, 13.90; IR: 2920, 
1614, 1514, 1444, 1381, 1101, 1045, 821, 732 cm-1; HRMS (ESI) calcd for 
C13H14OS2 m/z [M+H]
 +: 251.0564; found: 251.0562; [𝑎]𝐷
22= –162.9 (c 1.13, CHCl3); 
HPLC analysis: Chiralcel OD-H (Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 22°C), 17.5 
(major), 24.6 min, 95% ee. 
 
(R)-2-((4-chlorobenzyl)sulfinyl)-3-methylthiophene(116hc) Colourless oil; 87% 
yield; 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 5.0 Hz, 1H), 7.23 (d, J = 8.1 Hz, 
2H), 6.97 (d, J = 8.2 Hz, 2H), 6.79 (d, J = 5.0 Hz, 1H), 4.39 (d, J = 12.3 Hz, 1H), 4.09 
(d, J = 12.3 Hz, 1H), 1.91 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 142.09, 138.27, 
134.58, 131.47, 130.59, 129.98, 128.80, 127.71, 63.52, 14.02; HRMS (ESI) calcd for 
C12H11ClOS2 m/z [M+1]
 +: 271.0018; found: 271.0017; [𝑎]𝐷
22= –128.4 (c 1.35, CHCl3); 
HPLC analysis: Chiralcel OJ (Hex/IPA = 95/5, 1.0 mL/min, 230 nm, 22°C), 31.8 
(major), 43.1 min, 92% ee. 
 
(R)-3-methyl-2-((4-(trifluoromethyl)benzyl)sulfinyl)thiophene(116hd) White solid; 
89% yield; mp:107.1-108.5 °C; 1H NMR (400 MHz, CDCl3) δ 7.54 (dd, J = 8.5, 6.5 
Hz, 3H), 7.18 (d, J = 8.0 Hz, 2H), 6.80 (d, J = 5.0 Hz, 1H), 4.44 (d, J = 12.1 Hz, 1H), 
4.18 (d, J = 12.1 Hz, 1H), 1.92 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 141.95, 138.31, 
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133.37, 130.64(q, J = 10.3 Hz), 130.58, 130.06, 125.50(q, J = 3.7 Hz), 125.22, 122.51, 
63.79, 14.00; 19F NMR (376 MHz, CDCl3) δ -62.71; HRMS (ESI) calcd for 
C13H11F3OS2 m/z [M+1]
 +: 305.0282; found: 305.0281; [𝑎]𝐷
22= –78.0 (c 1.01, CHCl3); 
HPLC analysis: Chiralcel OJ (Hex/IPA = 95/5, 1.0 mL/min, 230 nm, 22°C), 21.8 
(major), 29.6 min, 90% ee. 
 
(R)-2-((3-methoxybenzyl)sulfinyl)-3-methylthiophene(116he) Colourless oil; 88% 
yield; 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 5.0 Hz, 1H), 7.16 (t, J = 7.9 Hz, 1H), 
6.82 (dd, J = 8.3, 2.4 Hz, 1H), 6.76 (d, J = 5.0 Hz, 1H), 6.65 (d, J = 7.5 Hz, 1H), 6.51 
(s, 1H), 4.45 (d, J = 12.0 Hz, 1H), 4.06 (d, J = 12.0 Hz, 1H), 3.70 (s, 3H), 1.84 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 159.65, 142.18, 138.85, 130.57, 130.28, 129.86, 
129.59, 122.49, 115.14, 114.38, 64.78, 55.18, 13.90; IR: 1600, 1490, 1165, 1045 cm-1; 
HRMS (ESI) calcd for C13H14O2S2 m/z [M+H]
 +: 267.0513; found: 267.0512; [𝑎]𝐷
22= –
136.7 (c 1.38, CHCl3); HPLC analysis: Chiralcel OJ (Hex/IPA = 95/5, 1.0 mL/min, 
230 nm, 22°C), 53.1 (major), 61.8 min, 94% ee. 
 
(R)-3-methyl-2-((naphthalen-2-ylmethyl)sulfinyl)thiophene(116hf) Colourless oil; 
87% yield; 1H NMR (400 MHz, CDCl3) δ 7.87 – 7.76 (m, 1H), 7.72 (t, J = 5.6 Hz, 
2H), 7.54 (d, J = 5.0 Hz, 1H), 7.52 – 7.41 (m, 3H), 7.14 (dd, J = 8.4, 1.7 Hz, 1H), 6.72 
(d, J = 5.0 Hz, 1H), 4.63 (d, J = 12.1 Hz, 1H), 4.28 (d, J = 12.1 Hz, 1H), 1.74 (s, 3H); 
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13C NMR (100 MHz, CDCl3) δ 142.17, 138.65, 133.14, 132.89, 130.40, 129.90, 
129.68, 128.31, 127.79, 127.64, 127.40, 126.62, 126.45, 126.42, 64.86, 13.94; HRMS 
(ESI) calcd for C16H14OS2 m/z [M+1]
 +: 287.0564; found: 287.0562; [𝑎]𝐷
22= –170.6 (c 
1.22, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 90/10, 1.0 mL/min, 254 
nm, 22°C), 26.5 (major), 40.6 min, 92% ee. 
 
1,3-bis(((R)-(3-methylthiophen-2-yl)sulfinyl)methyl)benzene(116hg) Colourless oil; 
87% yield; enantiomers: mesomer  = 4.75:1; 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J 
= 5.0 Hz, 2H), 7.18 (t, J = 7.7 Hz, 1H), 7.01 (dd, J = 7.7, 1.6 Hz, 2H), 6.80 (d, J = 5.0 
Hz, 2H), 6.75 (s, 1H), 4.32 (d, J = 12.3, 2H), 4.04 (d, J = 12.3 Hz, 2H), 1.94 (s, 
6H);13C NMR (100 MHz, CDCl3) δ 141.91, 138.83, 131.99, 130.47, 130.22, 130.08, 
130.03, 128.94, 64.01, 14.08; IR: 2991, 1606, 1531, 1487, 1446, 1384, 1217, 1099, 
1041, 1026 cm-1; HRMS (ESI) calcd for C18H18O2S4 m/z [M+H]
 +: 395.0268; found: 
395.0258; [𝑎]𝐷
22= –136.25 (c 1.84, CHCl3); HPLC analysis: Chiralcel OJ (Hex/IPA = 
80/20, 1.0 mL/min, 230 nm, 22°C), 64.1 (major), 90.7 min, 99% ee. 
 
(R)-2-(benzylsulfinyl)-5-methylthiophene(116ia) White solid; 85% yield; mp:109.3-
110.8 °C; 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.27 (m, 3H), 7.12 (dd, J = 6.3, 2.7 
Hz, 2H), 6.97 (d, J = 3.6 Hz, 1H), 6.67 (d, J = 3.6 Hz, 1H), 4.37 (d, J = 12.4 Hz, 1H), 
4.15 (d, J = 12.4 Hz, 1H), 2.54 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 146.99, 141.23, 
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130.88, 130.17, 129.50, 128.65, 128.36, 125.40, 64.61, 15.86; IR: 1494, 1440, 1213, 
1072, 1041 cm-1; HRMS (ESI) calcd for C12H12OS2 m/z [M+H]
 +: 237.0408; found: 
237.0439; [𝑎]𝐷
22= –132.4 (c 1.0, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 
90/10, 1.0 mL/min, 230 nm, 22°C), 16.5 (major), 24.5 min, 90% ee.
 
(R)-2-((4-chlorobenzyl)sulfinyl)-5-methylthiophene(116ib) White solid; 86% yield; 
mp:118.2-119.6 °C; 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.21 (m, 2H), 7.06 (s, 1H), 
6.99 (d, J = 3.6 Hz, 1H), 6.69 (d, J = 3.6 Hz, 1H), 4.28 (d, J = 12.5 Hz, 1H), 4.12 (d, J 
= 12.6 Hz, 1H), 2.55 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 147.20, 140.89, 134.54, 
131.48, 130.94, 128.84, 127.97, 125.51, 63.66, 15.87; IR: 1492, 1442, 1093, 1045, 
1016 cm-1; HRMS (ESI) calcd for C12H11ClOS2 m/z [M+H]
 +: 271.0018; found: 
271.0013; [𝑎]𝐷
22= –93.8 (c 1.19, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 
90/10, 1.0 mL/min, 230 nm, 22°C), 17.5 (major), 23.7 min, 84% ee. 
 
(R)-2-(benzylsulfinyl)-3,5-dimethylthiophene(116ja) Colourless oil; 93% yield; 1H 
NMR (400 MHz, CDCl3) δ 7.34 – 7.16 (m, 3H), 7.06 (dd, J = 7.5, 1.8 Hz, 2H), 6.41 (s, 
1H), 4.44 (d, J = 12.0 Hz, 1H), 4.08 (d, J = 12.0 Hz, 1H), 2.49 (s, 3H), 1.73 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 145.63, 142.91, 135.43, 130.16, 129.56, 128.58, 
128.34, 128.24, 64.50, 15.91, 13.87; HRMS (ESI) calcd for C13H14OS2 m/z [M+1]
 +: 
251.0564; found: 251.0563; [𝑎]𝐷
22= –297.8 (c 1.16, CHCl3); HPLC analysis: Chiralcel 
OD-H (Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 22°C), 15.6 (major), 25.3 min,95% ee. 
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(R)-2-(benzylsulfinyl)benzo[b]thiophene(116ka) White solid; 89% yield; mp:166.0-
167.1 °C; 1H NMR (400 MHz, CDCl3) δ 7.96 – 7.84 (m, 1H), 7.74 (dd, J = 6.8, 2.0 
Hz, 1H), 7.48 – 7.37 (m, 2H), 7.34 (s, 1H), 7.33 – 7.22 (m, 3H), 7.12 (dd, J = 7.8, 1.3 
Hz, 2H), 4.40 (d, J = 12.5 Hz, 1H), 4.24 (d, J = 12.5 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 145.64, 141.26, 138.09, 130.23, 129.05, 128.71, 128.55, 126.75, 126.21, 
125.10, 124.80, 122.84, 64.44; IR: 1651, 1454, 1417, 1027, 1037 cm-1; HRMS (ESI) 
calcd for C15H12OS2 m/z [M+H]
 +: 273.0408; found: 273.0405; [𝑎]𝐷
22= –58.9 (c 1.27, 
CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 
22°C), 32.4 (major), 41.6 min, 92% ee. 
 
(R)-2-((4-methylbenzyl)sulfinyl)benzo[b]thiophene(116kb) White solid; 91% yield; 
mp:152.0-152.5 °C; 1H NMR (400 MHz, CDCl3) δ 7.94 – 7.84 (m, 1H), 7.75 (dd, J = 
6.7, 2.2 Hz, 1H), 7.47 – 7.38 (m, 2H), 7.37 (s, 1H), 7.07 (d, J = 8.0 Hz, 2H), 7.01 (d, J 
= 8.0 Hz, 2H), 4.37 (d, J = 12.5 Hz, 1H), 4.21 (d, J = 12.5 Hz, 1H), 2.31 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 145.85, 141.28, 138.46, 138.12, 130.12, 129.42, 126.76, 
126.16, 125.91, 125.07, 124.79, 122.85, 64.21, 21.19; IR: 1506, 1417, 1049, 819 cm-1; 
HRMS (ESI) calcd for C16H14OS2 m/z [M+H]
 +: 287.0564; found: 287.0565; [𝑎]𝐷
22= –
84.5 (c 1.34, CHCl3); HPLC analysis: Chiralcel AD-H (Hex/IPA = 90/10, 1.0 mL/min, 
230 nm, 22°C), 20.3 (major), 27.3 min, 92% ee. 
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(R)-2-((4-chlorobenzyl)sulfinyl)benzo[b]thiophene(116kc) White solid; 81% yield; 
mp:178.3-179.0 °C; 1H NMR (400 MHz, CDCl3) δ 7.95 – 7.82 (m, 1H), 7.77 (dd, J = 
6.5, 2.4 Hz, 1H), 7.48 – 7.40 (m, 2H), 7.39 (s, 1H), 7.30 – 7.17 (m, 2H), 7.05 (d, J = 
8.4 Hz, 2H), 4.31 (d, J = 12.7 Hz, 1H), 4.23 (d, J = 12.7 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 145.18, 141.26, 138.01, 134.75, 131.53, 128.89, 127.45, 126.90, 126.36, 
125.23, 124.89, 122.86, 63.39; IR: 1247, 1037 cm-1; HRMS (ESI) calcd for 
C15H11ClOS2 m/z [M+H]
 +: 307.0018; found: 307.0015; [𝑎]𝐷
22= –20.3 (c 1.41, CHCl3); 
HPLC analysis: Chiralcel AD-H (Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 22°C), 25.8 
(major), 30.2 min, 90% ee. 
 
(R)-2-((4-(trifluoromethyl)benzyl)sulfinyl)benzo[b]thiophene(116kd) White solid; 
80% yield; mp:205.9-207.2 °C; 1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 7.6 Hz, 
1H), 7.80 – 7.71 (m, 1H), 7.53 (d, J = 8.0 Hz, 2H), 7.44 (ddd, J = 7.1, 6.2, 3.5 Hz, 2H), 
7.40 (s, 1H), 7.26 (d, J = 7.8 Hz, 2H), 4.38 (d, J = 12.6 Hz, 1H), 4.31 (d, J = 12.6 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 144.96(two peaks), 141.28, 137.98, 133.06, 
130.61, 126.96, 126.47, 125.59 (q, J = 3.8 Hz), 125.32, 124.92(two peaks), 122.87, 
63.57; 19F NMR (376 MHz, CDCl3) δ -62.73; IR: 2358, 1421, 1336, 1116, 1070, 1033, 
1018 cm-1; HRMS (ESI) calcd for C12H11ClOS2 m/z [M+1]
 +: 271.0018; found: 
271.0013. HRMS (ESI) calcd for C16H11F3OS2 m/z [M+H]
 +: 341.0282; found: 
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341.0280; [𝑎]𝐷
22= +27.4 (c 0.81, CHCl3); HPLC analysis: Chiralcel AD-H (Hex/IPA = 
90/10, 1.0 mL/min, 254 nm, 22°C), 19.9 (major), 24.8 min, 85% ee. 
 
(R)-2-((3-methoxybenzyl)sulfinyl)benzo[b]thiophene(116ke) White solid; 81% 
yield; mp:101.1-102.6 °C; 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 7.2 Hz, 1H), 
7.80 – 7.68 (m, 1H), 7.47 – 7.37 (m, 2H), 7.36 (s, 1H), 7.18 (t, J = 7.9 Hz, 1H), 6.83 
(dd, J = 8.3, 2.4 Hz, 1H), 6.72 (d, J = 7.5 Hz, 1H), 6.61 (s, 1H), 4.39 (d, J = 12.4 Hz, 
1H), 4.19 (d, J = 12.4 Hz, 1H), 3.61 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 159.69, 
145.75, 141.23, 138.08, 130.46, 129.71, 126.80, 126.23, 125.13, 124.80, 122.82, 
122.50, 115.09, 114.66, 64.62, 55.06; IR: 1568, 1489, 1321, 1166, 1155, 1039, 975 
cm-1; HRMS (ESI) calcd for C16H14O2S2 m/z [M+H]
 +: 303.0513; found: 303.0515; 
[𝑎]𝐷
22= –71.8 (c 1.42, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 90/10, 1.0 
mL/min, 230 nm, 22°C), 24.4 (major), 35.1 min, 92% ee. 
 
(R)-2-((naphthalen-2-ylmethyl)sulfinyl)benzo[b]thiophene(116kf) White solid; 90% 
yield; mp:198.3-199.7 °C; 1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 8.0 Hz, 1H), 
7.84 – 7.77 (m, 1H), 7.71 (dd, J = 18.3, 8.0 Hz, 3H), 7.62 (d, J = 6.2 Hz, 1H), 7.52 – 
7.36 (m, 4H), 7.34 (s, 1H), 7.21 (dd, J = 8.4, 1.7 Hz, 1H), 4.57 (d, J = 12.5 Hz, 1H), 
4.41 (d, J = 12.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 145.72, 141.28, 138.09, 
133.17, 133.06, 129.83, 128.48, 127.89, 127.68, 127.43, 126.87, 126.53, 126.51, 
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126.43, 126.24, 125.11, 124.84, 122.85, 64.80; IR: 1421, 1047 cm-1; HRMS (ESI) 
calcd for C19H14OS2 m/z [M+H]
 +: 323.0564; found: 323.0569; [𝑎]𝐷
22= –95.3 (c 0.78, 
CHCl3); HPLC analysis: Chiralcel AD-H (Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 
22°C), 32.8 (major), 42.6 min, 91% ee. 
 
(R)-2-(benzylsulfinyl)-3-methylbenzo[b]thiophene(116la) White solid; 83% yield; 
mp:137.8-138.7 °C; 1H NMR (400 MHz, CDCl3) δ 7.90 (dd, J = 7.0, 1.1 Hz, 1H), 
7.60 (dd, J = 7.1, 1.5 Hz, 1H), 7.50 – 7.37 (m, 2H), 7.27 (dt, J = 5.1, 3.8 Hz, 1H), 7.20 
(dd, J = 10.1, 4.7 Hz, 2H), 7.07 – 6.97 (m, 2H), 4.54 (d, J = 12.0 Hz, 1H), 4.22 (d, J = 
12.0 Hz, 1H), 1.90 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 140.47, 139.88, 139.05, 
136.99, 130.20, 129.03, 128.67, 128.47, 126.42, 124.69, 123.12, 122.74, 64.12, 12.04; 
IR: 1454, 1107, 1045, 960 cm-1; HRMS (ESI) calcd for C16H14OS2 m/z [M+H]
 +: 
287.0564; found: 287.0567; [𝑎]𝐷
22= –227.2 (c 1.3, CHCl3); HPLC analysis: Chiralcel 
OD-H (Hex/IPA = 90/10, 1.0 mL/min, 254 nm, 22°C), 31.4 (major), 64.6 min, 95% 
ee. 
 
(R)-3-methyl-2-((4-methylbenzyl)sulfinyl)benzo[b]thiophene(116lb) White solid; 
80% yield; mp:158.5-159.7 °C; 1H NMR (400 MHz, CDCl3) δ 7.94 – 7.87 (m, 1H), 
7.62 (dd, J = 6.9, 1.7 Hz, 1H), 7.43 (pd, J = 7.1, 1.3 Hz, 2H), 7.06 – 6.97 (m, 2H), 
6.92 (d, J = 8.0 Hz, 2H), 4.50 (d, J = 12.1 Hz, 1H), 4.19 (d, J = 12.1 Hz, 1H), 2.30 (s, 
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3H), 1.94 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 140.49, 140.06, 139.09, 138.38, 
136.94, 130.08, 129.34, 126.37, 125.88, 124.65, 123.12, 122.75, 63.80, 21.15, 12.13; 
IR: 1427, 1255, 1105, 1039, 1010, 966 cm-1; HRMS (ESI) calcd for C17H16OS2 m/z 
[M+H] +: 301.0721; found: 301.0716; [𝑎]𝐷
22= –240.2 (c 1.42, CHCl3); HPLC analysis: 
Chiralcel OJ (Hex/IPA = 95/5, 1.0 mL/min, 254 nm, 22°C), 46.2, 64.5(major) min, 94% 
ee. 
 
(R)-2-((4-chlorobenzyl)sulfinyl)-3-methylbenzo[b]thiophene(116lc) White solid; 
83% yield; mp:185.2-186.8 °C; 1H NMR (400 MHz, CDCl3) δ 7.93 – 7.83 (m, 1H), 
7.69 – 7.60 (m, 1H), 7.45 (dq, J = 7.3, 5.9 Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H), 6.98 (d, J 
= 8.3 Hz, 2H), 4.46 (d, J = 12.2 Hz, 1H), 4.20 (d, J = 12.2 Hz, 1H), 2.03 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 140.47, 139.64, 139.01, 136.98, 134.67, 131.49, 128.87, 
127.61, 126.60, 124.84, 123.14, 122.86, 63.11, 12.29; IR: 2985, 1421, 1095, 1045 cm-
1; HRMS (ESI) calcd for C16H13ClOS2 m/z [M+H]
 +: 321.0175; found: 321.0177; 
[𝑎]𝐷
22= –203.7 (c 1.73, CHCl3); HPLC analysis: Chiralcel OJ (Hex/IPA = 90/10, 1.0 
mL/min, 254 nm, 22°C), 35.7, 39.9(major) min, 91% ee. 
 
(R)-3-methyl-2-((4-(trifluoromethyl)benzyl)sulfinyl)benzo[b]thiophene(116ld) 
White solid; 75% yield; mp:178.7-180.0 °C; 1H NMR (400 MHz, CDCl3) δ 7.90 (dd, 
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J = 6.9, 1.5 Hz, 1H), 7.65 (dd, J = 6.9, 1.8 Hz, 1H), 7.54 – 7.37 (m, 4H), 7.20 (d, J = 
8.0 Hz, 2H), 4.53 (d, J = 12.2 Hz, 1H), 4.28 (d, J = 12.2 Hz, 1H), 2.04 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 140.46(two peaks), 139.52, 138.97, 136.91, 133.27, 
130.57, 126.70, 125.57 (q, J = 3.7 Hz), 124.92, 123.13, 122.87(two peaks), 63.31, 
12.24; 19F NMR (376 MHz, CDCl3) δ -62.72; HRMS (ESI) calcd for C17H13F3OS2 m/z 
[M+1] +: 355.0438; found: 355.0446; [𝑎]𝐷
22= –122.1 (c 1.5, CHCl3); HPLC analysis: 
Chiralcel OJ (Hex/IPA = 95/5, 1.0 mL/min, 254 nm, 22°C), 41.0, 49.4(major) min, 89% 
ee. 
 
(R)-2-((3-methoxybenzyl)sulfinyl)-3-methylbenzo[b]thiophene(116le) Pale yellow 
oil; 90% yield; 1H NMR (400 MHz, CDCl3) δ 7.90 (dd, J = 6.9, 1.6 Hz, 1H), 7.69 – 
7.58 (m, 1H), 7.43 (pd, J = 7.1, 1.4 Hz, 2H), 7.17 – 7.04 (m, 1H), 6.80 (dd, J = 8.3, 
1.9 Hz, 1H), 6.66 (d, J = 7.5 Hz, 1H), 6.50 – 6.35 (m, 1H), 4.52 (d, J = 11.9 Hz, 1H), 
4.17 (d, J = 11.9 Hz, 1H), 3.47 (s, 3H), 1.94 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
159.66, 140.42, 139.99, 139.05, 137.13, 130.42, 129.63, 126.46, 124.76, 123.09, 
122.77, 122.50, 114.82, 114.76, 64.26, 54.92, 12.12; IR: 1600, 1490, 1438, 1165, 
1105, 1045 cm-1; HRMS (ESI) calcd for C17H16O2S2 m/z [M+H]
 +: 317.0670; found: 
317.0674; [𝑎]𝐷
22= –184.8 (c 1.66, CHCl3); HPLC analysis: Chiralcel OJ (Hex/IPA = 
90/10, 1.0 mL/min, 210 nm, 22°C), 37.5, 45.2(major) min, 95% ee. 
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(R)-3-methyl-2-((naphthalen-2-ylmethyl)sulfinyl)benzo[b]thiophene(116lf) White 
solid; 88% yield; mp:168.5-169.8 °C; 1H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 7.9 
Hz, 1H), 7.78 (d, J = 7.8 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 7.7 Hz, 1H), 
7.53 (d, J = 7.3 Hz, 2H), 7.50 – 7.35 (m, 4H), 7.12 (dd, J = 8.4, 1.7 Hz, 1H), 4.69 (d, J 
= 12.1 Hz, 1H), 4.38 (d, J = 12.1 Hz, 1H), 1.83 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 140.45, 140.09, 139.10, 136.93, 133.11, 132.90, 129.70, 128.37, 127.75, 127.63, 
127.36, 126.50, 126.49, 126.44, 124.70, 123.10, 122.75(two peaks), 64.40, 12.19; IR: 
1102, 1037, 960, 746 cm-1; HRMS (ESI) calcd for C20H16OS2 m/z [M+H]
 +: 337.0721; 
found: 337.0724; [𝑎]𝐷
22= –249.3 (c 1.44, CHCl3); HPLC analysis: Chiralcel OD-H 
(Hex/IPA = 70/30, 1.0 mL/min, 254 nm, 22°C), 19.0 (major), 46.3 min, 92% ee.  
 
(R)-2-((4-chlorobenzyl)sulfinyl)furan(115ma) Colourless oil; 95% yield; 1H NMR 
(400 MHz, CDCl3) δ 7.69 (dd, J = 1.7, 0.7 Hz, 1H), 7.30 – 7.19 (m, 3H), 7.10 – 6.96 
(m, 2H), 6.75 (dd, J = 3.4, 0.6 Hz, 1H), 6.46 (dd, J = 3.4, 1.8 Hz, 1H), 4.41 (d, J = 
12.6 Hz, 1H), 4.34 (d, J = 12.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 150.33, 
146.83, 134.55, 131.31, 128.91, 127.72, 117.24, 111.45, 58.58; IR: 3051, 1490, 1460, 
1095, 1047, 1008 cm-1; HRMS (ESI) calcd for C11H9ClO2S m/z [M+H]
 +: 241.0090; 
found: 241.0082; [𝑎]𝐷
22= –77.5 (c 1.14, CHCl3); HPLC analysis: Chiralcel OD-H 
(Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 22°C), 20.6(major), 27.4min, 81% ee. 
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(R)-2-((4-(trifluoromethyl)benzyl)sulfinyl)furan(116mb) White solid; 87% yield; 
mp:124.9-126.3 °C; 1H NMR (400 MHz, CDCl3) δ 7.78 – 7.63 (m, 1H), 7.55 (d, J = 
8.1 Hz, 2H), 7.30 – 7.10 (m, 2H), 6.76 (d, J = 3.4 Hz, 1H), 6.47 (dd, J = 3.5, 1.8 Hz, 
1H), 4.45 (q, J = 12.6 Hz, 2H); 19F NMR (376 MHz, CDCl3) δ -62.76; 13C NMR (100 
MHz, CDCl3) δ 150.23, 146.94, 133.36, 130.77, 130.42, 125.61 (q, J = 3.8 Hz, 1H), 
122.50, 117.26, 111.53, 58.79; HRMS (ESI) calcd for C12H9F3O2S m/z [M+1]
 +: 
275.0354; found: 275.0352; [𝑎]𝐷
22= –24.2 (c 0.95, CHCl3); HPLC analysis: Chiralcel 
OD-H (Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 22°C), 19.5(major), 27.7min, 60% ee. 
 
(R)-3-(benzylsulfinyl)-2-methylfuran(116na) Colourless oil; 73% yield; 1H NMR 
(400 MHz, CDCl3) δ 7.37 (d, J = 2.1 Hz, 1H), 7.31 – 7.20 (m, 3H), 7.06 (dd, J = 7.3, 
2.1 Hz, 2H), 6.66 (d, J = 2.0 Hz, 1H), 4.32 (d, J = 12.1 Hz, 1H), 4.03 (d, J = 12.1 Hz, 
1H), 1.89 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 154.58, 142.36, 130.19, 129.46, 
128.61, 128.26, 120.79, 106.69, 61.67, 11.70; IR: 1589, 1514, 1454, 1388, 1228, 1126, 
1043, 1012 cm-1; HRMS (ESI) calcd for C12H12O2S m/z [M+H]
 +: 237.0408; found: 
237.0401; [𝑎]𝐷
22= –41.6 (c 0.68, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA = 
90/10, 1.0 mL/min, 254 nm, 22°C), 14.8(major), 21.1min, 81% ee.
 
(R)-2-((4-chlorobenzyl)sulfinyl)benzofuran(116oa) White solid; 83% yield; 
mp:156.3-157.4 °C; 1H NMR (400 MHz, CDCl3) δ 7.60 (dd, J = 8.1, 4.6 Hz, 2H), 
7.45 (dd, J = 11.5, 4.3 Hz, 1H), 7.32 (t, J = 7.5 Hz, 1H), 7.22 (d, J = 8.4 Hz, 2H), 7.12 
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– 7.01 (m, 3H), 4.50 (d, J = 12.8 Hz, 1H), 4.39 (d, J = 12.8 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ 156.46, 153.22, 134.72, 131.45, 128.95, 127.41, 126.98, 126.47, 
124.00, 122.38, 112.90, 111.96, 58.71; HRMS (ESI) calcd for C15H11ClO2S m/z [M+1]
 
+: 291.0247; found: 291.0249; [𝑎]𝐷
22 = –5.48 (c 0.73, CHCl3); HPLC analysis: 
Chiralcel OD-H (Hex/IPA = 95/5, 1.0 mL/min, 230 nm, 22°C), 37.8(major), 64.1min, 
79% ee. 
 
(R)-2-((4-chlorobenzyl)sulfinyl)pyridine(116pa) Colourless oil; 84% yield; 1H 
NMR (400 MHz, CDCl3) δ 8.66 (dd, J = 4.7, 0.7 Hz, 1H), 7.78 (td, J = 7.7, 1.7 Hz, 
1H), 7.57 (d, J = 7.9 Hz, 1H), 7.34 (ddd, J = 7.6, 4.7, 1.1 Hz, 1H), 7.23 – 7.12 (m, 2H), 
6.98 – 6.81 (m, 2H), 4.32 (d, J = 13.2 Hz, 1H), 4.04 (d, J = 13.2 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 163.33,149.33, 137.73, 134.30, 131.48, 128.41, 127.62, 124.65, 
120.70, 58.70; HRMS (ESI) calcd for C12H10ClNOS m/z [M+1]
 +: 252.0250; found: 
252.0248; [𝑎]𝐷
22 = +224.64 (c 1.27, CHCl3); HPLC analysis: Chiralcel OD-H 
(Hex/IPA = 95/5, 1.0 mL/min, 230 nm, 22°C), 24.0, 28.0(major) min, 70% ee. 
 
(R)-2-((4-(trifluoromethyl)benzyl)sulfinyl)pyridine(115pb) White solid; 79% yield; 
mp:103.4-104.1 °C; 1H NMR (400 MHz, CDCl3) δ 8.67 (dd, J = 4.7, 0.7 Hz, 1H), 
7.78 (td, J = 7.7, 1.7 Hz, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.47 (d, J = 8.1 Hz, 2H), 7.35 
(ddd, J = 7.6, 4.7, 1.0 Hz, 1H), 7.10 (d, J = 8.0 Hz, 2H), 4.40 (d, J = 13.1 Hz, 1H), 
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4.13 (d, J = 13.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 163.16, 149.40, 137.78, 
133.27, 130.54, 130.10, 125.09 (q, J = 3.8 Hz, 1H), 124.76, 122.60, 120.66, 58.85; 19F 
NMR (376 MHz, CDCl3) δ -62.70; HRMS (ESI) calcd for C13H10F3NOS m/z [M+1] +: 
286.0513; found: 286.0510; [𝑎]𝐷
22= +141.7 (c 1.36, CHCl3); HPLC analysis: Chiralcel 
OD-H (Hex/IPA = 95/5, 1.0 mL/min, 230 nm, 22°C), 18.1, 20.8(major) min, 65% ee. 
 
(R)-1-((4-chlorobenzyl)sulfinyl)-3,5-dimethylbenzene(116qa) White solid; 88% 
yield; mp:98.7-100.4 °C; 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.18 (m, 2H), 7.10 (s, 
1H), 6.99 (s, 2H), 6.94 (d, J = 8.4 Hz, 2H), 3.98 (s, 2H), 2.33 (s, 6H); 13C NMR (100 
MHz, CDCl3) δ 142.20, 138.92, 134.32, 132.95, 131.65, 128.46, 127.87, 121.75, 
62.59, 21.16; HRMS (ESI) calcd for C15H15ClOS m/z [M+1]
 +: 279.0610; found: 
279.0612; [𝑎]𝐷
22 = +132.92 (c 1.47, CHCl3); HPLC analysis: Chiralcel AD-H 
(Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 22°C), 10.6, 12.2(major) min, 88% ee. 
 
(R)-1,3-dimethyl-5-((4-(trifluoromethyl)benzyl)sulfinyl)benzene(116qb) White 
solid; 84% yield; mp:108.3-108.6 °C; 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.1 
Hz, 2H), 7.15 – 7.02 (m, 3H), 6.93 (s, 2H), 4.06 (d, J = 12.6 Hz, 1H), 3.99 (d, J = 12.6 
Hz, 1H), 2.29 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 141.92, 139.00, 133.34, 133.07, 
130.71, 130.18, 125.10 (q, J = 3.8 Hz),121.68, 119.97, 62.63, 21.10; 19F NMR (376 
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MHz, CDCl3) δ -62.72; HRMS (ESI) calcd for C16H15F3OS m/z [M+1] +: 313.0874; 
found: 313.0878; [𝑎]𝐷
22= +129.6 (c 1.58, CHCl3); HPLC analysis: Chiralcel AD-H 
(Hex/IPA = 90/10, 1.0 mL/min, 230 nm, 22°C), 8.6, 10.2(major) min, 84% ee. 
 
(R)-2-(benzylsulfinyl)-5-methoxy-1-methyl-1H-benzo[d]imidazole (115ra) 
Colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.31 (d, J = 7.1 Hz, 1H), 7.27 (dd, J = 
7.6, 2.5 Hz, 2H), 7.22 (d, J = 7.3 Hz, 1H), 7.16 (d, J = 8.9 Hz, 1H), 7.03 (dd, J = 13.9, 
4.9 Hz, 3H), 4.64 (d, J = 12.8 Hz, 1H), 4.46 (d, J = 12.8 Hz, 1H), 3.88 (s, 3H), 3.43 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 157.00, 149.76, 142.93, 131.28, 130.53, 128.94, 
128.71, 128.64, 115.39, 110.10, 102.00, 60.79, 55.76, 29.90; HRMS (ESI) calcd for 
C16H16N2O2S m/z [M+1]
 +: 301.1011; found: 301.1006; HPLC analysis: Chiralcel OJ 
(Hex/IPA = 50/50, 1.0 mL/min, 230 nm, 22°C), 23.1(major), 64.0min, 47% ee. 
 
(R)-5-methoxy-1-methyl-2-((4-methylbenzyl) sulfinyl)-1H-benzo[d]imidazole 
(116rb) Colourless oil;99% yield; 1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 6.6 Hz, 
1H), 7.18 (d, J = 8.9 Hz, 1H), 7.03 (t, J = 8.7 Hz, 3H), 6.94 (d, J = 7.5 Hz, 2H), 4.62 
(d, J = 12.8 Hz, 1H), 4.44 (d, J = 12.8 Hz, 1H), 3.88 (s, 3H), 3.48 (s, 3H), 2.31 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 157.00, 150.11, 142.97, 138.66, 131.32, 130.43, 
129.36, 125.81, 115.35, 110.11, 102.07, 60.52, 55.77, 30.01, 21.15; IR: 1490, 1411, 
1346, 1199, 1047, 1029 cm-1; HRMS (ESI) calcd for C17H18N2O2S m/z [M+H]
 +: 
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315.1167; found: 315.1171; [𝑎]𝐷
22 = +134.96 (c 1.35, CHCl3); HPLC analysis: 
Chiralcel OJ (Hex/IPA = 70/30, 1.0 mL/min, 230 nm, 22°C), 25.3(major), 42.1 min, 
90% ee. 
 
(R)-2-((4-chlorobenzyl) sulfinyl)-5-methoxy-1-methyl-1H-benzo[d]imidazole 
(116rc) White solid; 1H NMR (400 MHz, CDCl3) δ 7.26 (s, 1H), 7.22 (t, J = 8.7 Hz, 
3H), 7.04 (dd, J = 12.2, 5.3 Hz, 3H), 4.63 (d, J = 12.9 Hz, 1H), 4.46 (d, J = 13.0 Hz, 
1H), 3.89 (s, 3H), 3.57 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 157.10, 149.36, 142.84, 
134.98, 131.84, 131.32, 128.84, 127.52, 115.56, 110.21, 101.97, 59.76, 55.77, 30.15; 
HRMS (ESI) calcd for C16H15ClN2O2S m/z [M+1]
 +: 335.0621; found: 335.0617; 
HPLC analysis: Chiralcel OJ (Hex/IPA = 70/30, 1.0 mL/min, 230 nm, 22°C), 
24.7(major), 31.2min, 60% ee. 
 
(R)-5-methoxy-1-methyl-2-((4-(trifluoromethyl)benzyl)sulfinyl)-1H-
benzo[d]imidazole(116rd) Colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 
7.8 Hz, 2H), 7.25 (d, J = 11.7 Hz, 3H), 7.20 (d, J = 8.9 Hz, 1H), 7.04 (d, J = 8.9 Hz, 
1H), 4.71 (d, J = 12.9 Hz, 1H), 4.56 (d, J = 12.9 Hz, 1H), 3.89 (s, 3H), 3.57 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 157.12, 149.06, 142.77, 133.19, 131.32, 130.93, 
125.48 (dd, J = 7.4, 3.6 Hz).119.99, 115.70, 110.22, 101.90, 59.81, 55.75, 30.14; 19F 
NMR (376 MHz, CDCl3) δ -62.72; HRMS (ESI) calcd for C17H15F3N2O2S m/z [M+1] 
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+: 369.0885; found: 369.0879; HPLC analysis: Chiralcel OJ (Hex/IPA = 70/30, 1.0 
mL/min, 230 nm, 22°C), 16.2(major), 18.6min, 57% ee. 
 
(R)-5-methoxy-2-((3-methoxybenzyl)sulfinyl)-1-methyl-1H-
benzo[d]imidazole(116re) Colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 
1.9 Hz, 1H), 7.21 – 7.10 (m, 2H), 7.02 (dd, J = 8.9, 2.2 Hz, 1H), 6.89 – 6.79 (m, 1H), 
6.70 (d, J = 7.4 Hz, 1H), 6.46 (s, 1H), 4.61 (d, J = 12.7 Hz, 1H), 4.44 (d, J = 12.7 Hz, 
1H), 3.88 (s, 3H), 3.47 (d, J = 3.1 Hz, 6H).; 13C NMR (100 MHz, CDCl3) δ 159.74, 
157.02, 149.91, 142.94, 131.27, 130.24, 129.59, 122.91, 115.41, 115.27, 114.85, 
110.13, 101.98, 60.98, 55.78, 54.96, 29.98; HRMS (ESI) calcd for C17H18N2O3S m/z 
[M+1] +: 331.1116; found: 331.1109; HPLC analysis: Chiralcel OJ (Hex/IPA = 70/30, 
1.0 mL/min, 230 nm, 22°C), 34.4(major), 58.5min, 67% ee. 
 
(R)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1-
methyl-1H-benzo[d]imidazole(116rf) Colourless oil; 1H NMR (400 MHz, CDCl3) δ 
8.11 (s, 1H), 7.33 – 7.17 (m, 3H), 7.09 – 7.07 (m, 1H), 4.92 (d, J = 2.6 Hz, 2H), 3.94 
(s, 3H), 3.86 (s, 3H), 3.69 (s, 3H), 2.27 (s, 3H), 2.21 (s, 3H);13C NMR (100 MHz, 
CDCl3) δ 164.26, 156.91, 152.08, 149.45, 143.01, 131.18, 126.80, 126.05, 115.58, 
110.28, 102.16, 59.92, 59.35, 55.75, 30.68, 13.27, 11.54; HRMS (ESI) calcd for 
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C18H21N3O3S m/z [M+1]
 +: 360.1382; found: 360.1385; HPLC analysis: Chiralcel OJ 
(Hex/IPA = 70/30, 1.0 mL/min, 230 nm, 22°C), 16.0(major), 19.4 min, 46% ee. 
 
Methyl 3-((thiophen-2-ylthio)oxy)propanoate(117ba) Colorless oil; 1H NMR (400 
MHz, CDCl3) δ 7.75 (dd, J = 5.0, 1.3 Hz, 1H), 7.71 (dd, J = 3.8, 1.3 Hz, 1H), 7.18 (dd, 
J = 4.9, 3.8 Hz, 1H), 3.67 (s, 3H), 3.59 – 3.46 (m, 2H), 2.88 – 2.74 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 170.29, 139.46, 134.57, 134.47, 128.05, 52.91, 52.36, 28.01; 
HRMS (ESI) calcd for C8H10O3S2 m/z [M+1]
 +: 219.0150; found: 219.0141. 
 
 Alkaline hydrolized product of 2-thienyl sulfenate anion. Yellow oil; 1H NMR (400 
MHz, CDCl3) δ 7.50 (dd, J = 5.3, 1.2 Hz, 1H), 7.15 (dd, J = 3.6, 1.2 Hz, 1H), 7.01 (dd, 
J = 5.3, 3.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 135.74, 135.62, 132.24, 127.74. 
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